1
|
Monteagudo B, Marqués FM, Gibelin J, Orr NA, Corsi A, Kubota Y, Casal J, Gómez-Camacho J, Authelet G, Baba H, Caesar C, Calvet D, Delbart A, Dozono M, Feng J, Flavigny F, Gheller JM, Giganon A, Gillibert A, Hasegawa K, Isobe T, Kanaya Y, Kawakami S, Kim D, Kiyokawa Y, Kobayashi M, Kobayashi N, Kobayashi T, Kondo Y, Korkulu Z, Koyama S, Lapoux V, Maeda Y, Motobayashi T, Miyazaki T, Nakamura T, Nakatsuka N, Nishio Y, Obertelli A, Ohkura A, Ota S, Otsu H, Ozaki T, Panin V, Paschalis S, Pollacco EC, Reichert S, Rousse JY, Saito AT, Sakaguchi S, Sako M, Santamaria C, Sasano M, Sato H, Shikata M, Shimizu Y, Shindo Y, Stuhl L, Sumikama T, Sun YL, Tabata M, Togano Y, Tsubota J, Uesaka T, Yang ZH, Yasuda J, Yoneda K, Zenihiro J. Mass, Spectroscopy, and Two-Neutron Decay of ^{16}Be. Phys Rev Lett 2024; 132:082501. [PMID: 38457706 DOI: 10.1103/physrevlett.132.082501] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/19/2023] [Revised: 12/18/2023] [Accepted: 01/29/2024] [Indexed: 03/10/2024]
Abstract
The structure and decay of the most neutron-rich beryllium isotope, ^{16}Be, has been investigated following proton knockout from a high-energy ^{17}B beam. Two relatively narrow resonances were observed for the first time, with energies of 0.84(3) and 2.15(5) MeV above the two-neutron decay threshold and widths of 0.32(8) and 0.95(15) MeV, respectively. These were assigned to be the ground (J^{π}=0^{+}) and first excited (2^{+}) state, with E_{x}=1.31(6) MeV. The mass excess of ^{16}Be was thus deduced to be 56.93(13) MeV, some 0.5 MeV more bound than the only previous measurement. Both states were observed to decay by direct two-neutron emission. Calculations incorporating the evolution of the wave function during the decay as a genuine three-body process reproduced the principal characteristics of the neutron-neutron energy spectra for both levels, indicating that the ground state exhibits a strong spatially compact dineutron component, while the 2^{+} level presents a far more diffuse neutron-neutron distribution.
Collapse
Affiliation(s)
- B Monteagudo
- LPC Caen, ENSICAEN, CNRS/IN2P3, Université de Caen, Normandie Université, 14050 Caen, France
- FRIB, Michigan State University, East Lansing, Michigan 48824, USA
| | - F M Marqués
- LPC Caen, ENSICAEN, CNRS/IN2P3, Université de Caen, Normandie Université, 14050 Caen, France
| | - J Gibelin
- LPC Caen, ENSICAEN, CNRS/IN2P3, Université de Caen, Normandie Université, 14050 Caen, France
| | - N A Orr
- LPC Caen, ENSICAEN, CNRS/IN2P3, Université de Caen, Normandie Université, 14050 Caen, France
| | - A Corsi
- Département de Physique Nucléaire, IRFU, CEA, Université Paris-Saclay, 91191 Gif-sur-Yvette, France
| | - Y Kubota
- RIKEN Nishina Center, Hirosawa 2-1, Wako, Saitama 351-0198, Japan
- Center for Nuclear Study, University of Tokyo, Hongo 7-3-1, Bunkyo, Tokyo 113-0033, Japan
- Department of Physics, Institut für Kernphysik, Technische Universität Darmstadt, D-64289 Darmstadt, Germany
| | - J Casal
- Dipartimento di Fisica e Astronomia "G. Galilei" and INFN-Sezione di Padova, Via Marzolo 8, 35131 Padova, Italy
- Departamento de Física Atómica, Molecular y Nuclear, Facultad de Física, Universidad de Sevilla, Apartado 1065, E-41080 Sevilla, Spain
| | - J Gómez-Camacho
- Departamento de Física Atómica, Molecular y Nuclear, Facultad de Física, Universidad de Sevilla, Apartado 1065, E-41080 Sevilla, Spain
| | - G Authelet
- Département des Accélérateurs, de Cryogénie et de Magnétisme, IRFU, CEA, Université Paris-Saclay, 91191 Gif-sur-Yvette, France
| | - H Baba
- RIKEN Nishina Center, Hirosawa 2-1, Wako, Saitama 351-0198, Japan
| | - C Caesar
- Department of Physics, Institut für Kernphysik, Technische Universität Darmstadt, D-64289 Darmstadt, Germany
| | - D Calvet
- Département d'électronique des Détecteurs et d'Informatique pour la Physique, IRFU, CEA, Université Paris-Saclay, 91191 Gif-sur-Yvette, France
| | - A Delbart
- Département d'électronique des Détecteurs et d'Informatique pour la Physique, IRFU, CEA, Université Paris-Saclay, 91191 Gif-sur-Yvette, France
| | - M Dozono
- Center for Nuclear Study, University of Tokyo, Hongo 7-3-1, Bunkyo, Tokyo 113-0033, Japan
| | - J Feng
- School of Physics, Peking University, Beijing 100871, China
| | - F Flavigny
- Institut de Physique Nucléaire, IN2P3-CNRS, Université Paris-Sud, Université Paris-Saclay, 91406 Orsay Cedex, France
| | - J-M Gheller
- Département des Accélérateurs, de Cryogénie et de Magnétisme, IRFU, CEA, Université Paris-Saclay, 91191 Gif-sur-Yvette, France
| | - A Giganon
- Département d'électronique des Détecteurs et d'Informatique pour la Physique, IRFU, CEA, Université Paris-Saclay, 91191 Gif-sur-Yvette, France
| | - A Gillibert
- Département de Physique Nucléaire, IRFU, CEA, Université Paris-Saclay, 91191 Gif-sur-Yvette, France
| | - K Hasegawa
- Department of Physics, Tohoku University, Miyagi 980-8578, Japan
| | - T Isobe
- RIKEN Nishina Center, Hirosawa 2-1, Wako, Saitama 351-0198, Japan
| | - Y Kanaya
- Department of Applied Physics, University of Miyazaki, Gakuen-Kibanadai-Nishi 1-1, Miyazaki 889-2192, Japan
| | - S Kawakami
- Department of Applied Physics, University of Miyazaki, Gakuen-Kibanadai-Nishi 1-1, Miyazaki 889-2192, Japan
| | - D Kim
- Department of Physics, Ewha Womans University, Republic of Korea
| | - Y Kiyokawa
- Center for Nuclear Study, University of Tokyo, Hongo 7-3-1, Bunkyo, Tokyo 113-0033, Japan
| | - M Kobayashi
- Center for Nuclear Study, University of Tokyo, Hongo 7-3-1, Bunkyo, Tokyo 113-0033, Japan
| | - N Kobayashi
- Department of Physics, Tokyo Institute of Technology, 2-12-1 O-Okayama, Meguro, Tokyo 152-8551, Japan
| | - T Kobayashi
- Department of Physics, Tohoku University, Miyagi 980-8578, Japan
| | - Y Kondo
- Department of Physics, Tokyo Institute of Technology, 2-12-1 O-Okayama, Meguro, Tokyo 152-8551, Japan
| | - Z Korkulu
- RIKEN Nishina Center, Hirosawa 2-1, Wako, Saitama 351-0198, Japan
| | - S Koyama
- Department of Physics, University of Tokyo, Hongo 7-3-1, Bunkyo, Tokyo 113-0033, Japan
| | - V Lapoux
- Département de Physique Nucléaire, IRFU, CEA, Université Paris-Saclay, 91191 Gif-sur-Yvette, France
| | - Y Maeda
- Department of Applied Physics, University of Miyazaki, Gakuen-Kibanadai-Nishi 1-1, Miyazaki 889-2192, Japan
| | - T Motobayashi
- RIKEN Nishina Center, Hirosawa 2-1, Wako, Saitama 351-0198, Japan
| | - T Miyazaki
- Department of Physics, University of Tokyo, Hongo 7-3-1, Bunkyo, Tokyo 113-0033, Japan
| | - T Nakamura
- Department of Physics, Tokyo Institute of Technology, 2-12-1 O-Okayama, Meguro, Tokyo 152-8551, Japan
| | - N Nakatsuka
- Department of Physics, Kyoto University, Kyoto 606-8502, Japan
| | - Y Nishio
- Department of Physics, Kyushu University, Nishi, Fukuoka 819-0367, Japan
| | - A Obertelli
- Département de Physique Nucléaire, IRFU, CEA, Université Paris-Saclay, 91191 Gif-sur-Yvette, France
- Department of Physics, Institut für Kernphysik, Technische Universität Darmstadt, D-64289 Darmstadt, Germany
| | - A Ohkura
- Department of Physics, Kyushu University, Nishi, Fukuoka 819-0367, Japan
| | - S Ota
- Center for Nuclear Study, University of Tokyo, Hongo 7-3-1, Bunkyo, Tokyo 113-0033, Japan
| | - H Otsu
- RIKEN Nishina Center, Hirosawa 2-1, Wako, Saitama 351-0198, Japan
| | - T Ozaki
- Department of Physics, Tokyo Institute of Technology, 2-12-1 O-Okayama, Meguro, Tokyo 152-8551, Japan
| | - V Panin
- Département de Physique Nucléaire, IRFU, CEA, Université Paris-Saclay, 91191 Gif-sur-Yvette, France
- RIKEN Nishina Center, Hirosawa 2-1, Wako, Saitama 351-0198, Japan
| | - S Paschalis
- Department of Physics, Institut für Kernphysik, Technische Universität Darmstadt, D-64289 Darmstadt, Germany
| | - E C Pollacco
- Département de Physique Nucléaire, IRFU, CEA, Université Paris-Saclay, 91191 Gif-sur-Yvette, France
| | - S Reichert
- Department of Physics, Technische Universität Munchen, 85748 Garching bei München, Germany
| | - J-Y Rousse
- Département d'Ingénierie des Systèmes, IRFU, CEA, Université Paris-Saclay, 91191 Gif-sur-Yvette, France
| | - A T Saito
- Department of Physics, Tokyo Institute of Technology, 2-12-1 O-Okayama, Meguro, Tokyo 152-8551, Japan
| | - S Sakaguchi
- Department of Physics, Kyushu University, Nishi, Fukuoka 819-0367, Japan
| | - M Sako
- RIKEN Nishina Center, Hirosawa 2-1, Wako, Saitama 351-0198, Japan
| | - C Santamaria
- Département de Physique Nucléaire, IRFU, CEA, Université Paris-Saclay, 91191 Gif-sur-Yvette, France
| | - M Sasano
- RIKEN Nishina Center, Hirosawa 2-1, Wako, Saitama 351-0198, Japan
| | - H Sato
- RIKEN Nishina Center, Hirosawa 2-1, Wako, Saitama 351-0198, Japan
| | - M Shikata
- Department of Physics, Tokyo Institute of Technology, 2-12-1 O-Okayama, Meguro, Tokyo 152-8551, Japan
| | - Y Shimizu
- RIKEN Nishina Center, Hirosawa 2-1, Wako, Saitama 351-0198, Japan
| | - Y Shindo
- Department of Physics, Kyushu University, Nishi, Fukuoka 819-0367, Japan
| | - L Stuhl
- RIKEN Nishina Center, Hirosawa 2-1, Wako, Saitama 351-0198, Japan
| | - T Sumikama
- RIKEN Nishina Center, Hirosawa 2-1, Wako, Saitama 351-0198, Japan
| | - Y L Sun
- Département de Physique Nucléaire, IRFU, CEA, Université Paris-Saclay, 91191 Gif-sur-Yvette, France
- Department of Physics, Institut für Kernphysik, Technische Universität Darmstadt, D-64289 Darmstadt, Germany
| | - M Tabata
- Department of Physics, Kyushu University, Nishi, Fukuoka 819-0367, Japan
| | - Y Togano
- Department of Physics, Tokyo Institute of Technology, 2-12-1 O-Okayama, Meguro, Tokyo 152-8551, Japan
| | - J Tsubota
- Department of Physics, Tokyo Institute of Technology, 2-12-1 O-Okayama, Meguro, Tokyo 152-8551, Japan
| | - T Uesaka
- RIKEN Nishina Center, Hirosawa 2-1, Wako, Saitama 351-0198, Japan
| | - Z H Yang
- RIKEN Nishina Center, Hirosawa 2-1, Wako, Saitama 351-0198, Japan
| | - J Yasuda
- Department of Physics, Kyushu University, Nishi, Fukuoka 819-0367, Japan
| | - K Yoneda
- RIKEN Nishina Center, Hirosawa 2-1, Wako, Saitama 351-0198, Japan
| | - J Zenihiro
- RIKEN Nishina Center, Hirosawa 2-1, Wako, Saitama 351-0198, Japan
| |
Collapse
|
2
|
Matsumoto A, Jinno H, Naruse S, Isono Y, Maeda Y, Sato A, Yamada M, Ikeda T, Sasajima Y. Efficacy and safety of dose-dense neoadjuvant chemotherapy with nab-paclitaxel followed by epirubicin and cyclophosphamide for operable breast cancer. Jpn J Clin Oncol 2023; 53:1119-1124. [PMID: 37609671 DOI: 10.1093/jjco/hyad112] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/28/2023] [Accepted: 08/08/2023] [Indexed: 08/24/2023] Open
Abstract
OBJECTIVE Dose-dense chemotherapy has shown a better prognosis than standard interval chemotherapy in adjuvant settings for high-risk breast cancer. This study aimed to evaluate the efficacy and safety of dose-dense nanoparticle albumin-bound paclitaxel followed by dose-dense epirubicin and cyclophosphamide as neoadjuvant chemotherapy for human epidermal growth factor 2 (HER2)-negative operable breast cancer. METHODS Patients with histologically confirmed stage I-III HER2-negative breast cancer were enrolled in this study. Patients received nanoparticle albumin-bound paclitaxel (260 mg/m2) followed by epirubicin (90 mg/m2) and cyclophosphamide (600 mg/m2) every 2 weeks with pegfilgrastim. The primary endpoint was the pathological complete response rate. Patients also underwent prophylactic management for peripheral neuropathy, which involved a combination of cryotherapy, compression therapy using elastic stockings and medications including goshajinkigan. RESULTS Among the 55 patients enrolled in this study, 13 (23.6%) achieved pathological complete response, of whom 10/26 (38.5%) patients had triple-negative disease and 3/29 (10.3%) had luminal disease. The objective response was observed in 46 (83.6%) patients. Of the 36 patients who were initially planned for mastectomy, 11 (30.6%) underwent breast-conserving surgery after neoadjuvant chemotherapy. The most common grade 3-4 adverse events were myalgia (14.5%), fatigue (12.7%) and elevated transaminase levels (9.1%). No patients experienced febrile neutropenia. Eight (14.5%) patients discontinued treatments due to adverse events. CONCLUSIONS Neoadjuvant dose-dense biweekly nanoparticle albumin-bound paclitaxel followed by dose-dense epirubicin and cyclophosphamide was effective, especially in patients with triple-negative disease, and feasible with pegfilgrastim support.
Collapse
Affiliation(s)
- Akiko Matsumoto
- Department of Surgery, Teikyo University School of Medicine, Tokyo, Japan
| | - Hiromitsu Jinno
- Department of Surgery, Teikyo University School of Medicine, Tokyo, Japan
| | - Saki Naruse
- Department of Surgery, Teikyo University School of Medicine, Tokyo, Japan
| | - Yuka Isono
- Department of Surgery, Teikyo University School of Medicine, Tokyo, Japan
| | - Yuka Maeda
- Department of Surgery, Teikyo University School of Medicine, Tokyo, Japan
| | - Ayana Sato
- Department of Surgery, Teikyo University School of Medicine, Tokyo, Japan
| | - Miki Yamada
- Department of Surgery, Teikyo University School of Medicine, Tokyo, Japan
| | - Tatsuhiko Ikeda
- Department of Surgery, Teikyo University School of Medicine, Tokyo, Japan
| | - Yuko Sasajima
- Department of Pathology, Teikyo University School of Medicine, Tokyo, Japan
| |
Collapse
|
3
|
Hayashi K, Maeda Y, Yoshimura T, Huang M, Tamura T. Estimating Blood Pressure during Exercise with a Cuffless Sphygmomanometer. Sensors (Basel) 2023; 23:7399. [PMID: 37687854 PMCID: PMC10490341 DOI: 10.3390/s23177399] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/17/2023] [Revised: 08/05/2023] [Accepted: 08/23/2023] [Indexed: 09/10/2023]
Abstract
Accurately measuring blood pressure (BP) is essential for maintaining physiological health, which is commonly achieved using cuff-based sphygmomanometers. Several attempts have been made to develop cuffless sphygmomanometers. To increase their accuracy and long-term variability, machine learning methods can be applied for analyzing photoplethysmogram (PPG) signals. Here, we propose a method to estimate the BP during exercise using a cuffless device. The BP estimation process involved preprocessing signals, feature extraction, and machine learning techniques. To ensure the reliability of the signals extracted from the PPG, we employed the skewness signal quality index and the RReliefF algorithm for signal selection. Thereafter, the BP was estimated using the long short-term memory (LSTM)-based neural network. Seventeen young adult males participated in the experiments, undergoing a structured protocol composed of rest, exercise, and recovery for 20 min. Compared to the BP measured using a non-invasive voltage clamp-type continuous sphygmomanometer, that estimated by the proposed method exhibited a mean error of 0.32 ± 7.76 mmHg, which is equivalent to the accuracy of a cuff-based sphygmomanometer per regulatory standards. By enhancing patient comfort and improving healthcare outcomes, the proposed approach can revolutionize BP monitoring in various settings, including clinical, home, and sports environments.
Collapse
Affiliation(s)
- Kenta Hayashi
- Institute of Systems and Information Engineering, University of Tsukuba, Tsukuba 305-8577, Japan;
| | - Yuka Maeda
- Institute of Systems and Information Engineering, University of Tsukuba, Tsukuba 305-8577, Japan;
| | - Takumi Yoshimura
- Department of Medical and Welfare Engineering, Tokyo Metropolitan College of Industrial Technology, Tokyo 116-8523, Japan;
| | - Ming Huang
- School of Data Science, Nagoya City University, Nagoya 467-8501, Japan;
| | - Toshiyo Tamura
- Future Robotics Organization, Waseda University, Tokyo 169-8050, Japan;
| |
Collapse
|
4
|
Kurahara Y, Kanaoka K, Tanaka Y, Maeda Y, Kobayashi T, Takeuchi N, Kagawa T, Tachibana K, Yoshida S, Tsuyuguchi K. Management of dysphonia caused by amikacin liposome inhalation in M. avium complex pulmonary disease. Int J Tuberc Lung Dis 2023; 27:872-873. [PMID: 37880889 DOI: 10.5588/ijtld.23.0275] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2023] Open
Affiliation(s)
- Y Kurahara
- Department of Internal Medicine, Department of Infectious Diseases, and, Clinical Research Center, National Hospital Organization Kinki-Chuo Chest Medical Center, Osaka
| | - K Kanaoka
- Clinical Research Center, National Hospital Organization Kinki-Chuo Chest Medical Center, Osaka
| | - Y Tanaka
- Department of Internal Medicine, Department of Infectious Diseases, and
| | - Y Maeda
- Department of Otorhinolaryngology, Japan Community Healthcare Organization, Osaka Hospital, Osaka, Osaka, Japan
| | - T Kobayashi
- Department of Otorhinolaryngology, Japan Community Healthcare Organization, Osaka Hospital, Osaka, Osaka, Japan
| | | | | | - K Tachibana
- Department of Internal Medicine, Clinical Research Center, National Hospital Organization Kinki-Chuo Chest Medical Center, Osaka
| | - S Yoshida
- Clinical Research Center, National Hospital Organization Kinki-Chuo Chest Medical Center, Osaka
| | - K Tsuyuguchi
- Department of Internal Medicine, Department of Infectious Diseases, and, Clinical Research Center, National Hospital Organization Kinki-Chuo Chest Medical Center, Osaka
| |
Collapse
|
5
|
Gerrard AD, Maeda Y, Miller J, Gunn F, Theodoratou E, Noble C, Porteous L, Glancy S, MacLean P, Pattenden R, Dunlop MG, Din FVN. Double faecal immunochemical testing in patients with symptoms suspicious of colorectal cancer. Br J Surg 2023; 110:471-480. [PMID: 36785496 PMCID: PMC10364540 DOI: 10.1093/bjs/znad016] [Citation(s) in RCA: 4] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/23/2022] [Revised: 10/31/2022] [Accepted: 01/05/2023] [Indexed: 02/15/2023]
Abstract
BACKGROUND Faecal immunochemical test (FIT)-directed pathways based on a single test have been implemented for symptomatic patients. However, with a single test, the sensitivity is 87 per cent at 10 µg haemoglobin (Hb) per g faeces. This aims of this study were to define the diagnostic performance of a single FIT, compared with double FIT in symptomatic populations. METHODS Two sequential prospective patient cohorts referred with symptoms from primary care were studied. Patients in cohort 1 were sent a single FIT, and those in cohort 2 received two tests in succession before investigation. All patients were investigated, regardless of having a positive or negative test (threshold 10 µg Hb per g). RESULTS In cohort 1, 2260 patients completed one FIT and investigation. The sensitivity of single FIT was 84.1 (95 per cent c.i. 73.3 to 91.8) per cent for colorectal cancer and 67.4 (61.0 to 73.4) per cent for significant bowel pathology. In cohort 2, 3426 patients completed at least one FIT, and 2637 completed both FITs and investigation. The sensitivity of double FIT was 96.6 (90.4 to 99.3) per cent for colorectal cancer and 83.0 (77.4 to 87.8) per cent for significant bowel pathology. The second FIT resulted in a 50.0 per cent reduction in cancers missed by the first FIT, and 30.0 per cent for significant bowel pathology. Correlation between faecal Hb level was only modest (rs = 0.58), and 16.8 per cent of double tests were discordant, 11.4 per cent in patients with colorectal cancer and 18.3 per cent in those with significant bowel pathology. CONCLUSION FIT in patients with high-risk symptoms twice in succession reduces missed significant colorectal pathology and has an acceptable workload impact.
Collapse
Affiliation(s)
- A D Gerrard
- Cancer Research UK Scotland Centre, Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, UK
- Department of Colorectal surgery, Western General Hospital, Edinburgh, UK
| | - Y Maeda
- Cancer Research UK Scotland Centre, Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, UK
- Department of Surgery, Queen Elizabeth University Hospital, Glasgow, UK
| | - J Miller
- Department of Colorectal surgery, Western General Hospital, Edinburgh, UK
| | - F Gunn
- Department of Colorectal surgery, Western General Hospital, Edinburgh, UK
| | - E Theodoratou
- Cancer Research UK Scotland Centre, Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, UK
- Centre for Global Health, Usher Institute, University of Edinburgh, Edinburgh, UK
| | - C Noble
- Department of Gastroenterology, Western General Hospital, Edinburgh, UK
| | - L Porteous
- Lead GP for Cancer and Palliative Care, NHS Lothian, Edinburgh, UK
| | - S Glancy
- Department of Radiology, Western General Hospital, Edinburgh, UK
| | - P MacLean
- Department of Radiology, Western General Hospital, Edinburgh, UK
| | - R Pattenden
- Department of Biochemistry, Western General Hospital, Edinburgh, UK
| | - M G Dunlop
- Cancer Research UK Scotland Centre, Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, UK
- UK Colon Cancer Genetics Group, Medical Research Council Human Genetics Unit, Medical Research Council Institute of Genetics & Cancer, Western General Hospital, The University of Edinburgh, Edinburgh, UK
| | - F V N Din
- Cancer Research UK Scotland Centre, Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, UK
- Department of Colorectal surgery, Western General Hospital, Edinburgh, UK
| |
Collapse
|
6
|
Maeda Y, Naruse S, Isono Y, Sato A, Yamada M, Matsumoto A, Ikeda T, Jinno H. Abstract P2-03-19: The efficacy of neoadjuvant endocrine therapy during the waiting period for surgery in postmenopausal hormone receptor positive breast cancer. Cancer Res 2023. [DOI: 10.1158/1538-7445.sabcs22-p2-03-19] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/06/2023]
Abstract
Abstract
Background: Although neoadjuvant endocrine therapy has been used to improve breast conservation rate, its prognostic relevance is unknown. The search for a valid prognostic factor equivalent to pCR in neoadjuvant chemotherapy is a current challenge in neoadjuvant endocrine therapy. In this study, we investigated the efficacy of short term neoadjuvant endocrine therapy utilizing the waiting period for surgery and the prognostic factor including Preoperative Endocrine Prognostic Index (PEPI) score.
Patients and Methods: A total of 269 postmenopausal women with hormone receptor-positive, HER2-negative breast cancer was treated with endocrine therapy with non-steroidal aromatase inhibitor during the waiting period for surgery between October 2012 and November 2021. Of the entire 269 patients, 92 and 177 patients had anastrozole and letrozole, respectively. The primary endpoint was change in tumor size by ultrasound and Ki67 before and after short-term endocrine therapy. The secondary endpoint was prognosis of patients divided by PEPI score which was calculated using tumor size, lymph node metastasis, Ki67, and ER Allred score. This study was approved by the institutional review board of Teikyo University.
Results: Median age was 68 years old (range, 41-89). ER and PgR was positive in 266 (98%) and 232 (86%) of the entire 269 patients, respectively. Median tumor size was 1.65 cm (range, 0.4-7.5). Seventeen (6.3%) pts were clinically node-positive. Patients with histological grade I tumor were 190 (70.6%). The median duration of endocrine therapy was 39 days (range, 2-88). Average pretreatment Ki67 expression was 10% (range, 0-90). Tumor diameter was significantly decreased to 1.43cm (range,0.45-5.83) after short-term endocrine therapy (p=0.01). The Ki67 expression was significantly decreased to 3.0% (range, 0-85) after endocrine therapy (p< 0.01) and only five patients (1.9%) showed marked increase in Ki-67 expression. PEPI score 0, 1-3 and ≥ 4 was found in 83 (30.9%),147 (54.7%) and 39 patients (14.5%), respectively. After the median observation period of 928 days, patients with PEPI score ≥ 4 showed worse disease-free survival (Figure) compared with patients with PEPI score 0 and 1-3 (p=0.06). In terms of mortality, patients with PEPI score ≥ 4 had worse overall survival than patients with PEPI score 0 and 1-3 (p=0.07).
Conclusions: These results suggested that neoadjuvant endocrine therapy during the waiting period for surgery might be effective in reducing the size and Ki67 expression level and PEPI score might be useful in predicting the prognosis of postmenopausal hormone receptor positive breast cancer patients.
Citation Format: Yuka Maeda, Saki Naruse, Yuka Isono, Ayana Sato, Miki Yamada, Akiko Matsumoto, Tatsuhiko Ikeda, Hiromitsu Jinno. The efficacy of neoadjuvant endocrine therapy during the waiting period for surgery in postmenopausal hormone receptor positive breast cancer [abstract]. In: Proceedings of the 2022 San Antonio Breast Cancer Symposium; 2022 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2023;83(5 Suppl):Abstract nr P2-03-19.
Collapse
Affiliation(s)
- Yuka Maeda
- 1Department of Surgery, Teikyo University School of Medicine
| | - Saki Naruse
- 2Department of Surgery, Teikyo University School of Medicine
| | - Yuka Isono
- 3Department of Surgery, Teikyo University School of Medicine
| | - Ayana Sato
- 4Department of Surgery, Teikyo University School of Medicine
| | - Miki Yamada
- 5Department of Surgery, Teikyo University School of Medicine
| | - Akiko Matsumoto
- 6Department of Surgery, Teikyo University School of Medicine
| | - Tatsuhiko Ikeda
- 7Department of Surgery, Teikyo University School of Medicine
| | - Hiromitsu Jinno
- 8Department of Surgery, Teikyo University School of Medicine
| |
Collapse
|
7
|
Kato S, Maeda Y, Sugiyama D, Watanabe K, Nishikawa H, Hinohara K. The cancer epigenome: Non-cell autonomous player in tumor immunity. Cancer Sci 2023; 114:730-740. [PMID: 36468774 PMCID: PMC9986067 DOI: 10.1111/cas.15681] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/25/2022] [Revised: 11/28/2022] [Accepted: 12/02/2022] [Indexed: 12/12/2022] Open
Abstract
Dysregulation of the tumor-intrinsic epigenetic circuit is a key driver event for the development of cancer. Accumulating evidence suggests that epigenetic and/or genetic drivers stimulate intrinsic oncogenic pathways as well as extrinsic factors that modulate the immune system. These modulations indeed shape the tumor microenvironment (TME), allowing pro-oncogenic factors to become oncogenic, thereby contributing to cancer development and progression. Here we review the epigenetic dysregulation arising in cancer cells that disseminates throughout the TME and beyond. Recent CRISPR screening has elucidated key epigenetic drivers that play important roles in the proliferation of cancer cells (intrinsic) and inhibition of antitumor immunity (extrinsic), which lead to the development and progression of cancer. These epigenetic players can serve as promising targets for cancer therapy as a dual (two-in-one)-targeted approach. Considering the interplay between cancer and the immune system as a key determinant of immunotherapy, we discuss a novel lineage-tracing technology that enables longitudinal monitoring of cancer and immune phenotypic heterogeneity and fate paths during cancer development, progression, and therapeutic interventions.
Collapse
Affiliation(s)
- Shinichiro Kato
- Department of Immunology, Nagoya University Graduate School of Medicine, Nagoya, Japan.,Center for 5D Cell Dynamics, Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - Yuka Maeda
- Division of Cancer Immunology, Exploratory Oncology Research & Clinical Trial Center, National Cancer Center, Research Institute, Tokyo, Japan
| | - Daisuke Sugiyama
- Department of Immunology, Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - Keisuke Watanabe
- Division of Cancer Immunology, Exploratory Oncology Research & Clinical Trial Center, National Cancer Center, Research Institute, Tokyo, Japan
| | - Hiroyoshi Nishikawa
- Department of Immunology, Nagoya University Graduate School of Medicine, Nagoya, Japan.,Center for 5D Cell Dynamics, Nagoya University Graduate School of Medicine, Nagoya, Japan.,Division of Cancer Immunology, Exploratory Oncology Research & Clinical Trial Center, National Cancer Center, Research Institute, Tokyo, Japan.,Institute for Advanced Study, Nagoya University, Nagoya, Japan
| | - Kunihiko Hinohara
- Department of Immunology, Nagoya University Graduate School of Medicine, Nagoya, Japan.,Center for 5D Cell Dynamics, Nagoya University Graduate School of Medicine, Nagoya, Japan.,Institute for Advanced Study, Nagoya University, Nagoya, Japan
| |
Collapse
|
8
|
Matsumoto A, Naruse S, Isono Y, Maeda Y, Sato A, Yamada M, Ikeda T, Jinno H. Abstract P5-01-05: A Predictive Model for Axillary Pathologic Response after Neoadjuvant Chemotherapy for Clinically Node-Positive Breast Cancer. Cancer Res 2023. [DOI: 10.1158/1538-7445.sabcs22-p5-01-05] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/06/2023]
Abstract
Abstract
Purpose: Neoadjuvant chemotherapy (NAC) has resulted in the eradication of axillary lymph node metastasis in approximately 40% of patients. Sentinel lymph node biopsy (SLNB) could be an alternative surgical procedure for these patients to avoid complications from axillary lymph node dissection (ALND). However, high false-negative rates of SLNB for clinically node-positive patients were reported in previous prospective trials. The aim of the present study was to evaluate clinicopathological factors and imaging characteristics by MRI and ultrasound (US) as predictors of axillary pathologic complete response (ypN0) after NAC, which enables to identify candidates for SLNB in patients with clinically node-positive disease. Patients and methods: We identified 177 patients with clinically node-positive breast cancer who received NAC from May 2009 to May 2021. All patients underwent MRI and US before and after NAC. Patients were judged to be node-positive when they have the cytologically-proven nodal disease by fine-needle aspiration (FNA) or suspicious lymph nodes by diagnostic imaging. Lymph nodes with the cortical thickness (>3.5mm), loss of fatty hilum, or round shape (short-axis/long-axis ratio > 0.5) were defined as suspicious lymph nodes. To develop a predictive model for ypN0, the association between ypN0 status and clinicopathological and imaging characteristics was assessed by multivariate logistic regression analysis. The area under the receiver operating characteristic (ROC) curve was used to evaluate discrimination by the model. The model was further evaluated in the validation cohort with 20 patients who received NAC from March 2021 to December 2021. Results: The median age was 54.0 (range: 22-79) years and the mean tumor size was 3.97 ±2.29cm. Of 177 patients, 90 (50.8%) patients had luminal, 47 (26.6%) had HER2-positive, and 40 (22.6%) had triple-negative disease. Sequential anthracycline and taxane were administered for 157 (88.7%) patients, and 45 (95.7%) patients with HER2-positive-disease received concomitant anti-HER2 agents preoperatively. Overall, 77 (43.5%) patients achieved ypN0. Independent predictors of ypN0 status were clinical stage N1 (odds ratio [OR]: 9.17 vs. cN2-3, p=0.002), absence of lymphadenopathy after NAC (OR: 8.54, p< 0.001), breast complete response (CR) by MRI (OR: 5.96, p< 0.001), HER2 positivity (OR: 3.80, p=0.008), nuclear grade (NG) 3 (OR: 2.77 vs. NG1-2, P=0.020) and hormone receptor negativity (OR: 2.52, p=0.048). In a model using these predictors, the area under the ROC curve was 0.887 (95% confidence interval: 0.839-0.935, p< 0.001). The sensitivity, specificity, positive predictive value and negative predictive value of the model were 80.0%, 82.8%, 77.9% and 84.5%, respectively. In the validation cohort, the sensitivity, specificity, positive predictive value and negative predictive value were 66.7%, 90.9%, 85.7% and 76.9%, respectively. Among 84 patients who were predicted ypN0 by the model, SLNB was performed in 42 (50.0%) patients, and the identification rate of SLN was 95.2% (40/42). Overall, ALND was omitted in 38 (45.2%) patients and irradiation to regional lymph nodes was performed in 23 (60.5%) out of 38 patients. After a median follow-up of 53.9 months, 5-year recurrence-free survival was comparable between patients with or without ALND (78.0% vs. 94.4%, p=0.259). Conclusions: Our predictive model based on clinicopathological factors and imaging characteristics by MRI and US could help to identify good candidates for the omission of ALND after NAC in patients with clinically node-positive breast cancer.
Citation Format: Akiko Matsumoto, Saki Naruse, Yuka Isono, Yuka Maeda, Ayana Sato, Miki Yamada, Tatsuhiko Ikeda, Hiromitsu Jinno. A Predictive Model for Axillary Pathologic Response after Neoadjuvant Chemotherapy for Clinically Node-Positive Breast Cancer [abstract]. In: Proceedings of the 2022 San Antonio Breast Cancer Symposium; 2022 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2023;83(5 Suppl):Abstract nr P5-01-05.
Collapse
Affiliation(s)
- Akiko Matsumoto
- 1Department of Surgery, Teikyo University School of Medicine
| | - Saki Naruse
- 2Department of Surgery, Teikyo University School of Medicine
| | - Yuka Isono
- 3Department of Surgery, Teikyo University School of Medicine
| | - Yuka Maeda
- 4Department of Surgery, Teikyo University School of Medicine
| | - Ayana Sato
- 5Department of Surgery, Teikyo University School of Medicine
| | - Miki Yamada
- 6Department of Surgery, Teikyo University School of Medicine
| | - Tatsuhiko Ikeda
- 7Department of Surgery, Teikyo University School of Medicine
| | - Hiromitsu Jinno
- 8Department of Surgery, Teikyo University School of Medicine
| |
Collapse
|
9
|
Sawada H, Yabuuchi T, Higashi N, Iwasaki T, Kawasaki K, Maeda Y, Izumi T, Nakagawa Y, Shigemori K, Sakawa Y, Curry CB, Frost M, Iwata N, Ogitsu T, Sueda K, Togashi T, Glenzer SH, Kemp AJ, Ping Y, Sentoku Y. Ultrafast time-resolved 2D imaging of laser-driven fast electron transport in solid density matter using an x-ray free electron laser. Rev Sci Instrum 2023; 94:033511. [PMID: 37012804 DOI: 10.1063/5.0130953] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/16/2022] [Accepted: 03/08/2023] [Indexed: 06/19/2023]
Abstract
High-power, short-pulse laser-driven fast electrons can rapidly heat and ionize a high-density target before it hydrodynamically expands. The transport of such electrons within a solid target has been studied using two-dimensional (2D) imaging of electron-induced Kα radiation. However, it is currently limited to no or picosecond scale temporal resolutions. Here, we demonstrate femtosecond time-resolved 2D imaging of fast electron transport in a solid copper foil using the SACLA x-ray free electron laser (XFEL). An unfocused collimated x-ray beam produced transmission images with sub-micron and ∼10 fs resolutions. The XFEL beam, tuned to its photon energy slightly above the Cu K-edge, enabled 2D imaging of transmission changes induced by electron isochoric heating. Time-resolved measurements obtained by varying the time delay between the x-ray probe and the optical laser show that the signature of the electron-heated region expands at ∼25% of the speed of light in a picosecond duration. Time-integrated Cu Kα images support the electron energy and propagation distance observed with the transmission imaging. The x-ray near-edge transmission imaging with a tunable XFEL beam could be broadly applicable for imaging isochorically heated targets by laser-driven relativistic electrons, energetic protons, or an intense x-ray beam.
Collapse
Affiliation(s)
- H Sawada
- Department of Physics, University of Nevada, Reno, Nevada 89557, USA
| | - T Yabuuchi
- Japan Synchrotron Radiation Research Institute, Hyogo 679-5198, Japan
| | - N Higashi
- Institute of Laser Engineering, Osaka University, Suita 565-0871, Osaka, Japan
| | - T Iwasaki
- Institute of Laser Engineering, Osaka University, Suita 565-0871, Osaka, Japan
| | - K Kawasaki
- Institute of Laser Engineering, Osaka University, Suita 565-0871, Osaka, Japan
| | - Y Maeda
- Institute of Laser Engineering, Osaka University, Suita 565-0871, Osaka, Japan
| | - T Izumi
- Institute of Laser Engineering, Osaka University, Suita 565-0871, Osaka, Japan
| | - Y Nakagawa
- Institute of Laser Engineering, Osaka University, Suita 565-0871, Osaka, Japan
| | - K Shigemori
- Institute of Laser Engineering, Osaka University, Suita 565-0871, Osaka, Japan
| | - Y Sakawa
- Institute of Laser Engineering, Osaka University, Suita 565-0871, Osaka, Japan
| | - C B Curry
- SLAC National Accelerator Laboratory, Menlo Park, California 94025, USA
| | - M Frost
- SLAC National Accelerator Laboratory, Menlo Park, California 94025, USA
| | - N Iwata
- Institute of Laser Engineering, Osaka University, Suita 565-0871, Osaka, Japan
| | - T Ogitsu
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - K Sueda
- RIKEN SPring-8 Center, Hyogo 679-5148, Japan
| | - T Togashi
- Japan Synchrotron Radiation Research Institute, Hyogo 679-5198, Japan
| | - S H Glenzer
- SLAC National Accelerator Laboratory, Menlo Park, California 94025, USA
| | - A J Kemp
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - Y Ping
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - Y Sentoku
- Institute of Laser Engineering, Osaka University, Suita 565-0871, Osaka, Japan
| |
Collapse
|
10
|
Sato A, Matsumoto A, Naruse S, Isono Y, Maeda Y, Yamada M, Ikeda T, Sasajima Y, Jinno H. Acute arterial occlusive disease due to tumor thrombus from lung metastasis of breast cancer with cartilaginous and osseous metaplasia: a case report. Surg Case Rep 2023; 9:13. [PMID: 36723693 PMCID: PMC9892396 DOI: 10.1186/s40792-023-01598-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/04/2022] [Accepted: 01/24/2023] [Indexed: 02/02/2023] Open
Abstract
BACKGROUND Tumor embolization due to venous infiltration of breast cancer pulmonary metastases is very rare. CASE PRESENTATION A 72-year-old female was diagnosed with triple-negative breast cancer. Neoadjuvant chemotherapy was discontinued because of progressive disease, and a right mastectomy with sentinel lymph node biopsy was performed. The pathological analysis of surgical specimens revealed carcinoma with cartilaginous and/or osseous metaplasia. At 22 months after surgery, lung metastasis was observed, and 6 months after initiating treatment for lung metastases, she complained of sudden numbness in the left-lower limb with trouble walking. Ultrasonography showed an embolism in the left popliteal artery, and contrast computed tomography showed enlarged lung metastases and infiltration of the left-upper lobe disease into the left superior pulmonary vein and left atrium. Acute arterial occlusive disease in the left-lower limb caused by the tumor embolism was suspected, so an endovascular thrombectomy was performed. Tumor emboli were removed by embolectomy catheter. CONCLUSION This report of lung metastasis from breast cancer with cartilaginous and/or osseous metaplasia and acute lower-limb artery occlusion due to a tumor thrombus adds useful information to the literature on these extremely rare cases.
Collapse
Affiliation(s)
- Ayana Sato
- grid.264706.10000 0000 9239 9995Department of Surgery, Teikyo University School of Medicine, 2-11-1 Kaga, Itabashi, Tokyo, 173-8606 Japan
| | - Akiko Matsumoto
- grid.264706.10000 0000 9239 9995Department of Surgery, Teikyo University School of Medicine, 2-11-1 Kaga, Itabashi, Tokyo, 173-8606 Japan
| | - Saki Naruse
- grid.264706.10000 0000 9239 9995Department of Surgery, Teikyo University School of Medicine, 2-11-1 Kaga, Itabashi, Tokyo, 173-8606 Japan
| | - Yuka Isono
- grid.264706.10000 0000 9239 9995Department of Surgery, Teikyo University School of Medicine, 2-11-1 Kaga, Itabashi, Tokyo, 173-8606 Japan
| | - Yuka Maeda
- grid.264706.10000 0000 9239 9995Department of Surgery, Teikyo University School of Medicine, 2-11-1 Kaga, Itabashi, Tokyo, 173-8606 Japan
| | - Miki Yamada
- grid.264706.10000 0000 9239 9995Department of Surgery, Teikyo University School of Medicine, 2-11-1 Kaga, Itabashi, Tokyo, 173-8606 Japan
| | - Tatsuhiko Ikeda
- grid.264706.10000 0000 9239 9995Department of Surgery, Teikyo University School of Medicine, 2-11-1 Kaga, Itabashi, Tokyo, 173-8606 Japan
| | - Yuko Sasajima
- grid.264706.10000 0000 9239 9995Department of Pathology, Teikyo University School of Medicine, 2-11-1 Kaga, Itabashi, Tokyo, 173-8606 Japan
| | - Hiromitsu Jinno
- grid.264706.10000 0000 9239 9995Department of Surgery, Teikyo University School of Medicine, 2-11-1 Kaga, Itabashi, Tokyo, 173-8606 Japan
| |
Collapse
|
11
|
Tanikawa A, Fujihara T, Nakajima N, Maeda Y, Nogata Y, Yoshimura E, Okada Y, Chiba K, Kitano Y. Anti-Barnacle Activities of Isothiocyanates Derived from β-Citronellol and Their Structure-Activity Relationships. Chem Biodivers 2023; 20:e202200953. [PMID: 36567259 DOI: 10.1002/cbdv.202200953] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/05/2022] [Revised: 12/19/2022] [Accepted: 12/23/2022] [Indexed: 12/27/2022]
Abstract
Antifouling agents with low toxicity are in high demand for sustaining marine industries and the environment. This study aimed to synthesize 15 isothiocyanates derived from β-citronellol and evaluate their antifouling activities and toxicities against cypris larvae of the barnacle Amphibalanus amphitrite. The synthesized isothiocyanates exhibited effective antifouling activities (EC50 =0.10-3.33 μg mL-1 ) with high therapeutic ratios (LC50 /EC50 >30). Four isothiocyanates with an amide or isocyano group showed great potential as effective antifouling agents (EC50 =0.10-0.32 μg mL-1 , LC50 /EC50 =104-833). The enantiomers of the isothiocyanates only slightly differed in their antifouling activities. These results may serve as a basis for further research and development of β-citronellol-derived isothiocyanates as effective low-toxic antifouling agents. To the best of our knowledge, this study is the first to report the antifouling activities of isothiocyanates derived from accessible natural products.
Collapse
Affiliation(s)
- Aina Tanikawa
- Laboratory of Bio-organic Chemistry, Tokyo University of Agriculture and Technology, 3-5-8 Saiwai-cho, Fuchu-shi, Tokyo, 183-8509, Japan
| | - Takaya Fujihara
- Laboratory of Bio-organic Chemistry, Tokyo University of Agriculture and Technology, 3-5-8 Saiwai-cho, Fuchu-shi, Tokyo, 183-8509, Japan
| | - Natsumi Nakajima
- Laboratory of Bio-organic Chemistry, Tokyo University of Agriculture and Technology, 3-5-8 Saiwai-cho, Fuchu-shi, Tokyo, 183-8509, Japan
| | - Yuka Maeda
- Laboratory of Bio-organic Chemistry, Tokyo University of Agriculture and Technology, 3-5-8 Saiwai-cho, Fuchu-shi, Tokyo, 183-8509, Japan
| | - Yasuyuki Nogata
- Sustainable System Research Laboratory, Central Research Institute of Electric Power Industry, 1646 Abiko, Abiko-shi, Chiba, 270-1194, Japan
| | | | - Yohei Okada
- Laboratory of Bio-organic Chemistry, Tokyo University of Agriculture and Technology, 3-5-8 Saiwai-cho, Fuchu-shi, Tokyo, 183-8509, Japan
| | - Kazuhiro Chiba
- Laboratory of Bio-organic Chemistry, Tokyo University of Agriculture and Technology, 3-5-8 Saiwai-cho, Fuchu-shi, Tokyo, 183-8509, Japan
| | - Yoshikazu Kitano
- Laboratory of Bio-organic Chemistry, Tokyo University of Agriculture and Technology, 3-5-8 Saiwai-cho, Fuchu-shi, Tokyo, 183-8509, Japan
| |
Collapse
|
12
|
Nakatsubo D, Maeda Y, Hosokawa K, Kawada S, Okamoto M, Shimagami H, Tada T, Kiyokawa H, Sato K, Tahara S, Morii E, Narazaki M, Kumanogoh A. A case of relapsing polychondritis localized to the laryngeal cartilage in which FDG-PET/CT was helpful for diagnosis. Scand J Rheumatol 2023; 52:102-104. [PMID: 35946909 DOI: 10.1080/03009742.2022.2103937] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/05/2023]
Affiliation(s)
- D Nakatsubo
- Department of Respiratory Medicine and Clinical Immunology, Osaka University Graduate School of Medicine, Osaka, Japan
| | - Y Maeda
- Department of Respiratory Medicine and Clinical Immunology, Osaka University Graduate School of Medicine, Osaka, Japan
| | - K Hosokawa
- Department of Otorhinolaryngology-Head and Neck Surgery, Osaka University Graduate School of Medicine, Osaka, Japan
| | - S Kawada
- Department of Respiratory Medicine and Clinical Immunology, Osaka University Graduate School of Medicine, Osaka, Japan
| | - M Okamoto
- Department of Respiratory Medicine and Clinical Immunology, Osaka University Graduate School of Medicine, Osaka, Japan
| | - H Shimagami
- Department of Respiratory Medicine and Clinical Immunology, Osaka University Graduate School of Medicine, Osaka, Japan
| | - T Tada
- Department of Respiratory Medicine and Clinical Immunology, Osaka University Graduate School of Medicine, Osaka, Japan
| | - H Kiyokawa
- Department of Pathology, Osaka University Graduate School of Medicine, Osaka, Japan
| | - K Sato
- Department of Pathology, Osaka University Graduate School of Medicine, Osaka, Japan
| | - S Tahara
- Department of Pathology, Osaka University Graduate School of Medicine, Osaka, Japan
| | - E Morii
- Department of Pathology, Osaka University Graduate School of Medicine, Osaka, Japan
| | - M Narazaki
- Department of Respiratory Medicine and Clinical Immunology, Osaka University Graduate School of Medicine, Osaka, Japan
| | - A Kumanogoh
- Department of Respiratory Medicine and Clinical Immunology, Osaka University Graduate School of Medicine, Osaka, Japan.,Department of Immunopathology, WPI, Immunology Frontier Research Center (iFReC) Osaka University, Osaka, Japan.,Integrated Frontier Research for Medical Science Division, Institute for Open and Transdisciplinary Research Initiatives (OTRI) Osaka University, Osaka, Japan.,Center for Infectious Disease for Education and Research (CiDER), Osaka University, Osaka, Japan
| |
Collapse
|
13
|
Maeda Y, Nishimura K, Terada F, Kushibiki S. Developing models to predict feces and urine excretion in Japanese Black fattening steer by multiple regression analysis. Anim Sci J 2023; 94:e13874. [PMID: 37731178 DOI: 10.1111/asj.13874] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/12/2023] [Revised: 08/24/2023] [Accepted: 08/28/2023] [Indexed: 09/22/2023]
Abstract
The objective of this study was to develop models for predicting the amount of feces and urine excreted by Japanese Black fattening steer using a dataset of 119 digestion trials for a total of 46 animals. Correlation analysis was used to analyze the relationships between feces and urine excretion and feed intake, feed digestibility, and nitrogen balance. Multiple regression analysis was conducted to develop models for predicting the amount of feces and urine excreted using the explanatory variables selected from various animal and dietary parameters based on P-value (<0.10) and variance inflation factor (<3.0). Resultingly, dry matter intake was a primary predictor of feces excreted. The prediction equation for the amount of feces excretion as a function of body weight, dry matter intake, and calculated total digestible nutrients fits the data well (adjusted coefficient of determination [adj R2 ] = 0.519, root mean square error = 1.57). Furthermore, the nitrogen content in the urine was the primary predictor of the urine excretion amount. Thus, the prediction equation for the amount of urine excreted using the nitrogen content in urine yielded a highly accurate model (adj R2 = 0.813, root mean square error = 4.12).
Collapse
Affiliation(s)
- Yuka Maeda
- Miyazaki Livestock Research Institute, Miyazaki, Japan
| | | | | | - Shiro Kushibiki
- Institute of Livestock and Grassland Science, NARO, Ibaraki, Japan
| |
Collapse
|
14
|
Kodate N, Maeda Y, Hauray B, Tsujimura M, Chan WCH, Mannan H, Yu W, Dalgalarrondo S, Cheung MC, Yumoto A, Suwa S, Donnelly S, Sakata N, O’Shea D, Obayashi K, Masuyama S. Hopes and fears regarding care robots: Content analysis of newspapers in East Asia and Western Europe, 2001-2020. Front Rehabil Sci 2022; 3:1019089. [PMID: 36569638 PMCID: PMC9773842 DOI: 10.3389/fresc.2022.1019089] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 08/14/2022] [Accepted: 11/08/2022] [Indexed: 12/14/2022]
Abstract
Background As a type of welfare technology, care robotics is now widely seen as a potential aide to rehabilitation, increasing independence and enhancing the wellbeing of people with disabilities and older adults. Research into and development of care robots have both been vigorously promoted in North America, Europe and Asia, and the competition for technological advancement in robotics is becoming fierce. AI ethics and policy guidelines are being established. However, there are still differences in attitudes and perceptions, as well as national policies regarding this type of welfare technology. Moreover, despite the anticipated usefulness, it is believed that progress has been slow in the diffusion of care robots. Purpose In order to explore how public discourses support technological innovation, such as care robots, while preparing society for potential risks and impact, we sought to ascertain whether public discourse on care robots varies from region to region. For example, what are the hopes and promises associated with care robots and what are the concerns? Methods To address these questions, this article explored how care robots have been portrayed in five major broadsheet newspapers in five jurisdictions in Asia and Europe (France, Great Britain, Hong Kong SAR, Ireland and Japan). We obtained 545 articles for the period between January 2001 and September 2020, more than half of which originated in Japan. A thematic analysis was conducted of these articles written in four languages (Chinese, English, French and Japanese). Results Positive and negative narratives were teased out, alongside other key prominent themes identified, such as Japan as the land of robots, the pandemic, and the impact of robots on the economy. As the number of robot-related articles grew from the year 2012 onwards, narratives became more nuanced in European newspapers, but not in Asian ones. Furthermore, recent articles began to address the social and relational impact of care robots, while providing concrete examples of improvements in the quality of life for users. Further careful examination will be necessary in the future in order to establish the impact of robotics use in rehabilitation for people with disabilities, older adults, their carers and society at large.
Collapse
Affiliation(s)
- N. Kodate
- School of Social Policy, Social Work and Social Justice, University College Dublin, Dublin, Ireland,Public Policy Research Center, Hokkaido University, Sapporo, Japan,La Fondation France-Japon, School for Advanced Studies in the Social Sciences (EHESS), Paris, France,Institute for Future Initiatives, University of Tokyo, Tokyo, Japan,Universal Accessibility and Ageing Research Centre, Nishitokyo, Japan,Correspondence: N. Kodate
| | - Y. Maeda
- Faculty of Business, Technological University DublinDublin, Ireland
| | - B. Hauray
- Institut de recherche interdisciplinaire sur les enjeux sociaux, School for Advanced Studies in the Social Sciences (EHESS), Paris, France,French National Institute of Health and Medical Research (INSERM), Paris, France
| | - M. Tsujimura
- School of Nursing, Shiga University of Medical Science, Otsu, Japan
| | - W. C. H. Chan
- Department of Social Work, The Chinese University of Hong Kong, Hong Kong, Hong Kong SAR, China
| | - H. Mannan
- School of Nursing, Midwifery and Health Systems, University College Dublin, Dublin, Ireland,Flame University, Pune, India
| | - W. Yu
- Center for Frontier Medical Engineering, Chiba University, Chiba, Japan
| | - S. Dalgalarrondo
- Institut de recherche interdisciplinaire sur les enjeux sociaux, School for Advanced Studies in the Social Sciences (EHESS), Paris, France,French National Centre for Scientific Research (CNRS), Paris, France
| | - M. C. Cheung
- Department of Social Work, The Chinese University of Hong Kong, Hong Kong, Hong Kong SAR, China
| | - A. Yumoto
- Graduate School of Nursing, Chiba University, Chiba, Japan
| | - S. Suwa
- Graduate School of Nursing, Chiba University, Chiba, Japan
| | - S. Donnelly
- School of Social Policy, Social Work and Social Justice, University College Dublin, Dublin, Ireland
| | - N. Sakata
- Center for Information and Communication Technology, Dokkyo Medical University, Mibu, Japan
| | - D. O’Shea
- St Vincent’s University Hospital, Dublin, Ireland,Royal College of Physicians of Ireland, Dublin, Ireland
| | - K. Obayashi
- Universal Accessibility and Ageing Research Centre, Nishitokyo, Japan,Faculty of Healthcare Management, Nihon Fukushi University, Mihama, Japan,Social Welfare Corporation Tokyo Seishin-kai, Nishitokyo, Japan
| | - S. Masuyama
- Universal Accessibility and Ageing Research Centre, Nishitokyo, Japan,Traveler’s Medical Center, Tokyo Medical University, Tokyo, Japan
| |
Collapse
|
15
|
Maeda Y, Fujikura C, Asama T, Yagi M, Okumura N, Yamaki A, Ohkuma A, Numano K. Effect of facial application of essence containing royal jelly extract on stratum corneum moisture content: A placebo-controlled, double-blind, parallel-group study. J Cosmet Dermatol 2022; 21:5747-5754. [PMID: 35778882 DOI: 10.1111/jocd.15168] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/03/2021] [Revised: 05/13/2022] [Accepted: 06/15/2022] [Indexed: 01/06/2023]
Abstract
OBJECTIVES To evaluate the moisturizing function and other effects of royal jelly extract on the skin. The effects of applying an essence containing royal jelly extract on the skin of healthy Japanese males and females were examined. METHODS Thirty-five healthy Japanese men and women who were aware of their skin dryness applied an essence containing royal jelly extract or placebo for 4 weeks using the split-face method in a placebo-controlled, double-blind, parallel comparative study. The stratum corneum water content, transepidermal water evaporation, pigmentation, pores, and redness were evaluated. RESULTS The stratum corneum water content significantly increased by the application of essence containing royal jelly extract to the cheeks for 4 weeks compared with placebo. CONCLUSION The application of an essence containing royal jelly extract significantly improved the moisture content of the stratum corneum of the cheeks, confirming the improvement in the moisturizing function of the royal jelly extract. Furthermore, no adverse events were observed at the application site during the application period, and the test products and royal jelly extract contained in the test product were considered highly safe.
Collapse
Affiliation(s)
- Yuka Maeda
- Group Cosmetics Central Laboratory, R&D Department, Yamada Bee Company, Inc., Tokyo, Japan
| | - Chizuru Fujikura
- Institute for Bee Products and Health Science, R&D Department, Yamada Bee Company, Inc., Okayama, Japan
| | - Takashi Asama
- Institute for Bee Products and Health Science, R&D Department, Yamada Bee Company, Inc., Okayama, Japan
| | - Masayuki Yagi
- Group Cosmetics Central Laboratory, R&D Department, Yamada Bee Company, Inc., Tokyo, Japan
| | - Nobuaki Okumura
- Group Cosmetics Central Laboratory, R&D Department, Yamada Bee Company, Inc., Tokyo, Japan.,Institute for Bee Products and Health Science, R&D Department, Yamada Bee Company, Inc., Okayama, Japan
| | - Ayanori Yamaki
- Institute for Bee Products and Health Science, R&D Department, Yamada Bee Company, Inc., Okayama, Japan
| | - Akio Ohkuma
- Research Center for Immunological Analysis, Inc., Okayama, Japan
| | | |
Collapse
|
16
|
Kodate N, Kohli P, McGinn C, Scott R, Ross E, Treusch P, Maeda Y, Donnelly S, Leonard C, Cogan L, Mannan H, O’Shea D, Obayashi K, Masuyama S. 43 EXPLORING STAFF PERCEPTIONS AND ATTITUDES TO CARE AND CAREBOTS: THE CASE OF AN ORIGINAL AIR-DISINFECTION ROBOT IN IRELAND. Age Ageing 2022. [DOI: 10.1093/ageing/afac218.034] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Background
The pandemic heightened the sense of security and safety in care settings, with cleanliness and infection control becoming an even more important aspect of care delivery. Although the impact of new welfare technology on health and social care has been discussed in recent years, few studies have reported the implementation processes or human-robot interactions in care facilities in different cultural settings. The aims of this interdisciplinary research therefore were to understand needs and aspects that have to be considered for implementing an assistive robot, and to explore user perceptions, and the process by which the robots are adopted in Ireland and Japan.
Methods
An original air-disinfection robot (V-Air) was developed by Akara Robotics, as part of research project “Harmonisation towards the establishment of Person-centred, Robotics-aided Care System” (Toyota Foundation, D18-ST-0005). Prior to its instalment in a rehabilitation centre in Dublin, semi-structured interviews were conducted, and observations carried out with seven care professionals, as they interacted with V-Air. The robot was then trialled for eight weeks (March-May 2022) in selected areas of the facility. After four weeks, the users filled out the System Usability Score and were asked questions at the end of the trial. Their scores and answers to the questions revealed staff perceptions and attitudes to care robots.
Results
Overall, the users had positive perceptions of V-Air and its usability. Initial differences existed in staff’s confidence levels, depending on prior experiences with technologies. Collective sensemaking was observed, particularly, around care delivery processes and robot functionalities. The adoption process was facilitated by several factors such as the timing of introduction, user-centred design, concept of care and organisational support.
Conclusion
The findings suggest that the introduction of care robots in care settings can offer an additional layer of organisational safety, while highlighting the significance of the iterative process in adopting assistive technologies.
Collapse
Affiliation(s)
- N Kodate
- University College Dublin School of Social Policy, Social Work and Social Justice, , Dublin, Ireland
- Universal Accessibility & Ageing Research Centre , Nishitokyo, Japan
- Hokkaido University Public Policy Research Center, , Sapporo, Japan
- L’École des Hautes Etudes En Sciences Sociales, Fondation France Japon , Paris, France
- University of Tokyo Institute for Future Initiatives, , Tokyo, Japan
| | - P Kohli
- Maynooth University Department of Sociology, , Maynooth, Ireland
| | - C McGinn
- Trinity College Dublin Department of Mechanical, Manufacturing & Biomedical Engineering, , Dublin, Ireland
- Akara Robotics , Dublin, Ireland
| | - R Scott
- Akara Robotics , Dublin, Ireland
| | - E Ross
- Royal Hospital Donnybrook , Dublin, Ireland
| | - P Treusch
- Trinity College Dublin Trinity Long Room Hub, , Dublin, Ireland
| | - Y Maeda
- Technological University Dublin , Dublin, Ireland
| | - S Donnelly
- University College Dublin School of Social Policy, Social Work and Social Justice, , Dublin, Ireland
| | - C Leonard
- Royal Hospital Donnybrook , Dublin, Ireland
| | - L Cogan
- Royal Hospital Donnybrook , Dublin, Ireland
| | - H Mannan
- University College Dublin School of Nursing, Midwifery and Health System, , Dublin, Ireland
| | - D O’Shea
- St. Vincent’s University Hospital , Dublin, Ireland
| | - K Obayashi
- Nihon Fukushi University Faculty of Healthcare Management, , Mihama, Japan
- Social Welfare Corporation Tokyo Seishin-kai , Nishitokyo, Japan
| | | |
Collapse
|
17
|
Hodgkinson J, Al-Kizwini E, Leo CA, Maeda Y, Constantinides J, Mehta A, Warusavitarne J, Vaizey C. OC-001 SINGLE-STAGED ABDOMINAL WALL RECONSTRUCTION IN CONJUNCTION WITH ENTEROCUTANEOUS FISTULA REPAIR WITH AND WITHOUT ACELLULAR DERMAL MATRICES: A SINGLE CENTRE OBSERVATIONAL COMPARISON OF SHORT-TERM OUTCOMES. Br J Surg 2022. [DOI: 10.1093/bjs/znac308.013] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
Abstract
Aim
Single-staged abdominal wall reconstruction (AWR) with simultaneous enterocutaneous fistula (ECF) repair is safe. This study aims to evaluate short-term outcomes from AWR with ECF repair and compare short-term outcomes between two commonly used acellular dermal matrices (ADM) as well as suture repair alone, with focus on ECF recurrence.
Methods
Data were collected between 2011 and 2019 from a prospectively maintained operative database. A retrospective case-note review identifed patient demographics and post-operative outcomes. Kruskal-Wallis test was used for categorical variables and one-way ANOVA for continuous variables to evaluate between groups.
Results
One hundred and fifteen cases were performed in the study period: 70 primary suture repair, 28 Surgimend and 17 Strattice. Fifty-eight patients (50.4%) were female with a mean age of 55.3 years (SD 13.9), BMI of 26.9 (SD 5.18) and 75 (65.2%) had intestinal failure. Median length of stay was 25 days (range 7–176).
Overall, fistula recurrence rate was 10.4% (12 cases). Of these, 9 (12.8%) occurred in the suture repair group, 2 (11.8%) where a Strattice mesh was used and 1 (3.6%) where a Surgimend mesh was used (p=0.54). Forty-six patients (40%) had a Clavien Dindo complication of >3 and 73 patients (53.2%) had an SSI. Mortality was low at 2.8%.
Conclusion
Single-staged AWR in conjunction with ECF repair remains a complex but safe undertaking. Initial experience suggests Surgimend is safe to use in the context of single-staged AWR and ECF recurrence rates are lower than with a comparable ADM with similar short-term outcomes.
Collapse
Affiliation(s)
- J Hodgkinson
- Colorectal Surgery, St Mark's Hospital , London , United Kingdom
| | - E Al-Kizwini
- Colorectal Surgery, St Mark's Hospital , London , United Kingdom
| | - C A Leo
- Colorectal Surgery, St Mark's Hospital , London , United Kingdom
| | - Y Maeda
- Colorectal Surgery, St Mark's Hospital , London , United Kingdom
| | - J Constantinides
- Colorectal Surgery, St Mark's Hospital , London , United Kingdom
| | - A Mehta
- Colorectal Surgery, St Mark's Hospital , London , United Kingdom
| | - J Warusavitarne
- Colorectal Surgery, St Mark's Hospital , London , United Kingdom
| | - C Vaizey
- Colorectal Surgery, St Mark's Hospital , London , United Kingdom
| |
Collapse
|
18
|
Yamada M, Jinno H, Maeda Y, Sato A, Matsumoto A, Ikeda T, Sasajima Y. Management of Crohn’s disease relapse during neoadjuvant chemotherapy for bilateral breast cancer: a case report. Oxf Med Case Reports 2022; 2022:omac095. [PMID: 36176955 PMCID: PMC9514111 DOI: 10.1093/omcr/omac095] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/24/2022] [Revised: 07/17/2022] [Accepted: 08/01/2022] [Indexed: 11/19/2022] Open
Abstract
Diagnosis of breast cancer in a patient with Crohn’s disease (CD) is uncommon. However, cytotoxic chemotherapy might help control CD during the treatment period. Here, we report a case of CD relapse during treatment with neoadjuvant chemotherapy (NAC) for bilateral breast cancer. A 39-year-old woman with CD controlled by infliximab and mesalazine was diagnosed with bilateral breast cancer. Infliximab treatment was discontinued temporarily so that the patient could receive NAC. However, her CD symptoms intensified during chemotherapy, and after her symptoms improved after a one-time administration of infliximab, the remainder of NAC was completed with a corticosteroid. Bilateral breast conservation surgery was performed. Histopathological examination revealed partial response of the left breast cancer and no residual cancer in the right breast. Breast irradiation and hormone therapy were added and no signs of recurrence have been observed for 5 years. CD has been well controlled with adalimumab and mesalazine.
Collapse
Affiliation(s)
- Miki Yamada
- Teikyo University School of Medicine Department of Surgery, , Tokyo, Japan
| | - Hiromitsu Jinno
- Teikyo University School of Medicine Department of Surgery, , Tokyo, Japan
| | - Yuka Maeda
- Teikyo University School of Medicine Department of Surgery, , Tokyo, Japan
| | - Ayana Sato
- Teikyo University School of Medicine Department of Surgery, , Tokyo, Japan
| | - Akiko Matsumoto
- Teikyo University School of Medicine Department of Surgery, , Tokyo, Japan
| | - Tatsuhiko Ikeda
- Teikyo University School of Medicine Department of Surgery, , Tokyo, Japan
| | - Yuko Sasajima
- Teikyo University School of Medicine Department of Pathology, , Tokyo, Japan
| |
Collapse
|
19
|
Kelkka T, Tyster M, Lundgren S, Feng X, Kerr C, Hosokawa K, Huuhtanen J, Keränen M, Patel B, Kawakami T, Maeda Y, Nieminen O, Kasanen T, Aronen P, Yadav B, Rajala H, Nakazawa H, Jaatinen T, Hellström-Lindberg E, Ogawa S, Ishida F, Nishikawa H, Nakao S, Maciejewski J, Young NS, Mustjoki S. Anti-COX-2 autoantibody is a novel biomarker of immune aplastic anemia. Leukemia 2022; 36:2317-2327. [PMID: 35927326 PMCID: PMC9417997 DOI: 10.1038/s41375-022-01654-6] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/13/2022] [Revised: 07/06/2022] [Accepted: 07/11/2022] [Indexed: 11/09/2022]
Abstract
In immune aplastic anemia (IAA), severe pancytopenia results from the immune-mediated destruction of hematopoietic stem cells. Several autoantibodies have been reported, but no clinically applicable autoantibody tests are available for IAA. We screened autoantibodies using a microarray containing >9000 proteins and validated the findings in a large international cohort of IAA patients (n = 405) and controls (n = 815). We identified a novel autoantibody that binds to the C-terminal end of cyclooxygenase 2 (COX-2, aCOX-2 Ab). In total, 37% of all adult IAA patients tested positive for aCOX-2 Ab, while only 1.7% of the controls were aCOX-2 Ab positive. Sporadic non-IAA aCOX-2 Ab positive cases were observed among patients with related bone marrow failure diseases, multiple sclerosis, and type I diabetes, whereas no aCOX-2 Ab seropositivity was detected in the healthy controls, in patients with non-autoinflammatory diseases or rheumatoid arthritis. In IAA, anti-COX-2 Ab positivity correlated with age and the HLA-DRB1*15:01 genotype. 83% of the >40 years old IAA patients with HLA-DRB1*15:01 were anti-COX-2 Ab positive, indicating an excellent sensitivity in this group. aCOX-2 Ab positive IAA patients also presented lower platelet counts. Our results suggest that aCOX-2 Ab defines a distinct subgroup of IAA and may serve as a valuable disease biomarker.
Collapse
Affiliation(s)
- Tiina Kelkka
- Hematology Research Unit Helsinki, University of Helsinki and Department of Hematology, Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland.,Translational Immunology Research Program and Department of Clinical Chemistry and Hematology, University of Helsinki, Helsinki, Finland
| | - Mikko Tyster
- Hematology Research Unit Helsinki, University of Helsinki and Department of Hematology, Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland.,Translational Immunology Research Program and Department of Clinical Chemistry and Hematology, University of Helsinki, Helsinki, Finland
| | - Sofie Lundgren
- Hematology Research Unit Helsinki, University of Helsinki and Department of Hematology, Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland.,Translational Immunology Research Program and Department of Clinical Chemistry and Hematology, University of Helsinki, Helsinki, Finland
| | - Xingmin Feng
- Hematology Branch, National Heart, Lung, and Blood Institute, NIH, Bethesda, MD, USA
| | - Cassandra Kerr
- Department of Translational Hematology and Oncology Research and Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA
| | - Kohei Hosokawa
- Department of Hematology, Faculty of Medicine, Institute of Medical Pharmaceutical and Health Sciences, Kanazawa University, Kanazawa, Japan
| | - Jani Huuhtanen
- Hematology Research Unit Helsinki, University of Helsinki and Department of Hematology, Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland.,Translational Immunology Research Program and Department of Clinical Chemistry and Hematology, University of Helsinki, Helsinki, Finland
| | - Mikko Keränen
- Hematology Research Unit Helsinki, University of Helsinki and Department of Hematology, Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland.,Translational Immunology Research Program and Department of Clinical Chemistry and Hematology, University of Helsinki, Helsinki, Finland
| | - Bhavisha Patel
- Hematology Branch, National Heart, Lung, and Blood Institute, NIH, Bethesda, MD, USA
| | - Toru Kawakami
- Division of Hematology, Department of Internal Medicine, Shinshu University School of Medicine, Matsumoto, Japan
| | - Yuka Maeda
- Division of Cancer Immunology, Research Institute/Exploratory Oncology Research and Clinical Trial Center, National Cancer Center Japan, Tokyo, Japan
| | - Otso Nieminen
- Hematology Research Unit Helsinki, University of Helsinki and Department of Hematology, Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland.,Translational Immunology Research Program and Department of Clinical Chemistry and Hematology, University of Helsinki, Helsinki, Finland
| | - Tiina Kasanen
- Hematology Research Unit Helsinki, University of Helsinki and Department of Hematology, Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland.,Translational Immunology Research Program and Department of Clinical Chemistry and Hematology, University of Helsinki, Helsinki, Finland
| | - Pasi Aronen
- Biostatistics Unit, Faculty of Medicine, University of Helsinki and Helsinki-Uusimaa Hospital District, Helsinki, Finland
| | - Bhagwan Yadav
- Hematology Research Unit Helsinki, University of Helsinki and Department of Hematology, Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland.,Translational Immunology Research Program and Department of Clinical Chemistry and Hematology, University of Helsinki, Helsinki, Finland
| | - Hanna Rajala
- Hematology Research Unit Helsinki, University of Helsinki and Department of Hematology, Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland.,Translational Immunology Research Program and Department of Clinical Chemistry and Hematology, University of Helsinki, Helsinki, Finland
| | - Hideyuki Nakazawa
- Department of Hematology, Shinshu University School of Medicine, Matsumoto, Japan
| | - Taina Jaatinen
- Histocompatibility Testing Laboratory, Finnish Red Cross Blood Service, Helsinki, Finland
| | - Eva Hellström-Lindberg
- Division of Hematology, Department of Medicine, Karolinska University Hospital, Stockholm, Sweden
| | - Seishi Ogawa
- Department of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Kyoto, Japan
| | - Fumihiro Ishida
- Department of Biomedical Laboratory Sciences, Shinshu University School of Medicine, Matsumoto, Japan
| | - Hiroyoshi Nishikawa
- Division of Cancer Immunology, Research Institute/Exploratory Oncology Research and Clinical Trial Center, National Cancer Center Japan, Tokyo, Japan
| | - Shinji Nakao
- Department of Hematology, Faculty of Medicine, Institute of Medical Pharmaceutical and Health Sciences, Kanazawa University, Kanazawa, Japan
| | - Jaroslaw Maciejewski
- Department of Translational Hematology and Oncology Research and Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA
| | - Neal S Young
- Hematology Branch, National Heart, Lung, and Blood Institute, NIH, Bethesda, MD, USA
| | - Satu Mustjoki
- Hematology Research Unit Helsinki, University of Helsinki and Department of Hematology, Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland. .,Translational Immunology Research Program and Department of Clinical Chemistry and Hematology, University of Helsinki, Helsinki, Finland. .,iCAN Digital Precision Cancer Medicine Flagship, Helsinki, Finland.
| |
Collapse
|
20
|
Watanabe R, Okano T, Yamada S, Yamamoto W, Murata K, Murakami K, Ebina K, Maeda Y, Jinno S, Shirasugi I, Son Y, Amuro H, Katayama M, Hara R, Hata K, Yoshikawa A, Hashimoto M. POS0532 DRUG RETENTION OF BIOLOGICS OR JAK INHIBITORS IN PATIENTS WITH DIFFICULT-TO-TREAT RHEUMATOID ARTHRITIS: RESULTS FROM THE ANSWER COHORT. Ann Rheum Dis 2022. [DOI: 10.1136/annrheumdis-2022-eular.1994] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
BackgroundDifficult-to-treat rheumatoid arthritis (D2T RA) is defined as RA in which disease activity is uncontrolled despite the use of two or more biologics or Janus kinase inhibitors (JAKi) with different mechanisms of action (MOA).ObjectivesTo explore the optimal treatment strategy for D2T RA, we evaluated the drug retention, efficacy, and reasons for discontinuation of biologics or JAKi used for patients with D2T RA in a longitudinal multicenter cohort.MethodsRA patients with clinical disease activity index (CDAI) >10 despite the use of at least two biologics or JAKi with different MOA and further treated with biologics or JAKi were included. The drug retention rates of biologics (TNFi, IL-6Ri, and CTLA4-Ig) or JAKi were estimated at 12 months using the Kaplan-Meier method and adjusted for potential confounders (age, sex, disease duration, concomitant MTX and PSL use, and the number of switched biologics or JAKi) using Cox proportional hazards models.ResultsA total of 251 treatment courses (TCs) from 167 patients were included (TNFi: 97 TCs, IL-6Ri: 67 TCs, CTLA4-Ig: 27 TCs, JAKi: 60 TCs). Baseline characteristics showed no difference in age, sex, disease duration, ACPA positivity, CDAI, and concomitant MTX and PSL use between the four groups. Drug retention excluding non-toxic reasons and remission was significantly higher in patients treated with JAKi or IL-6Ri than in patients treated with TNFi or CTLA4-Ig (P=0.00172). Multivariate analysis using Cox proportional hazards models demonstrated that discontinuation of the drug was associated with the use of TNFi or CTLA4-Ig (HR: 3.29, 95%CI: 1.15-9.42, P=0.027) and concomitant PSL use (HR: 1.14, 95%CI: 1.04-1.26, P=0.0084). In terms of disease activity evaluated with CDAI, no difference was observed between the four groups at 3 months (P=0.90), at 6 months (P=0.77), and at 12 months (P=0.75).ConclusionIn patients with D2T RA, JAKi or IL-6Ri may have treatment advantages compared with TNFi or CTLA4-Ig.References[1] EULAR definition of difficult-to-treat rheumatoid arthritis.Nagy G, Roodenrijs NMT, Welsing PM, Kedves M, Hamar A, van der Goes MC, Kent A, Bakkers M, Blaas E, Senolt L, Szekanecz Z, Choy E, Dougados M, Jacobs JW, Geenen R, Bijlsma HW, Zink A, Aletaha D, Schoneveld L, van Riel P, Gutermann L, Prior Y, Nikiphorou E, Ferraccioli G, Schett G, Hyrich KL, Mueller-Ladner U, Buch MH, McInnes IB, van der Heijde D, van Laar JM.Ann Rheum Dis. 2021 Jan;80(1):31-35.[2] Prevalence and predictive factors of difficult-to-treat rheumatoid arthritis: the KURAMA cohort.Watanabe R, Hashimoto M, Murata K, Murakami K, Tanaka M, Ohmura K, Ito H, Matsuda S.Immunol Med. 2021 May 25:1-10.Disclosure of InterestsRyu Watanabe Speakers bureau: Eli Lilly, Mitsubishi Tanabe, Pfizer, Sanofi, AbbVie, Asahi Kasei, Eisai, Bristol-Myers Squibb, UCB Japan, Chugai, Janssen, Astellas, Nippon Shinyaku, Daiichi Sankyo, Gilead Sciences Japan, and Boehringer ingelheim., Tadashi Okano Speakers bureau: Asahi Kasei, Astellas, Abbvie, Amgen, Ayumi, Chugai, Daiichi-Sankyo, Eisai, Eli Lilly, Gilead Sciences, Janssen, Kyowa Kirin, Mitsubishi Tanabe, Novartis, Ono, Pfizer, Sanofi, Takeda, UCB, Grant/research support from: Asahi Kasei, Abbvie, Chugai, Eisai, Mitsubishi Tanabe, Shinsuke Yamada: None declared, Wataru Yamamoto: None declared, Koichi Murata Speakers bureau: Eisai Co., Ltd., Chugai Pharmaceutical Co., Ltd.; Asahi Kasei Pharma Corp.; and Mitsubishi Tanabe Pharma Co., and Daiichi Sankyo Co. Ltd., Kosaku Murakami: None declared, Kosuke Ebina Speakers bureau: AbbVie, Amgen, Asahi-Kasei, Astellas, Ayumi, Bristol-Myers Squibb, Chugai, Eisai, Eli Lilly, Janssen, Mitsubishi-Tanabe, Ono Pharmaceutical, Pfizer, Sanofi, and UCB Japan., Grant/research support from: AbbVie, Amgen, Asahi-Kasei, Astellas, Chugai, Eisai, Mitsubishi-Tanabe, Ono Pharmaceutical, Teijin Pharma, and UCB Japan, Yuichi Maeda Speakers bureau: Eli Lilly Japan K.K., Chugai Pharmaceutical Co. Ltd., Pfizer Inc., Bristol Myers Squibb, and Mitsubishi Tanabe Pharma Corporation., Sadao Jinno Speakers bureau: AbbVie G.K., Asahi Kasei Pharma., Bristol-Myers Squibb., Chugai Pharmaceutical Co., Ltd., Eisai Co., Ltd., Eli Lilly Japan K.K., Janssen Pharmaceutical K.K., and Mitsubishi Tanabe Pharma, and Ono Pharmaceutical Co, Iku Shirasugi: None declared, Yonsu Son: None declared, Hideki Amuro Speakers bureau: Chugai Pharmaceutical Co.,Ltd, Masaki Katayama: None declared, Ryota Hara: None declared, Kenichiro Hata Speakers bureau: AbbVie, Asahi-Kasei, Chugai, Janssen, Mitsubishi-Tanabe, Eisai, Ayaka Yoshikawa: None declared, Motomu Hashimoto Grant/research support from: Abbvie, Asahi-Kasei, Brystol-Meyers, Eisai, Eli Lilly, Novartis Pharma.
Collapse
|
21
|
Ikeda T, Maeda Y, Sato A, Yamada M, Matsumoto A, Jinno H. [Ⅱ. Current Systemic Therapy for Breast Cancer Brain Metastases]. Gan To Kagaku Ryoho 2022; 49:654-659. [PMID: 35799391] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/15/2023]
|
22
|
Matsumoto A, Maeda Y, Sato A, Yamada M, Ikeda T, Jinno H. Abstract P5-18-13: Compression therapy and goshajinkigan for prevention of nab-paclitaxel-induced peripheral neuropathy in patients with operable breast cancer. Cancer Res 2022. [DOI: 10.1158/1538-7445.sabcs21-p5-18-13] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Purpose: Peripheral neuropathy (PN) is one of the most common toxicities of taxane. Grade2-4 PN occurs in 27-35% of patients treated with taxane and 50-80% of them have persistent symptoms after chemotherapy. PN may result in dose reduction or treatment discontinuation and negatively affect quality of life (QOL). However, there are no established methods for preventing chemotherapy-induced PN. Therefore, we conducted the phase II study to evaluate the efficacy of compression therapy with elastic stockings and oral goshajinkigan (GJG), a traditional Japanese herbal medicine, for prevention of chemotherapy-induced PN in breast cancer patients who treated with dose-dense (DD) nab-paclitaxel (nab-PTX) followed by epirubicin and cycrlophosphamide (EC) as neoadjuvant chemotherapy. Patients and methods: Patients with clinical stage I-III human epidermal growth factor 2 (HER2)-negative breast cancer were included in the study. Nab-PTX (260mg/m2) followed by epirubicin (90mg/m2) plus cycrlophosphamide (600mg/m2) administered every 2 weeks with pegfilgrastim support. Patients wore elastic stockings (ALCARE, Tokyo, Japan) for 24 h from the beginning of each treatment. Oral GJG (7.5g/day) was initiated on day 1 of first cycle of nab-PTX and continued to last cycle of EC. The primary endpoint was the rates of pathological complete response (pCR). Secondary endpoints were clinical response rate, breast conservation rate, safety, and health-related QOL using the Functional Assessment of Cancer Therapy-Neurotoxicity (FACT-NTX). An 11-item FACT-NTX component of FACT-Taxane scale assessed chemotherapy-induced PN at baseline, after each cycle of nab-paclitaxel and EC, and 2 months after last cycle of EC. Lower score indicates worse PN and a 10% or greater decrease in FACT-NTX score was defined as a clinically meaningful worsening of PN. Results: From February 2017 to August 2019, 58 patients were enrolled and 55 of these patients were included in the analysis. Overall, pCR was observed in 13 (23.6%) patients. In patients with triple-negative disease, 10 (38.5%) of 26 achieved pCR, whereas it was observed in 3 (10.3%) of 29 patients with luminal disease. Objective response (complete response or partial response) was achieved in 46 (83.6%) patients, overall. Of 36 patients originally deemed to require mastectomy, conversion to breast-conserving surgery after NAC was achieved by 11 (20.0%) patients. The most common adverse events of grade 3 or higher were myalgia (16.4%), fatigue (14.5%) and transaminase elevation (9.1%). Grade 3 peripheral sensory neuropathy and motor neuropathy occurred in 4 (7.3%) and 3 (5.5%) patients, respectively. No patient experienced grade 4 PN. The dose of nab-PTX had to be reduced in 8 (14.5%) patients, two (3.6%) of whom were due to PN. The EC dose was reduced in 10 (18.2%) patients, this occurred more frequently for non-hematological adverse events (14.5%). The average relative dose intensity of nab-PTX and EC part was 97.4% and 96.3%, respectively. Adverse events led to treatment discontinuation in 8 (14.5%) patients, but there was no discontinuation due to PN. After last cycle of nab-PTX, the average decrease in FACT-NTX scores was 19.9% from baseline, however, it improved to 8.6% decrease at 2 months after last cycle of EC. Conclusions: Compression therapy with elastic stockings and GJG were effective to prevent PN associated with DD nab-PTX regimen. Preventive approach for PN may improve dose intensity of taxane and long-term QOL of breast cancer patients.
Citation Format: Akiko Matsumoto, Yuka Maeda, Ayana Sato, Miki Yamada, Tatsuhiko Ikeda, Hiromitsu Jinno. Compression therapy and goshajinkigan for prevention of nab-paclitaxel-induced peripheral neuropathy in patients with operable breast cancer [abstract]. In: Proceedings of the 2021 San Antonio Breast Cancer Symposium; 2021 Dec 7-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2022;82(4 Suppl):Abstract nr P5-18-13.
Collapse
Affiliation(s)
| | - Yuka Maeda
- Teikyo University School of Medicine, Tokyo, Japan
| | - Ayana Sato
- Teikyo University School of Medicine, Tokyo, Japan
| | - Miki Yamada
- Teikyo University School of Medicine, Tokyo, Japan
| | | | | |
Collapse
|
23
|
Kumagai S, Koyama S, Itahashi K, Tanegashima T, Lin YT, Togashi Y, Kamada T, Irie T, Okumura G, Kono H, Ito D, Fujii R, Watanabe S, Sai A, Fukuoka S, Sugiyama E, Watanabe G, Owari T, Nishinakamura H, Sugiyama D, Maeda Y, Kawazoe A, Yukami H, Chida K, Ohara Y, Yoshida T, Shinno Y, Takeyasu Y, Shirasawa M, Nakama K, Aokage K, Suzuki J, Ishii G, Kuwata T, Sakamoto N, Kawazu M, Ueno T, Mori T, Yamazaki N, Tsuboi M, Yatabe Y, Kinoshita T, Doi T, Shitara K, Mano H, Nishikawa H. Lactic acid promotes PD-1 expression in regulatory T cells in highly glycolytic tumor microenvironments. Cancer Cell 2022; 40:201-218.e9. [PMID: 35090594 DOI: 10.1016/j.ccell.2022.01.001] [Citation(s) in RCA: 258] [Impact Index Per Article: 129.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/01/2021] [Revised: 11/07/2021] [Accepted: 01/05/2022] [Indexed: 12/13/2022]
Abstract
The balance of programmed death-1 (PD-1)-expressing CD8+ T cells and regulatory T (Treg) cells in the tumor microenvironment (TME) determines the clinical efficacy of PD-1 blockade therapy through the competition of their reactivation. However, factors that determine this balance remain unknown. Here, we show that Treg cells gain higher PD-1 expression than effector T cells in highly glycolytic tumors, including MYC-amplified tumors and liver tumors. Under low-glucose environments via glucose consumption by tumor cells, Treg cells actively absorbed lactic acid (LA) through monocarboxylate transporter 1 (MCT1), promoting NFAT1 translocation into the nucleus, thereby enhancing the expression of PD-1, whereas PD-1 expression by effector T cells was dampened. PD-1 blockade invigorated the PD-1-expressing Treg cells, resulting in treatment failure. We propose that LA in the highly glycolytic TME is an active checkpoint for the function of Treg cells in the TME via upregulation of PD-1 expression.
Collapse
MESH Headings
- Animals
- Biomarkers, Tumor
- CD8-Positive T-Lymphocytes/immunology
- CD8-Positive T-Lymphocytes/metabolism
- CD8-Positive T-Lymphocytes/pathology
- Cell Line, Tumor
- Disease Models, Animal
- Fluorescent Antibody Technique
- Gene Expression Regulation, Neoplastic/drug effects
- Glycolysis
- Humans
- Immune Checkpoint Inhibitors/pharmacology
- Immune Checkpoint Inhibitors/therapeutic use
- Immune Checkpoint Proteins/metabolism
- Immunophenotyping
- Lactic Acid/metabolism
- Lactic Acid/pharmacology
- Lymphocyte Activation
- Lymphocyte Count
- Lymphocytes, Tumor-Infiltrating/immunology
- Lymphocytes, Tumor-Infiltrating/metabolism
- Lymphocytes, Tumor-Infiltrating/pathology
- Mice
- Molecular Targeted Therapy
- Prognosis
- Programmed Cell Death 1 Receptor/antagonists & inhibitors
- Programmed Cell Death 1 Receptor/genetics
- Programmed Cell Death 1 Receptor/metabolism
- T-Lymphocytes, Regulatory/drug effects
- T-Lymphocytes, Regulatory/immunology
- T-Lymphocytes, Regulatory/metabolism
- Treatment Outcome
- Tumor Microenvironment/drug effects
- Tumor Microenvironment/genetics
Collapse
Affiliation(s)
- Shogo Kumagai
- Division of Cellular Signaling, National Cancer Center Research Institute, Tokyo 104-0045, Japan; Division of Cancer Immunology, Research Institute/Exploratory Oncology Research & Clinical Trial Center (EPOC), National Cancer Center, Tokyo 104-0045/Chiba 277-8577, Japan; Department of Immunology, Nagoya University Graduate School of Medicine, Nagoya 466-8550, Japan
| | - Shohei Koyama
- Division of Cancer Immunology, Research Institute/Exploratory Oncology Research & Clinical Trial Center (EPOC), National Cancer Center, Tokyo 104-0045/Chiba 277-8577, Japan; Department of Respiratory Medicine and Clinical Immunology, Osaka University Graduate School of Medicine, Osaka 565-0871, Japan.
| | - Kota Itahashi
- Division of Cancer Immunology, Research Institute/Exploratory Oncology Research & Clinical Trial Center (EPOC), National Cancer Center, Tokyo 104-0045/Chiba 277-8577, Japan
| | - Tokiyoshi Tanegashima
- Division of Cancer Immunology, Research Institute/Exploratory Oncology Research & Clinical Trial Center (EPOC), National Cancer Center, Tokyo 104-0045/Chiba 277-8577, Japan
| | - Yi-Tzu Lin
- Division of Cancer Immunology, Research Institute/Exploratory Oncology Research & Clinical Trial Center (EPOC), National Cancer Center, Tokyo 104-0045/Chiba 277-8577, Japan; Department of Immunology, Nagoya University Graduate School of Medicine, Nagoya 466-8550, Japan
| | - Yosuke Togashi
- Division of Cancer Immunology, Research Institute/Exploratory Oncology Research & Clinical Trial Center (EPOC), National Cancer Center, Tokyo 104-0045/Chiba 277-8577, Japan
| | - Takahiro Kamada
- Division of Cancer Immunology, Research Institute/Exploratory Oncology Research & Clinical Trial Center (EPOC), National Cancer Center, Tokyo 104-0045/Chiba 277-8577, Japan
| | - Takuma Irie
- Division of Cancer Immunology, Research Institute/Exploratory Oncology Research & Clinical Trial Center (EPOC), National Cancer Center, Tokyo 104-0045/Chiba 277-8577, Japan
| | - Genki Okumura
- Division of Cancer Immunology, Research Institute/Exploratory Oncology Research & Clinical Trial Center (EPOC), National Cancer Center, Tokyo 104-0045/Chiba 277-8577, Japan
| | - Hidetoshi Kono
- Division of Cancer Immunology, Research Institute/Exploratory Oncology Research & Clinical Trial Center (EPOC), National Cancer Center, Tokyo 104-0045/Chiba 277-8577, Japan
| | - Daisuke Ito
- Division of Cancer Immunology, Research Institute/Exploratory Oncology Research & Clinical Trial Center (EPOC), National Cancer Center, Tokyo 104-0045/Chiba 277-8577, Japan
| | - Rika Fujii
- Division of Cancer Immunology, Research Institute/Exploratory Oncology Research & Clinical Trial Center (EPOC), National Cancer Center, Tokyo 104-0045/Chiba 277-8577, Japan
| | - Sho Watanabe
- Division of Cancer Immunology, Research Institute/Exploratory Oncology Research & Clinical Trial Center (EPOC), National Cancer Center, Tokyo 104-0045/Chiba 277-8577, Japan
| | - Atsuo Sai
- Division of Cancer Immunology, Research Institute/Exploratory Oncology Research & Clinical Trial Center (EPOC), National Cancer Center, Tokyo 104-0045/Chiba 277-8577, Japan; Department of Immunology, Nagoya University Graduate School of Medicine, Nagoya 466-8550, Japan
| | - Shota Fukuoka
- Division of Cancer Immunology, Research Institute/Exploratory Oncology Research & Clinical Trial Center (EPOC), National Cancer Center, Tokyo 104-0045/Chiba 277-8577, Japan
| | - Eri Sugiyama
- Division of Cancer Immunology, Research Institute/Exploratory Oncology Research & Clinical Trial Center (EPOC), National Cancer Center, Tokyo 104-0045/Chiba 277-8577, Japan
| | - Go Watanabe
- Division of Cancer Immunology, Research Institute/Exploratory Oncology Research & Clinical Trial Center (EPOC), National Cancer Center, Tokyo 104-0045/Chiba 277-8577, Japan
| | - Takuya Owari
- Division of Cancer Immunology, Research Institute/Exploratory Oncology Research & Clinical Trial Center (EPOC), National Cancer Center, Tokyo 104-0045/Chiba 277-8577, Japan
| | - Hitomi Nishinakamura
- Division of Cancer Immunology, Research Institute/Exploratory Oncology Research & Clinical Trial Center (EPOC), National Cancer Center, Tokyo 104-0045/Chiba 277-8577, Japan
| | - Daisuke Sugiyama
- Department of Immunology, Nagoya University Graduate School of Medicine, Nagoya 466-8550, Japan
| | - Yuka Maeda
- Division of Cancer Immunology, Research Institute/Exploratory Oncology Research & Clinical Trial Center (EPOC), National Cancer Center, Tokyo 104-0045/Chiba 277-8577, Japan
| | - Akihito Kawazoe
- Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Chiba 277-8577, Japan
| | - Hiroki Yukami
- Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Chiba 277-8577, Japan
| | - Keigo Chida
- Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Chiba 277-8577, Japan
| | - Yuuki Ohara
- Pathology and Clinical Laboratories, National Cancer Center Hospital East, Chiba 277-8577, Japan
| | - Tatsuya Yoshida
- Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo 104-0045, Japan
| | - Yuki Shinno
- Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo 104-0045, Japan
| | - Yuki Takeyasu
- Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo 104-0045, Japan
| | - Masayuki Shirasawa
- Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo 104-0045, Japan
| | - Kenta Nakama
- Department of Dermatologic Oncology, National Cancer Center Hospital, Tokyo 104-0045, Japan
| | - Keiju Aokage
- Department of Thoracic Surgery, National Cancer Center Hospital East, Chiba 277-8577, Japan
| | - Jun Suzuki
- Department of Thoracic Surgery, National Cancer Center Hospital East, Chiba 277-8577, Japan
| | - Genichiro Ishii
- Pathology and Clinical Laboratories, National Cancer Center Hospital East, Chiba 277-8577, Japan
| | - Takeshi Kuwata
- Pathology and Clinical Laboratories, National Cancer Center Hospital East, Chiba 277-8577, Japan
| | - Naoya Sakamoto
- Pathology and Clinical Laboratories, National Cancer Center Hospital East, Chiba 277-8577, Japan
| | - Masahito Kawazu
- Division of Cellular Signaling, National Cancer Center Research Institute, Tokyo 104-0045, Japan
| | - Toshihide Ueno
- Division of Cellular Signaling, National Cancer Center Research Institute, Tokyo 104-0045, Japan
| | - Taisuke Mori
- Department of Pathology, National Cancer Center Hospital, Tokyo 104-0045, Japan
| | - Naoya Yamazaki
- Department of Dermatologic Oncology, National Cancer Center Hospital, Tokyo 104-0045, Japan
| | - Masahiro Tsuboi
- Department of Thoracic Surgery, National Cancer Center Hospital East, Chiba 277-8577, Japan
| | - Yasushi Yatabe
- Department of Pathology, National Cancer Center Hospital, Tokyo 104-0045, Japan
| | - Takahiro Kinoshita
- Department of Gastric Surgery, National Cancer Center Hospital East, Chiba 277-8577, Japan
| | - Toshihiko Doi
- Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Chiba 277-8577, Japan
| | - Kohei Shitara
- Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Chiba 277-8577, Japan
| | - Hiroyuki Mano
- Division of Cellular Signaling, National Cancer Center Research Institute, Tokyo 104-0045, Japan
| | - Hiroyoshi Nishikawa
- Division of Cancer Immunology, Research Institute/Exploratory Oncology Research & Clinical Trial Center (EPOC), National Cancer Center, Tokyo 104-0045/Chiba 277-8577, Japan; Department of Immunology, Nagoya University Graduate School of Medicine, Nagoya 466-8550, Japan.
| |
Collapse
|
24
|
Takigawa M, Tanaka H, Obara T, Maeda Y, Sato M, Shimazaki Y, Mori Y, Ishigami A, Ishii T. Utility of the Berlin Initiative Study-1 equation for the prediction of serum vancomycin concentration in elderly patients aged 75 years and older. Pharmazie 2022; 77:76-80. [PMID: 35209967 DOI: 10.1691/ph.2022.1972] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Subscribe] [Scholar Register] [Indexed: 09/29/2022]
Abstract
Accurate assessment of renal function is essential for determining serum vancomycin (VCM) concentration. Creatinine clearance (Ccr)-calculated using the Cockcroft and Gault (CG) equation-can be used to evaluate renal function for determining VCM dosage. However, Ccr-based evaluation may not be an accurate representation of the renal function in the elderly. Herein, we examine the effectiveness of estimated glomerular filtration rate (eGFR) calculated using the Berlin Initiative Study-1 (BIS1) equation, for predicting the serum VCM concentration. Herein, we retrospectively analyzed patients (aged ≥ 75 years) who had received VCM. Serum VCM concentration was predicted based on Ccr and eGFR. eGFR was calculated using the Japanese equation for eGFR (eGFRJAP), Modification of Diet in Renal Disease (MDRD) equation (eGFRMDRD), chronic kidney disease epidemiology collaboration (CKD-EPI) equation (eGFRCKD-EPI), and BIS1 equation (eGFRBIS1). The predicted serum VCM concentration was compared with the measured values. Prediction bias, accuracy, and precision were evaluated by calculating the mean prediction error (ME), mean absolute prediction error (MAE), and root mean squared prediction error (RMSE). Our results showed that the ME between the measured and the predicted values calculated using Ccr and each eGFR was the largest and smallest when calculated based on Ccr and eGFRMDRD, respectively. MAE and RMSE were the largest and smallest when calculated based on Ccr and eGFRBIS1, respectively. A significant difference was observed in the MAE associated with eGFRJAP, eGFRMDRD, and eGFRCKD-EPI compared to that associated with eGFRBIS1. In conclusion, our results suggest that the BIS1 equation might be useful for determining the VCM dosage in the elderly.
Collapse
Affiliation(s)
- M Takigawa
- Department of Pharmacy, Tokyo Metropolitan Geriatric Hospital, Tokyo, Japan; Molecular Regulation of Aging, Tokyo Metropolitan Institute of Gerontology, Tokyo, Japan; Department of Practical Pharmacy, Faculty of Pharmaceutical Sciences, Toho University, Chiba, Japan
| | - H Tanaka
- Department of Practical Pharmacy, Faculty of Pharmaceutical Sciences, Toho University, Chiba, Japan;,
| | - T Obara
- Department of Pharmacy, Tokyo Metropolitan Geriatric Hospital, Tokyo, Japan
| | - Y Maeda
- Department of Pharmacy, Tokyo Metropolitan Geriatric Hospital, Tokyo, Japan
| | - M Sato
- Department of Pharmacy, Tokyo Metropolitan Geriatric Hospital, Tokyo, Japan
| | - Y Shimazaki
- Department of Pharmacy, Tokyo Metropolitan Geriatric Hospital, Tokyo, Japan
| | - Y Mori
- Department of Pharmacy, Tokyo Metropolitan Geriatric Hospital, Tokyo, Japan
| | - A Ishigami
- Molecular Regulation of Aging, Tokyo Metropolitan Institute of Gerontology, Tokyo, Japan
| | - T Ishii
- Department of Practical Pharmacy, Faculty of Pharmaceutical Sciences, Toho University, Chiba, Japan
| |
Collapse
|
25
|
Maeda Y, Nishimura K, Kurosu K, Mizuguchi H, Terada F, Kushibiki S. Effects of feeding wood kraft pulp silage containing sweet‐potato shochu distillery by‐product on feed intake, feed digestibility, rumen fermentation, blood components, and growth performance in Japanese Black fattening steers during early period. Anim Sci J 2022; 93:e13772. [PMID: 36289593 DOI: 10.1111/asj.13772] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/26/2022] [Revised: 09/13/2022] [Accepted: 09/15/2022] [Indexed: 11/28/2022]
Abstract
The effects of long-term feeding of wood kraft pulp (KP) silage containing sweet-potato shochu distillery by-product (SDP) on feed intake, feed digestibility, rumen fermentation, and growth performance of Japanese Black steers were investigated during the early fattening period. Ten Japanese Black steers (9.8 ± 0.6 months of age) were used in this study. Five steers (KP group) were fed KP silage as a replacement for 10% timothy hay (dry matter bases), in contrast to the other five (control group). KP silage consisted of 92.9% KP and 7.1% SDP (dry matter bases). The experiment was conducted for 18 weeks. No significant differences were observed in terms of feed intake, feed digestibility, or daily body weight gain between the groups. In addition, diurnal changes in the rumen pH and ruminal lipopolysaccharide activity did not differ between the groups. However, the plasma concentration of aspartate transaminase in the KP group was slightly lower (P = 0.078) than that in the control group. Thus, our study suggested that feeding KP silage does not reduce feed intake or affect the rumen fermentation or growth performance of Japanese Black fattening steer.
Collapse
Affiliation(s)
- Yuka Maeda
- Miyazaki Livestock Research Institute Miyazaki Japan
| | | | | | | | | | - Shiro Kushibiki
- Institute of Livestock and Grassland Science, NARO Ibaraki Japan
| |
Collapse
|
26
|
Maeda Y, Wada H, Sugiyama D, Saito T, Irie T, Itahashi K, Minoura K, Suzuki S, Kojima T, Kakimi K, Nakajima J, Funakoshi T, Iida S, Oka M, Shimamura T, Doi T, Doki Y, Nakayama E, Ueda R, Nishikawa H. Depletion of central memory CD8 + T cells might impede the antitumor therapeutic effect of Mogamulizumab. Nat Commun 2021; 12:7280. [PMID: 34907192 PMCID: PMC8671535 DOI: 10.1038/s41467-021-27574-0] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/07/2020] [Accepted: 11/29/2021] [Indexed: 11/09/2022] Open
Abstract
Regulatory T (Treg) cells are important negative regulators of immune homeostasis, but in cancers they tone down the anti-tumor immune response. They are distinguished by high expression levels of the chemokine receptor CCR4, hence their targeting by the anti-CCR4 monoclonal antibody mogamulizumab holds therapeutic promise. Here we show that despite a significant reduction in peripheral effector Treg cells, clinical responses are minimal in a cohort of patients with advanced CCR4-negative solid cancer in a phase Ib study (NCT01929486). Comprehensive immune-monitoring reveals that the abundance of CCR4-expressing central memory CD8+ T cells that are known to play roles in the antitumor immune response is reduced. In long survivors, characterised by lower CCR4 expression in their central memory CD8+ T cells possessed and/or NK cells with an exhausted phenotype, cell numbers are eventually maintained. Our study thus shows that mogamulizumab doses that are currently administered to patients in clinical studies may not differentiate between targeting effector Treg cells and central memory CD8+ T cells, and dosage refinement might be necessary to avoid depletion of effector components during immune therapy.
Collapse
MESH Headings
- Aged
- Aged, 80 and over
- Antibodies, Monoclonal, Humanized/therapeutic use
- Antineoplastic Agents/therapeutic use
- CD8-Positive T-Lymphocytes/drug effects
- CD8-Positive T-Lymphocytes/metabolism
- Dose-Response Relationship, Drug
- Female
- Humans
- Immunotherapy
- Killer Cells, Natural/drug effects
- Killer Cells, Natural/metabolism
- Male
- Memory T Cells/drug effects
- Middle Aged
- Neoplasms/drug therapy
- Neoplasms/immunology
- Receptors, CCR4/antagonists & inhibitors
- Receptors, CCR4/metabolism
- T-Lymphocytes, Regulatory/drug effects
- T-Lymphocytes, Regulatory/metabolism
- Treatment Outcome
Collapse
Grants
- Research Activity Start-up grant no. 15H06878, for Young Scientists (B) grant no. 17K15738 from the Ministry of Education, Culture, Sports, Science and Technology of Japan.the Projects for Cancer Research by Therapeutic Evolution [P-CREATE, no. 17cm0106322h0002]
- Scientific Research (B) grant no. 19H03729 from the Ministry of Education, Culture, Sports, Science and Technology of Japan.
- the Development of Technology for Patient Stratification Biomarker Discovery grant [no.19ae0101074s0401] from the Japan Agency for Medical Research and Development (AMED)
- Grants-in-Aid for Scientific Research (S) grant no. 17H06162, for Challenging Exploratory Research grant no. 16K15551, from the Ministry of Education, Culture, Sports, Science and Technology of Japan; the Projects for Cancer Research by Therapeutic Evolution [P-CREATE, no. 16cm0106301h0001, the Development of Technology for Patient Stratification Biomarker Discovery grant [no.19ae0101074s0401] from the Japan Agency for Medical Research and Development (AMED), the National Cancer Center Research and Development Fund [no. 28-A-7 and 31-A-7]
Collapse
Affiliation(s)
- Yuka Maeda
- Division of Cancer Immunology, Research Institute/Exploratory Oncology Research & Clinical Trial Center (EPOC), National Cancer Center, Tokyo, 104-0045/Chiba, 277-8577, Japan
| | - Hisashi Wada
- Department of Clinical Research in Tumor Immunology, Osaka University Graduate School of Medicine, Osaka, 565-0871, Japan.
| | - Daisuke Sugiyama
- Department of Immunology, Nagoya University Graduate School of Medicine, Nagoya, 466-8550, Japan
| | - Takuro Saito
- Department of Gastroenterological Surgery, Osaka University Graduate School of Medicine, Osaka, 565-0871, Japan
| | - Takuma Irie
- Division of Cancer Immunology, Research Institute/Exploratory Oncology Research & Clinical Trial Center (EPOC), National Cancer Center, Tokyo, 104-0045/Chiba, 277-8577, Japan
| | - Kota Itahashi
- Division of Cancer Immunology, Research Institute/Exploratory Oncology Research & Clinical Trial Center (EPOC), National Cancer Center, Tokyo, 104-0045/Chiba, 277-8577, Japan
| | - Kodai Minoura
- Department of Systems Biology, Nagoya University Graduate School of Medicine, Nagoya, 466-8550, Japan
| | - Susumu Suzuki
- Department of Tumor Immunology, Aichi Medical University, Aichi, 480-1195, Japan
| | - Takashi Kojima
- Department of Gastrointestinal Oncology, National Cancer Center Hospital East, Chiba, 277-8577, Japan
| | - Kazuhiro Kakimi
- Department of Immunotherapeutics, The University of Tokyo Hospital, Tokyo, 113-8655, Japan
| | - Jun Nakajima
- Department of Thoracic Surgery, Graduate School of Medicine, The University of Tokyo, Tokyo, 113-8655, Japan
| | - Takeru Funakoshi
- Department of Dermatology, Keio University School of Medicine, Tokyo, 160-8582, Japan
| | - Shinsuke Iida
- Department of Hematology and Oncology, Nagoya City University Institute of Medical and Pharmaceutical Sciences, Nagoya, 467-8601, Japan
| | - Mikio Oka
- Department of Respiratory Medicine, Kawasaki Medical School, Okayama 701-0192, Japan
| | - Teppei Shimamura
- Department of Systems Biology, Nagoya University Graduate School of Medicine, Nagoya, 466-8550, Japan
| | - Toshihiko Doi
- Department of Gastrointestinal Oncology, National Cancer Center Hospital East, Chiba, 277-8577, Japan
| | - Yuichiro Doki
- Department of Gastroenterological Surgery, Osaka University Graduate School of Medicine, Osaka, 565-0871, Japan
| | - Eiichi Nakayama
- Faculty of Health and Welfare, Kawasaki University of Medical Welfare, Okayama, 701-0192, Japan
| | - Ryuzo Ueda
- Department of Tumor Immunology, Aichi Medical University, Aichi, 480-1195, Japan.
| | - Hiroyoshi Nishikawa
- Division of Cancer Immunology, Research Institute/Exploratory Oncology Research & Clinical Trial Center (EPOC), National Cancer Center, Tokyo, 104-0045/Chiba, 277-8577, Japan.
- Department of Immunology, Nagoya University Graduate School of Medicine, Nagoya, 466-8550, Japan.
| |
Collapse
|
27
|
Kodate N, Donnelly S, Cheung MC, Maeda Y, Mannan H, Chan WCH, O'Shea D. 39 CAN CARE ROBOTS ASSIST OLDER PEOPLE AND LONG-TERM CARE SYSTEMS? KEY STAKEHOLDERS’ PERCEPTIONS IN HONG KONG SAR, CHINA AND IRELAND. Age Ageing 2021. [DOI: 10.1093/ageing/afab219.39] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/25/2023] Open
Abstract
Abstract
Background
Robotics is now seen as part of the solution to the ageing population internationally, and is deployed in care settings. Care robots are designed to enable active ageing as well as ageing in place, with support to older persons, their families, and care professionals. The aim of this study was to understand the perceptions of stakeholders in Hong Kong and Ireland regarding the current state of affairs surrounding the use of care robots in their jurisdictions.
Methods
Semi-structured, in-depth interviews were conducted with 30 experts (15 from each jurisdiction). The participants included care professionals, service providers, researchers, and advocacy group representatives and policymakers. The questions explored their knowledge of and perceptions regarding the current use of assistive technologies, long-term care systems, and their own future vision of care provision for old age.
Results
In both jurisdictions, the use of care robots is relatively new, although many respondents were familiar with the seal robot PARO and the humanoid robot Pepper. In Hong Kong, a gerontechnology-specific exposition has become an annual feature in recent years, and the government’s investment has stepped up. In Ireland, a more general ehealth agenda has been adopted within the government’s planned care reform (Sláintecare). Older people in Hong Kong and Ireland are believed to fall through the cracks in their respective two-tier care systems, and many respondents stated that care robots are most needed in order to fill the gaps (e.g. safety monitoring, mobility support). Concerns regarding the impact of using robots included a possible reduction in human-to-human contact and deskilling of older people themselves.
Conclusion
There was a sense of urgency in both jurisdictions that more smart and digital technologies should be utilised to ease the pressures on care professionals and systems. However, a degree of optimism was noted for technological leapfrogging after the pandemic.
Collapse
Affiliation(s)
- N Kodate
- School of Social Policy , Social Work and Social Justice, , Dublin, Ireland
- University College Dublin , Social Work and Social Justice, , Dublin, Ireland
- UCD Centre for Interdisciplinary Research, Education and Innovation in Health Systems , Dublin, Ireland
- UCD Centre for Japanese Studies , Dublin, Ireland
- Universal Accessibility & Ageing Research Centre , Nishitokyo, Japan
- La Fondation France-Japon, School for Advanced Studies in the Social Sciences (EHESS) , Paris, France
- Public Policy Research Center, Hokkaido University , Sapporo, Japan
- Institute for Future Initiatives, University of Tokyo , Tokyo, Japan
| | - S Donnelly
- School of Social Policy , Social Work and Social Justice, , Dublin, Ireland
- University College Dublin , Social Work and Social Justice, , Dublin, Ireland
- UCD Centre for Interdisciplinary Research, Education and Innovation in Health Systems , Dublin, Ireland
| | - M-c Cheung
- Department of Social Work, The Chinese University of Hong Kong , Hong Kong SAR, China
| | - Y Maeda
- School of Business, Technological University Dublin , Dublin, Ireland
- UCD Centre for Japanese Studies , Dublin, Ireland
| | - H Mannan
- School of Nursing , Midwifery and Health Systems, , Dublin, Ireland
- University College Dublin , Midwifery and Health Systems, , Dublin, Ireland
- Flame University , Pune, India
- UCD Centre for Interdisciplinary Research, Education and Innovation in Health Systems , Dublin, Ireland
- UCD Centre for Japanese Studies , Dublin, Ireland
| | - WC-h Chan
- Department of Social Work, The Chinese University of Hong Kong , Hong Kong SAR, China
| | - D O'Shea
- St Vincent’s University Hospital , Dublin, Ireland
- Royal College of Physicians of Ireland , Dublin, Ireland
| |
Collapse
|
28
|
Au S, Bellato V, Carvas JM, Córdoba CD, Daudu D, Dziakova J, Eltarhoni K, El Feituri N, Fung ACH, Fysaraki C, Gallo G, Gultekin FA, Harbjerg JL, Hatem F, Ioannidis A, Jakobsen L, Clinch D, Kristensen HØ, Kuiper SZ, Kwok AMF, Kwok W, Millan M, Milto KM, Ng HJ, Pellino G, Picciariello A, Pronin S, van Ramshorst GH, Ramser M, Jiménez-Rodríguez RM, Sainz Hernandez JC, Samadov E, Sohrabi S, Uchiyama M, Wang JHS, Younis MU, Fleming S, Alhomoud S, Mayol J, Moeslein G, Smart NJ, Soreide K, Teh C, Verran D, Maeda Y. Global parental leave in surgical careers: differences according to gender, geographical regions and surgical career stages. Br J Surg 2021; 108:1315-1322. [PMID: 34467970 DOI: 10.1093/bjs/znab275] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/14/2021] [Revised: 03/24/2021] [Accepted: 07/01/2021] [Indexed: 11/12/2022]
Abstract
BACKGROUND There is a lack of information regarding the provision of parental leave for surgical careers. This survey study aims to evaluate the experience of maternity/paternity leave and views on work-life balance globally. METHODS A 55-item online survey in 24 languages was distributed via social media as per CHERRIES guideline from February to March 2020. It explored parental leave entitlements, attitude towards leave taking, financial impact, time spent with children and compatibility of parenthood with surgical career. RESULTS Of the 1393 (male : female, 514 : 829) respondents from 65 countries, there were 479 medical students, 349 surgical trainees and 513 consultants. Consultants had less than the recommended duration of maternity leave (43.8 versus 29.1 per cent), no paid maternity (8.3 versus 3.2 per cent) or paternity leave (19.3 versus 11.0 per cent) compared with trainees. Females were less likely to have children than males (36.8 versus 45.6 per cent, P = 0.010) and were more often told surgery is incompatible with parenthood (80.2 versus 59.5 per cent, P < 0.001). Males spent less than 20 per cent of their salary on childcare and fewer than 30 hours/week with their children. More than half (59.2 per cent) of medical students did not believe a surgical career allowed work-life balance. CONCLUSION Surgeons across the globe had inadequate parental leave. Significant gender disparity was seen in multiple aspects.
Collapse
Affiliation(s)
- S Au
- NHS Education for Scotland, Edinburgh, UK
| | | | | | - C D Córdoba
- University of Lausanne, Lausanne, Switzerland
| | - D Daudu
- Faculty of Health and Medical Sciences, University of Western Australia, Australia
| | - J Dziakova
- Hospital Clinico San Carlos, IDISSC, Madrid, Spain
| | | | | | - A C H Fung
- Department of Surgery, The University of Hong Kong, Hong Kong SAR, China
| | - C Fysaraki
- Urology Department, Mid Yorkshire Hospitals NHS Trust, UK
| | - G Gallo
- Department of Medical and Surgical Sciences, University of Catanzaro, Catanzaro, Italy
| | - F Ayca Gultekin
- General Surgery Department, Zonguldak Bulent, Ecevit University School of Medicine, Zonguldak, Turkey
| | - J L Harbjerg
- Department of Surgery, Research Unit C119, Aarhus University Hospital, Palle Juul-Jensens, Aarhus N, Denmark
| | - F Hatem
- Glasgow Royal Infirmary, Glasgow, UK
| | | | - L Jakobsen
- UiT, The Arctic University of Norway, University Hospital of North Norway, Tromso, Norway
| | - D Clinch
- Department of General Surgery, Royal Infirmary of Edinburgh, Edinburgh, UK
| | - H Ø Kristensen
- Department of Surgery, Research Unit C119, Aarhus University Hospital, Palle Juul-Jensens, Aarhus N, Denmark
| | - S Z Kuiper
- School of Nutrition and Translational Research in Metabolism (NUTRIM), Maastricht University, Maastricht, the Netherlands
| | | | - W Kwok
- Royal Infirmary of Edinburgh, Edinburgh, UK
| | - M Millan
- Coloproctology Unit, Department of Surgery, La Fe University Hospital, Valencia, Spain
| | - K M Milto
- NHS Education for Scotland, Edinburgh, UK
| | - H J Ng
- Royal Alexandra Hospital, NHS Greater Glasgow and Clyde, UK
| | - G Pellino
- Department of Advanced Medical and Surgical Sciences, Università degli Studi della Campania 'Luigi Vanvitelli', Naples, Italy
| | - A Picciariello
- Department of Emergency and Organ Transplantation, University 'Aldo Moro' of Bari, Italy
| | - S Pronin
- College of Medicine and Veterinary Medicine, University of Edinburgh, Edinburgh, UK
| | | | - M Ramser
- Department of Surgery, Solothurner Spitäler SoH, Bürgerspital Solothurn, Solothurn, Switzerland
| | | | - J C Sainz Hernandez
- Instituto Nacional de Ciencias Médicas y Nutrición 'Salvador Zubirán', Mexico City, Mexico
| | - E Samadov
- Surgical Department, LEYLA Medical Centre, Baku, Azerbaijan
| | | | - M Uchiyama
- Showa University School of Medicine, Tokyo, Japan
| | - J H-S Wang
- Australasian Students' Surgical Association, New Zealand
| | - M U Younis
- Mediclinic City Hospital, Dubai, United Arab Emirates
| | - S Fleming
- Barts and the London School of Medicine and Dentistry, London, UK
| | - S Alhomoud
- King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia
| | - J Mayol
- Hospital Clinico San Carlos, Instituto de Investigación Sanitaria San Carlos, Universidad Complutense, Madrid, Spain
| | - G Moeslein
- Ev. Bethesda Khs Duisburg, University of Witten, Herdecke, Germany
| | - N J Smart
- Royal Devon & Exeter Hospital & University of Exeter Medical School, Exeter, UK
| | - K Soreide
- Department of Gastrointestinal Surgery, Stavanger University Hospital, Stavanger, Norway
| | - C Teh
- Department of Surgery, Makati Medical Centre, Makati, Philippines.,Department of General Surgery, National Kidney & Transplant Institute, Quezon City, Philippines
| | - D Verran
- Ramsey Health Care, Sydney, Australia
| | - Y Maeda
- Department of Colorectal Surgery, Western General Hospital and University of Edinburgh, Edinburgh, UK
| |
Collapse
|
29
|
Abozeid F, Maeda Y, Kudo SE. Gastrointestinal: Real-time observation in vivo by endocytoscope: a case of colonic leiomyosarcoma compared to adenocarcinoma. J Gastroenterol Hepatol 2021; 36:2335. [PMID: 33615564 DOI: 10.1111/jgh.15421] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/12/2020] [Accepted: 01/31/2021] [Indexed: 12/09/2022]
Affiliation(s)
- F Abozeid
- Digestive Disease Center, Showa University Northern Yokohama Hospital, Yokohama, Japan.,Mansoura Specialized Medical Hospital, Mansoura University, Mansoura, Egypt
| | - Y Maeda
- Digestive Disease Center, Showa University Northern Yokohama Hospital, Yokohama, Japan
| | - S-E Kudo
- Digestive Disease Center, Showa University Northern Yokohama Hospital, Yokohama, Japan
| |
Collapse
|
30
|
Hayama M, Maeda Y, Tsuda T, Akazawa H, Nakatani A, Obata S, Takeda K, Inohara H. Epistaxis limits the performed activities of daily living in proportion to its severity: a cross-sectional survey among patients with hereditary haemorrhagic telangiectasia. RHINOL 2021. [DOI: 10.4193/rhinol/21.028] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022] Open
Abstract
Background: We examined the severity of epistaxis in patients with hereditary haemorrhagic telangiectasia (HHT) and its relationship with the performed activities of daily living. Methodology: This cross-sectional survey included 36 patients with HHT in Japan. An anonymous questionnaire survey was conducted regarding the severity of epistaxis, the measures adopted to prevent epistaxis, and the limitations in the performed activities of daily living. The latter was assessed using a visual analogue scale (VAS). The correlation between epistaxis severity and the VAS score was analysed using Spearman’s rank correlation coefficient. Results: Of the 36 participants surveyed, 94.4% had >1 episode of epistaxis/week. The mean epistaxis severity score (ESS) was 4.3 (range, 0.9–8.4). Limitations in daily life, going out (within a day), meeting with others, eating with others, and going on overnight trips were positively correlated with the ESS. To prevent nosebleeds, 44.4% and 41.7% of the participants used medications and avoided drying their nasal cavities, respectively. Conclusions: Epistaxis impacted the daily life of patients with HHT in proportion to its severity. Nonetheless, less than half of the patients used medications or took precautions. Hence, further educational activities should be considered for medical professionals and patients.
Collapse
|
31
|
Mizuguchi H, Maeda Y, Nishimura K, Shinkura H, Kurosu K, Terada F, Kushibiki S. Effects of wood kraft pulp feeding on feed digestibility and rumen fermentation of Japanese Black steer in the middle fattening stage. Anim Sci J 2021; 92:e13589. [PMID: 34318555 DOI: 10.1111/asj.13589] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/28/2020] [Revised: 06/01/2021] [Accepted: 06/11/2021] [Indexed: 11/28/2022]
Abstract
We investigated the effects of wood kraft pulp (KP) feeding on feed digestibility and rumen fermentation of Japanese Black (JB) steer in the middle fattening stage. The feeding experiment was carried out a replicated 3 × 3 Latin square design using six JB steers (16.2 ± 0.8 months of age). Steers were fed rice straw and three concentrated feeds: commercial formula feed (control), formula feed containing 7.5% KP on a dry matter (DM) basis (7.5% KP), and formula feed containing 15% KP on a DM basis (15% KP). Feed digestibility and rumen fermentation parameters were recorded for 3 days during the measurement period, after an adaptation phase of 11 days. There was no significant difference in DM intake per day among diets. A slightly higher digestibility of neutral detergent fiber was observed in steers fed 15% KP, compared with those fed other diets (P = 0.059). The butyric acid ratio in rumen fluid was higher in steers fed KP diets than in steers fed control (P = 0.083). The average ruminal pH was unaffected by KP diets. This study suggests that replacing 15% of concentrated feed with KP has little effect on feed digestibility and rumen fermentation in JB fattening steer.
Collapse
Affiliation(s)
- Hitoshi Mizuguchi
- Development & Design Department, DKK-Toa Yamagata Corporation, Shinjo, Japan
| | - Yuka Maeda
- Beef Cattle Research Division, Miyazaki Livestock Research Institute, Miyazaki, Japan
| | - Keiko Nishimura
- Beef Cattle Research Division, Miyazaki Livestock Research Institute, Miyazaki, Japan
| | - Hiroshi Shinkura
- NPi Research Laboratory, Nippon Paper Industries Co., Ltd., Tokyo, Japan
| | - Kazuhiro Kurosu
- NPi Research Laboratory, Nippon Paper Industries Co., Ltd., Tokyo, Japan
| | | | - Shiro Kushibiki
- Division of Animal Metabolism and Nutrition, Institute of Livestock and Grassland Science, NARO, Tsukuba, Japan
| |
Collapse
|
32
|
Minoura K, Abe K, Maeda Y, Nishikawa H, Shimamura T. CYBERTRACK2.0: zero-inflated model-based cell clustering and population tracking method for longitudinal mass cytometry data. Bioinformatics 2021; 37:1632-1634. [PMID: 33051653 PMCID: PMC8275981 DOI: 10.1093/bioinformatics/btaa873] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/24/2020] [Revised: 09/16/2020] [Accepted: 09/28/2020] [Indexed: 11/15/2022] Open
Abstract
Summary Recent advancements in high-dimensional single-cell technologies, such as mass cytometry, enable longitudinal experiments to track dynamics of cell populations and identify change points where the proportions vary significantly. However, current research is limited by the lack of tools specialized for analyzing longitudinal mass cytometry data. In order to infer cell population dynamics from such data, we developed a statistical framework named CYBERTRACK2.0. The framework’s analytic performance was validated against synthetic and real data, showing that its results are consistent with previous research. Availability and implementation CYBERTRACK2.0 is available at https://github.com/kodaim1115/CYBERTRACK2. Supplementary information Supplementary data are available at Bioinformatics online.
Collapse
Affiliation(s)
- Kodai Minoura
- Division of Systems Biology.,Division of Immunology, Graduate School of Medicine, Nagoya University, Nagoya 4668550, Japan
| | - Ko Abe
- Division of Systems Biology
| | - Yuka Maeda
- Division of Cancer Immunology, Research Institute/EPOC, National Cancer Center, Tokyo, Chiba 1040045/2778577, Japan
| | - Hiroyoshi Nishikawa
- Division of Immunology, Graduate School of Medicine, Nagoya University, Nagoya 4668550, Japan.,Division of Cancer Immunology, Research Institute/EPOC, National Cancer Center, Tokyo, Chiba 1040045/2778577, Japan
| | | |
Collapse
|
33
|
Maeda Y, Gray E, Figueroa JD, Hall PS, Weller D, Dunlop MG, Din FVN. Risk of missing colorectal cancer with a COVID-adapted diagnostic pathway using quantitative faecal immunochemical testing. BJS Open 2021; 5:zrab056. [PMID: 34228096 PMCID: PMC8259497 DOI: 10.1093/bjsopen/zrab056] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/11/2021] [Accepted: 05/17/2021] [Indexed: 11/17/2022] Open
Abstract
BACKGROUND COVID-19 has brought an unprecedented challenge to healthcare services. The authors' COVID-adapted pathway for suspected bowel cancer combines two quantitative faecal immunochemical tests (qFITs) with a standard CT scan with oral preparation (CT mini-prep). The aim of this study was to estimate the degree of risk mitigation and residual risk of undiagnosed colorectal cancer. METHOD Decision-tree models were developed using a combination of data from the COVID-adapted pathway (April-May 2020), a local audit of qFIT for symptomatic patients performed since 2018, relevant data (prevalence of colorectal cancer and sensitivity and specificity of diagnostic tools) obtained from literature and a local cancer data set, and expert opinion for any missing data. The considered diagnostic scenarios included: single qFIT; two qFITs; single qFIT and CT mini-prep; two qFITs and CT mini-prep (enriched pathway). These were compared to the standard diagnostic pathway (colonoscopy or CT virtual colonoscopy (CTVC)). RESULTS The COVID-adapted pathway included 422 patients, whereas the audit of qFIT included more than 5000 patients. The risk of missing a colorectal cancer, if present, was estimated as high as 20.2 per cent with use of a single qFIT as a triage test. Using both a second qFIT and a CT mini-prep as add-on tests reduced the risk of missed cancer to 6.49 per cent. The trade-off was an increased rate of colonoscopy or CTVC, from 287 for a single qFIT to 418 for the double qFIT and CT mini-prep combination, per 1000 patients. CONCLUSION Triage using qFIT alone could lead to a high rate of missed cancers. This may be reduced using CT mini-prep as an add-on test for triage to colonoscopy or CTVC.
Collapse
Affiliation(s)
- Y Maeda
- Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, Scotland
| | - E Gray
- Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, Scotland
| | - J D Figueroa
- Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, Scotland
| | - P S Hall
- Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, Scotland
| | - D Weller
- Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, Scotland
| | - M G Dunlop
- Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, Scotland
| | - F V N Din
- Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, Scotland
| |
Collapse
|
34
|
Tsuda T, Hayama M, Maeda Y, Takeda K, Nishiike S, Kawashima K, Inohara H. Online workshops on the teaching and practice of endoscopic sinus surgery techniques during the COVID-19 pandemic. RHINOL 2021. [DOI: 10.4193/rhinol/21.025] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022] Open
|
35
|
Kelkka T, Savola P, Bhattacharya D, Huuhtanen J, Lönnberg T, Kankainen M, Paalanen K, Tyster M, Lepistö M, Ellonen P, Smolander J, Eldfors S, Yadav B, Khan S, Koivuniemi R, Sjöwall C, Elo LL, Lähdesmäki H, Maeda Y, Nishikawa H, Leirisalo-Repo M, Sokka-Isler T, Mustjoki S. Corrigendum: Adult-Onset Anti-Citrullinated Peptide Antibody-Negative Destructive Rheumatoid Arthritis Is Characterized by a Disease-Specific CD8+ T Lymphocyte Signature. Front Immunol 2021; 12:710831. [PMID: 34135915 PMCID: PMC8202119 DOI: 10.3389/fimmu.2021.710831] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/17/2021] [Accepted: 05/19/2021] [Indexed: 11/13/2022] Open
Abstract
[This corrects the article DOI: 10.3389/fimmu.2020.578848.].
Collapse
Affiliation(s)
- Tiina Kelkka
- Hematology Research Unit Helsinki, University of Helsinki, Helsinki, Finland.,Department of Hematology, Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland.,Department of Clinical Chemistry and Hematology, University of Helsinki, Helsinki, Finland.,Translational Immunology Research Program, University of Helsinki, Helsinki, Finland
| | - Paula Savola
- Hematology Research Unit Helsinki, University of Helsinki, Helsinki, Finland.,Department of Hematology, Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland.,Department of Clinical Chemistry and Hematology, University of Helsinki, Helsinki, Finland.,Translational Immunology Research Program, University of Helsinki, Helsinki, Finland
| | - Dipabarna Bhattacharya
- Hematology Research Unit Helsinki, University of Helsinki, Helsinki, Finland.,Department of Hematology, Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland.,Department of Clinical Chemistry and Hematology, University of Helsinki, Helsinki, Finland.,Translational Immunology Research Program, University of Helsinki, Helsinki, Finland
| | - Jani Huuhtanen
- Hematology Research Unit Helsinki, University of Helsinki, Helsinki, Finland.,Department of Hematology, Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland.,Department of Clinical Chemistry and Hematology, University of Helsinki, Helsinki, Finland.,Translational Immunology Research Program, University of Helsinki, Helsinki, Finland
| | - Tapio Lönnberg
- Turku Bioscience Centre, University of Turku and Åbo Akademi University, Turku, Finland
| | - Matti Kankainen
- Hematology Research Unit Helsinki, University of Helsinki, Helsinki, Finland.,Department of Hematology, Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland.,Translational Immunology Research Program, University of Helsinki, Helsinki, Finland
| | - Kirsi Paalanen
- Rheumatology, Jyväskylä Central Hospital, Jyväskylä, Finland
| | - Mikko Tyster
- Hematology Research Unit Helsinki, University of Helsinki, Helsinki, Finland.,Department of Hematology, Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland.,Department of Clinical Chemistry and Hematology, University of Helsinki, Helsinki, Finland.,Translational Immunology Research Program, University of Helsinki, Helsinki, Finland
| | - Maija Lepistö
- Institute for Molecular Medicine Finland (FIMM), Helsinki Institute of Life Science (HiLIFE), University of Helsinki, Helsinki, Finland
| | - Pekka Ellonen
- Institute for Molecular Medicine Finland (FIMM), Helsinki Institute of Life Science (HiLIFE), University of Helsinki, Helsinki, Finland
| | - Johannes Smolander
- Turku Bioscience Centre, University of Turku and Åbo Akademi University, Turku, Finland
| | - Samuli Eldfors
- Institute for Molecular Medicine Finland (FIMM), Helsinki Institute of Life Science (HiLIFE), University of Helsinki, Helsinki, Finland
| | - Bhagwan Yadav
- Hematology Research Unit Helsinki, University of Helsinki, Helsinki, Finland.,Department of Hematology, Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland.,Department of Clinical Chemistry and Hematology, University of Helsinki, Helsinki, Finland.,Translational Immunology Research Program, University of Helsinki, Helsinki, Finland
| | - Sofia Khan
- Turku Bioscience Centre, University of Turku and Åbo Akademi University, Turku, Finland
| | - Riitta Koivuniemi
- Rheumatology, University of Helsinki, Helsinki University Hospital, Helsinki, Finland
| | - Christopher Sjöwall
- Department of Biomedical and Clinical Sciences, Division of Inflammation and Infection, Linköping University, Linköping, Sweden
| | - Laura L Elo
- Turku Bioscience Centre, University of Turku and Åbo Akademi University, Turku, Finland.,Institute of Biomedicine, University of Turku, Turku, Finland
| | - Harri Lähdesmäki
- Department of Computer Science, Aalto University School of Science, Espoo, Finland
| | - Yuka Maeda
- Division of Cancer Immunology, Research Institute/Exploratory Oncology Research and Clinical Trial Center (EPOC), National Cancer Center, Tokyo, Japan
| | - Hiroyoshi Nishikawa
- Division of Cancer Immunology, Research Institute/Exploratory Oncology Research and Clinical Trial Center (EPOC), National Cancer Center, Tokyo, Japan
| | | | - Tuulikki Sokka-Isler
- Rheumatology, Jyväskylä Central Hospital, Jyväskylä, Finland.,University of Eastern Finland, Faculty of Health Sciences, Kuopio, Finland
| | - Satu Mustjoki
- Hematology Research Unit Helsinki, University of Helsinki, Helsinki, Finland.,Department of Hematology, Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland.,Department of Clinical Chemistry and Hematology, University of Helsinki, Helsinki, Finland.,Translational Immunology Research Program, University of Helsinki, Helsinki, Finland
| |
Collapse
|
36
|
Nagao S, Kumamoto K, Kugita M, Yoshimura A, Murakami R, Fujigaki H, Yamamoto Y, Maeda Y, Yamaguchi T, Takahashi K, Saito K, Yuzawa Y. POS-431 ALTERED REGULATION OF TRYPTOPHAN METABOLISM AND ARYL HYDROCARBON RECEPTOR DISTRIBUTION IN RODENT POLYCYSTIC KIDNEYS. Kidney Int Rep 2021. [DOI: 10.1016/j.ekir.2021.03.454] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022] Open
|
37
|
Ong K, Bordeianou L, Brunner M, Buntzen S, Collie MHS, Hanly A, Hunt CW, Matzel KE, O'Connell PR, Rydningen M, Savitt L, Totaro A, Vaizey CJ, Maeda Y. Changing paradigm of sacral neuromodulation and external anal sphincter repair for faecal incontinence in specialist centres. Colorectal Dis 2021; 23:710-715. [PMID: 32894636 DOI: 10.1111/codi.15349] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/15/2020] [Accepted: 08/26/2020] [Indexed: 02/08/2023]
Abstract
AIM The aim of this study was to determine whether the paradigm of surgical intervention for faecal incontinence (FI) has changed between 2000 and 2013. METHOD This was a multi-centre retrospective study of patients who had undergone either sacral neuromodulation (SNM) or delayed sphincter repair or sphincteroplasty (SR) as a primary surgical intervention for FI in five centres in Europe and one in the United States. The flow of patients according to the intervention, sustainability of the treatment at a minimum follow-up of 5 years, complications and requirement for further interventions were recorded. RESULTS A total of 461 patients (median age 56 years, range 24-90 years, 41 men) had either SNM or SR as an index operation during the study period [SNM 284 (61.6%), SR 177 (38.4%)]. Among SNM patients, there were 169 revisional operations (change of battery and/or lead, re-siting or removal). At the time of last follow-up 203 patients (71.4%) continued to use SNM. Among SR patients, 30 (16.9%) had complications, most notably wound infection (22, 12.4%). During follow-up 32 patients (18.1%) crossed over to SNM. Comparing two 4-year periods (2000-2003 and 2007-2010), the proportion of patients operated on who had a circumferential sphincter defect of less than 90° was 48 (68%) and 45 (46%), respectively (P = 0.03), while those who had SNM as the primary intervention increased from 29% to 89% (P < 0.05). CONCLUSION The paradigm of surgical intervention for FI has changed with increasing use of SNM.
Collapse
Affiliation(s)
- K Ong
- Department of Colorectal Surgery, Western General Hospital, Edinburgh, UK
| | - L Bordeianou
- Colorectal Surgery Center, Massachusetts General Hospital, Boston, Massachusetts, USA
| | - M Brunner
- Department of Surgery, University Hospital Erlangen, Erlangen, Germany
| | - S Buntzen
- Department of Gastroenterological Surgery, University Hospital of North Norway, Tromsoe, Norway
| | - M H S Collie
- Department of Colorectal Surgery, Western General Hospital, Edinburgh, UK
| | - A Hanly
- Centre for Colorectal Disease, St Vincent's University Hospital, Dublin, Ireland
| | - C W Hunt
- Colorectal Surgery Center, Massachusetts General Hospital, Boston, Massachusetts, USA
| | - K E Matzel
- Department of Surgery, University Hospital Erlangen, Erlangen, Germany
| | - P R O'Connell
- Centre for Colorectal Disease, St Vincent's University Hospital, Dublin, Ireland
| | - M Rydningen
- Department of Gastroenterological Surgery, University Hospital of North Norway, Tromsoe, Norway
| | - L Savitt
- Colorectal Surgery Center, Massachusetts General Hospital, Boston, Massachusetts, USA
| | - A Totaro
- Sir Alan Parks Physiology Unit, St Mark's Hospital, Harrow, UK
| | - C J Vaizey
- Sir Alan Parks Physiology Unit, St Mark's Hospital, Harrow, UK
| | - Y Maeda
- Department of Colorectal Surgery, Western General Hospital, Edinburgh, UK
| |
Collapse
|
38
|
Yang ZH, Kubota Y, Corsi A, Yoshida K, Sun XX, Li JG, Kimura M, Michel N, Ogata K, Yuan CX, Yuan Q, Authelet G, Baba H, Caesar C, Calvet D, Delbart A, Dozono M, Feng J, Flavigny F, Gheller JM, Gibelin J, Giganon A, Gillibert A, Hasegawa K, Isobe T, Kanaya Y, Kawakami S, Kim D, Kiyokawa Y, Kobayashi M, Kobayashi N, Kobayashi T, Kondo Y, Korkulu Z, Koyama S, Lapoux V, Maeda Y, Marqués FM, Motobayashi T, Miyazaki T, Nakamura T, Nakatsuka N, Nishio Y, Obertelli A, Ohkura A, Orr NA, Ota S, Otsu H, Ozaki T, Panin V, Paschalis S, Pollacco EC, Reichert S, Roussé JY, Saito AT, Sakaguchi S, Sako M, Santamaria C, Sasano M, Sato H, Shikata M, Shimizu Y, Shindo Y, Stuhl L, Sumikama T, Sun YL, Tabata M, Togano Y, Tsubota J, Xu FR, Yasuda J, Yoneda K, Zenihiro J, Zhou SG, Zuo W, Uesaka T. Quasifree Neutron Knockout Reaction Reveals a Small s-Orbital Component in the Borromean Nucleus ^{17}B. Phys Rev Lett 2021; 126:082501. [PMID: 33709737 DOI: 10.1103/physrevlett.126.082501] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/06/2020] [Revised: 12/07/2020] [Accepted: 01/27/2021] [Indexed: 06/12/2023]
Abstract
A kinematically complete quasifree (p,pn) experiment in inverse kinematics was performed to study the structure of the Borromean nucleus ^{17}B, which had long been considered to have a neutron halo. By analyzing the momentum distributions and exclusive cross sections, we obtained the spectroscopic factors for 1s_{1/2} and 0d_{5/2} orbitals, and a surprisingly small percentage of 9(2)% was determined for 1s_{1/2}. Our finding of such a small 1s_{1/2} component and the halo features reported in prior experiments can be explained by the deformed relativistic Hartree-Bogoliubov theory in continuum, revealing a definite but not dominant neutron halo in ^{17}B. The present work gives the smallest s- or p-orbital component among known nuclei exhibiting halo features and implies that the dominant occupation of s or p orbitals is not a prerequisite for the occurrence of a neutron halo.
Collapse
Affiliation(s)
- Z H Yang
- Research Center for Nuclear Physics (RCNP), Osaka University, 10-1 Mihogaoka, Ibaraki, Osaka 567-0047, Japan
- RIKEN Nishina Center, Hirosawa 2-1, Wako, Saitama 351-0198, Japan
| | - Y Kubota
- RIKEN Nishina Center, Hirosawa 2-1, Wako, Saitama 351-0198, Japan
- Center for Nuclear Study, The University of Tokyo, Hongo 7-3-1, Bunkyo, Tokyo 113-0033, Japan
| | - A Corsi
- Département de Physique Nucléaire, IRFU, CEA, Université Paris-Saclay, F-91191 Gif-sur-Yvette, France
| | - K Yoshida
- Advanced Science Research Center, Japan Atomic Energy Agency, Tokai, Ibaraki 319-1195, Japan
| | - X-X Sun
- CAS Key Laboratory of Theoretical Physics, Institute of Theoretical Physics, Chinese Academy of Sciences, Beijing 100190, China
- School of Physical Sciences, University of Chinese Academy of Sciences, Beijing 100049, China
| | - J G Li
- School of Physics and State Key Laboratory of Nuclear Physics and Technology, Peking University, Beijing 100871, China
| | - M Kimura
- Research Center for Nuclear Physics (RCNP), Osaka University, 10-1 Mihogaoka, Ibaraki, Osaka 567-0047, Japan
- Department of Physics, Hokkaido University, Sapporo 060-0810, Japan
- Nuclear Reaction Data Centre, Hokkaido University, Sapporo 060-0810, Japan
| | - N Michel
- Institute of Modern Physics, Chinese Academy of Sciences, Lanzhou 730000, China
- School of Nuclear Science and Technology, University of Chinese Academy of Sciences, Beijing 100049, China
| | - K Ogata
- Research Center for Nuclear Physics (RCNP), Osaka University, 10-1 Mihogaoka, Ibaraki, Osaka 567-0047, Japan
- Department of Physics, Osaka City University, Osaka 558-8585, Japan
| | - C X Yuan
- Sino-French Institute of Nuclear Engineering and Technology, Sun Yat-Sen University, Zhuhai, 519082, Guangdong, China
| | - Q Yuan
- School of Physics and State Key Laboratory of Nuclear Physics and Technology, Peking University, Beijing 100871, China
| | - G Authelet
- Département de Physique Nucléaire, IRFU, CEA, Université Paris-Saclay, F-91191 Gif-sur-Yvette, France
| | - H Baba
- RIKEN Nishina Center, Hirosawa 2-1, Wako, Saitama 351-0198, Japan
| | - C Caesar
- Institut für Kernphysik, Technische Universität Darmstadt, D-64289 Darmstadt, Germany
| | - D Calvet
- Département de Physique Nucléaire, IRFU, CEA, Université Paris-Saclay, F-91191 Gif-sur-Yvette, France
| | - A Delbart
- Département de Physique Nucléaire, IRFU, CEA, Université Paris-Saclay, F-91191 Gif-sur-Yvette, France
| | - M Dozono
- Center for Nuclear Study, The University of Tokyo, Hongo 7-3-1, Bunkyo, Tokyo 113-0033, Japan
| | - J Feng
- School of Physics and State Key Laboratory of Nuclear Physics and Technology, Peking University, Beijing 100871, China
| | - F Flavigny
- IPN Orsay, Université Paris Sud, IN2P3-CNRS, F-91406 Orsay Cedex, France
| | - J-M Gheller
- Département de Physique Nucléaire, IRFU, CEA, Université Paris-Saclay, F-91191 Gif-sur-Yvette, France
| | - J Gibelin
- LPC Caen, ENSICAEN, Université de Caen Normandie, CNRS/IN2P3, F-14050 Caen Cedex, France
| | - A Giganon
- Département de Physique Nucléaire, IRFU, CEA, Université Paris-Saclay, F-91191 Gif-sur-Yvette, France
| | - A Gillibert
- Département de Physique Nucléaire, IRFU, CEA, Université Paris-Saclay, F-91191 Gif-sur-Yvette, France
| | - K Hasegawa
- Department of Physics, Tohoku University, Aramaki Aza-Aoba 6-3, Aoba, Sendai, Miyagi 980-8578, Japan
| | - T Isobe
- RIKEN Nishina Center, Hirosawa 2-1, Wako, Saitama 351-0198, Japan
| | - Y Kanaya
- Department of Applied Physics, University of Miyazaki, Gakuen-Kibanadai-Nishi 1-1, Miyazaki 889-2192, Japan
| | - S Kawakami
- Department of Applied Physics, University of Miyazaki, Gakuen-Kibanadai-Nishi 1-1, Miyazaki 889-2192, Japan
| | - D Kim
- Center for Exotic Nuclear Studies, Institute for Basic Science, Daejeon 34126, Republic of Korea
| | - Y Kiyokawa
- Center for Nuclear Study, The University of Tokyo, Hongo 7-3-1, Bunkyo, Tokyo 113-0033, Japan
| | - M Kobayashi
- Center for Nuclear Study, The University of Tokyo, Hongo 7-3-1, Bunkyo, Tokyo 113-0033, Japan
| | - N Kobayashi
- Department of Physics, The University of Tokyo, Hongo 7-3-1, Bunkyo, Tokyo 113-0033, Japan
| | - T Kobayashi
- Department of Physics, Tohoku University, Aramaki Aza-Aoba 6-3, Aoba, Sendai, Miyagi 980-8578, Japan
| | - Y Kondo
- Department of Physics, Tokyo Institute of Technology, 2-12-1 O-Okayama, Meguro, Tokyo 152-8551, Japan
| | - Z Korkulu
- Center for Exotic Nuclear Studies, Institute for Basic Science, Daejeon 34126, Republic of Korea
- Institute for Nuclear Research, Hungarian Academy of Sciences (MTA Atomki), P.O. Box 51, H-4001 Debrecen, Hungary
| | - S Koyama
- Department of Physics, The University of Tokyo, Hongo 7-3-1, Bunkyo, Tokyo 113-0033, Japan
| | - V Lapoux
- Département de Physique Nucléaire, IRFU, CEA, Université Paris-Saclay, F-91191 Gif-sur-Yvette, France
| | - Y Maeda
- Department of Applied Physics, University of Miyazaki, Gakuen-Kibanadai-Nishi 1-1, Miyazaki 889-2192, Japan
| | - F M Marqués
- LPC Caen, ENSICAEN, Université de Caen Normandie, CNRS/IN2P3, F-14050 Caen Cedex, France
| | - T Motobayashi
- RIKEN Nishina Center, Hirosawa 2-1, Wako, Saitama 351-0198, Japan
| | - T Miyazaki
- Department of Physics, The University of Tokyo, Hongo 7-3-1, Bunkyo, Tokyo 113-0033, Japan
| | - T Nakamura
- Department of Physics, Tokyo Institute of Technology, 2-12-1 O-Okayama, Meguro, Tokyo 152-8551, Japan
| | - N Nakatsuka
- Department of Physics, Kyoto University, Kitashirakawa, Sakyo, Kyoto 606-8502, Japan
| | - Y Nishio
- Department of Physics, Kyushu University, Nishi, Fukuoka 819-0395, Japan
| | - A Obertelli
- Département de Physique Nucléaire, IRFU, CEA, Université Paris-Saclay, F-91191 Gif-sur-Yvette, France
| | - A Ohkura
- Department of Physics, Kyushu University, Nishi, Fukuoka 819-0395, Japan
| | - N A Orr
- LPC Caen, ENSICAEN, Université de Caen Normandie, CNRS/IN2P3, F-14050 Caen Cedex, France
| | - S Ota
- Center for Nuclear Study, The University of Tokyo, Hongo 7-3-1, Bunkyo, Tokyo 113-0033, Japan
| | - H Otsu
- RIKEN Nishina Center, Hirosawa 2-1, Wako, Saitama 351-0198, Japan
| | - T Ozaki
- Department of Physics, Tokyo Institute of Technology, 2-12-1 O-Okayama, Meguro, Tokyo 152-8551, Japan
| | - V Panin
- RIKEN Nishina Center, Hirosawa 2-1, Wako, Saitama 351-0198, Japan
| | - S Paschalis
- Institut für Kernphysik, Technische Universität Darmstadt, D-64289 Darmstadt, Germany
| | - E C Pollacco
- Département de Physique Nucléaire, IRFU, CEA, Université Paris-Saclay, F-91191 Gif-sur-Yvette, France
| | - S Reichert
- Physik Department, Technische Universität München, D-85748 Garching, Germany
| | - J-Y Roussé
- Département de Physique Nucléaire, IRFU, CEA, Université Paris-Saclay, F-91191 Gif-sur-Yvette, France
| | - A T Saito
- Department of Physics, Tokyo Institute of Technology, 2-12-1 O-Okayama, Meguro, Tokyo 152-8551, Japan
| | - S Sakaguchi
- Department of Physics, Kyushu University, Nishi, Fukuoka 819-0395, Japan
| | - M Sako
- RIKEN Nishina Center, Hirosawa 2-1, Wako, Saitama 351-0198, Japan
| | - C Santamaria
- Département de Physique Nucléaire, IRFU, CEA, Université Paris-Saclay, F-91191 Gif-sur-Yvette, France
| | - M Sasano
- RIKEN Nishina Center, Hirosawa 2-1, Wako, Saitama 351-0198, Japan
| | - H Sato
- RIKEN Nishina Center, Hirosawa 2-1, Wako, Saitama 351-0198, Japan
| | - M Shikata
- Department of Physics, Tokyo Institute of Technology, 2-12-1 O-Okayama, Meguro, Tokyo 152-8551, Japan
| | - Y Shimizu
- RIKEN Nishina Center, Hirosawa 2-1, Wako, Saitama 351-0198, Japan
| | - Y Shindo
- Department of Physics, Kyushu University, Nishi, Fukuoka 819-0395, Japan
| | - L Stuhl
- RIKEN Nishina Center, Hirosawa 2-1, Wako, Saitama 351-0198, Japan
- Center for Exotic Nuclear Studies, Institute for Basic Science, Daejeon 34126, Republic of Korea
| | - T Sumikama
- Department of Physics, Tohoku University, Aramaki Aza-Aoba 6-3, Aoba, Sendai, Miyagi 980-8578, Japan
| | - Y L Sun
- Département de Physique Nucléaire, IRFU, CEA, Université Paris-Saclay, F-91191 Gif-sur-Yvette, France
| | - M Tabata
- Department of Physics, Kyushu University, Nishi, Fukuoka 819-0395, Japan
| | - Y Togano
- Department of Physics, Tokyo Institute of Technology, 2-12-1 O-Okayama, Meguro, Tokyo 152-8551, Japan
- Department of Physics, Rikkyo University, 3-34-1, Nishi-Ikebukuro, Toshima, Tokyo 171-8501, Japan
| | - J Tsubota
- Department of Physics, Tokyo Institute of Technology, 2-12-1 O-Okayama, Meguro, Tokyo 152-8551, Japan
| | - F R Xu
- School of Physics and State Key Laboratory of Nuclear Physics and Technology, Peking University, Beijing 100871, China
| | - J Yasuda
- Department of Physics, Kyushu University, Nishi, Fukuoka 819-0395, Japan
| | - K Yoneda
- RIKEN Nishina Center, Hirosawa 2-1, Wako, Saitama 351-0198, Japan
| | - J Zenihiro
- RIKEN Nishina Center, Hirosawa 2-1, Wako, Saitama 351-0198, Japan
| | - S-G Zhou
- CAS Key Laboratory of Theoretical Physics, Institute of Theoretical Physics, Chinese Academy of Sciences, Beijing 100190, China
- School of Physical Sciences, University of Chinese Academy of Sciences, Beijing 100049, China
| | - W Zuo
- Institute of Modern Physics, Chinese Academy of Sciences, Lanzhou 730000, China
- School of Nuclear Science and Technology, University of Chinese Academy of Sciences, Beijing 100049, China
| | - T Uesaka
- RIKEN Nishina Center, Hirosawa 2-1, Wako, Saitama 351-0198, Japan
- Cluster for Pioneering Research, RIKEN, Hirosawa 2-1, Wako, Saitama 351-0198, Japan
| |
Collapse
|
39
|
Ohtsuka H, Yamaguchi T, Maeda Y, Tomioka M, Tajima M. Effect of administering activated lymphocytes originated from the dam on the immune cell reaction in Holstein calves. Pol J Vet Sci 2021; 23:109-117. [PMID: 32233303 DOI: 10.24425/pjvs.2020.132754] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
Injection of lymphokine activated killer (LAK) cells is known as useful for activation of cellular immune system. Although the effect of LAK cells has been clarified in human or mice, this effect on function of immune cells has not been examined in calves. Healthy ten Holstein calves were injected with the LAK cells 2 days after birth (LAK Group), and another eight calves were observed as controls (Control Group). All calves received the colostrum formulation on the day of birth, and then, were inoculated with a live attenuated vaccine of bovine herpesvirus (BHV)-1 at 2 (the first vaccination) and 6 (the second vaccination) weeks after birth. Peripheral blood of their dam obtained 3 weeks before calving was used for preparation of LAK cells. Blood samples were taken prior to vaccine inoculation and 3 days after the first inoculation, as well as 3 and 6 days after the second vaccination from all calves. Numbers of CD8+ and CD21+ cells increased significantly after the second vaccination in the LAK Group compared with Control Group. The present study suggested the improved effect of injecting LAK cells originated from dams on immune cells function of young calves after BHV-1 live vaccine.
Collapse
Affiliation(s)
- H Ohtsuka
- Department of Veterinary Medicine, School of Veterinary Medicine, Rakuno Gakuen University, 582 Bunkyo-dai Midorimachi, Ebetsu, Hokkaido, 069-8501, Japan
| | - T Yamaguchi
- Canine-Lab., 2-7-24 Midori-cho, Koganei, Tokyo, 184-0003, Japan
| | - Y Maeda
- Laboratory of Large Animal Internal Medicine, Faculty of Veterinary Medicine, Kitasato University, 35-1 Higashi 23 bancho, Towada, Aomori 034-8628, Japan
| | - M Tomioka
- Department of Veterinary Medicine, School of Veterinary Medicine, Rakuno Gakuen University, 582 Bunkyo-dai Midorimachi, Ebetsu, Hokkaido, 069-8501, Japan
| | - M Tajima
- Department of Veterinary Medicine, School of Veterinary Medicine, Rakuno Gakuen University, 582 Bunkyo-dai Midorimachi, Ebetsu, Hokkaido, 069-8501, Japan
| |
Collapse
|
40
|
Kelkka T, Savola P, Bhattacharya D, Huuhtanen J, Lönnberg T, Kankainen M, Paalanen K, Tyster M, Lepistö M, Ellonen P, Smolander J, Eldfors S, Yadav B, Khan S, Koivuniemi R, Sjöwall C, Elo LL, Lähdesmäki H, Maeda Y, Nishikawa H, Leirisalo-Repo M, Sokka-Isler T, Mustjoki S. Adult-Onset Anti-Citrullinated Peptide Antibody-Negative Destructive Rheumatoid Arthritis Is Characterized by a Disease-Specific CD8+ T Lymphocyte Signature. Front Immunol 2020; 11:578848. [PMID: 33329548 PMCID: PMC7732449 DOI: 10.3389/fimmu.2020.578848] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/01/2020] [Accepted: 10/15/2020] [Indexed: 11/30/2022] Open
Abstract
Rheumatoid arthritis (RA) is a complex autoimmune disease targeting synovial joints. Traditionally, RA is divided into seropositive (SP) and seronegative (SN) disease forms, the latter consisting of an array of unrelated diseases with joint involvement. Recently, we described a severe form of SN-RA that associates with characteristic joint destruction. Here, we sought biological characteristics to differentiate this rare but aggressive anti-citrullinated peptide antibody-negative destructive RA (CND-RA) from early seropositive (SP-RA) and seronegative rheumatoid arthritis (SN-RA). We also aimed to study cytotoxic CD8+ lymphocytes in autoimmune arthritis. CND-RA, SP-RA and SN-RA were compared to healthy controls to reveal differences in T-cell receptor beta (TCRβ) repertoire, cytokine levels and autoantibody repertoires. Whole-exome sequencing (WES) followed by single-cell RNA-sequencing (sc-RNA-seq) was performed to study somatic mutations in a clonally expanded CD8+ lymphocyte population in an index patient. A unique TCRβ signature was detected in CND-RA patients. In addition, CND-RA patients expressed higher levels of the bone destruction-associated TNFSF14 cytokine. Blood IgG repertoire from CND-RA patients recognized fewer endogenous proteins than SP-RA patients’ repertoires. Using WES, we detected a stable mutation profile in the clonally expanded CD8+ T-cell population characterized by cytotoxic gene expression signature discovered by sc-RNA-sequencing. Our results identify CND-RA as an independent RA subset and reveal a CND-RA specific TCR signature in the CD8+ lymphocytes. Improved classification of seronegative RA patients underlines the heterogeneity of RA and also, facilitates development of improved therapeutic options for the treatment resistant patients.
Collapse
Affiliation(s)
- Tiina Kelkka
- Hematology Research Unit Helsinki, University of Helsinki, Helsinki, Finland.,Department of Hematology, Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland.,Department of Clinical Chemistry and Hematology, University of Helsinki, Helsinki, Finland.,Translational Immunology Research Program, University of Helsinki, Helsinki, Finland
| | - Paula Savola
- Hematology Research Unit Helsinki, University of Helsinki, Helsinki, Finland.,Department of Hematology, Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland.,Department of Clinical Chemistry and Hematology, University of Helsinki, Helsinki, Finland.,Translational Immunology Research Program, University of Helsinki, Helsinki, Finland
| | - Dipabarna Bhattacharya
- Hematology Research Unit Helsinki, University of Helsinki, Helsinki, Finland.,Department of Hematology, Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland.,Department of Clinical Chemistry and Hematology, University of Helsinki, Helsinki, Finland.,Translational Immunology Research Program, University of Helsinki, Helsinki, Finland
| | - Jani Huuhtanen
- Hematology Research Unit Helsinki, University of Helsinki, Helsinki, Finland.,Department of Hematology, Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland.,Department of Clinical Chemistry and Hematology, University of Helsinki, Helsinki, Finland.,Translational Immunology Research Program, University of Helsinki, Helsinki, Finland
| | - Tapio Lönnberg
- Turku Bioscience Centre, University of Turku and Åbo Akademi University, Turku, Finland
| | - Matti Kankainen
- Hematology Research Unit Helsinki, University of Helsinki, Helsinki, Finland.,Department of Hematology, Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland.,Translational Immunology Research Program, University of Helsinki, Helsinki, Finland
| | - Kirsi Paalanen
- Rheumatology, Jyväskylä Central Hospital, Jyväskylä, Finland
| | - Mikko Tyster
- Hematology Research Unit Helsinki, University of Helsinki, Helsinki, Finland.,Department of Hematology, Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland.,Department of Clinical Chemistry and Hematology, University of Helsinki, Helsinki, Finland.,Translational Immunology Research Program, University of Helsinki, Helsinki, Finland
| | - Maija Lepistö
- Institute for Molecular Medicine Finland (FIMM), Helsinki Institute of Life Science (HiLIFE), University of Helsinki, Helsinki, Finland
| | - Pekka Ellonen
- Institute for Molecular Medicine Finland (FIMM), Helsinki Institute of Life Science (HiLIFE), University of Helsinki, Helsinki, Finland
| | - Johannes Smolander
- Turku Bioscience Centre, University of Turku and Åbo Akademi University, Turku, Finland
| | - Samuli Eldfors
- Institute for Molecular Medicine Finland (FIMM), Helsinki Institute of Life Science (HiLIFE), University of Helsinki, Helsinki, Finland
| | - Bhagwan Yadav
- Hematology Research Unit Helsinki, University of Helsinki, Helsinki, Finland.,Department of Hematology, Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland.,Department of Clinical Chemistry and Hematology, University of Helsinki, Helsinki, Finland.,Translational Immunology Research Program, University of Helsinki, Helsinki, Finland
| | - Sofia Khan
- Turku Bioscience Centre, University of Turku and Åbo Akademi University, Turku, Finland
| | - Riitta Koivuniemi
- Rheumatology, University of Helsinki, Helsinki University Hospital, Helsinki, Finland
| | - Christopher Sjöwall
- Department of Biomedical and Clinical Sciences, Division of Inflammation and Infection, Linköping University, Linköping, Sweden
| | - Laura L Elo
- Turku Bioscience Centre, University of Turku and Åbo Akademi University, Turku, Finland.,Institute of Biomedicine, University of Turku, Turku, Finland
| | - Harri Lähdesmäki
- Department of Computer Science, Aalto University School of Science, Espoo, Finland
| | - Yuka Maeda
- Division of Cancer Immunology, Research Institute/Exploratory Oncology Research and Clinical Trial Center (EPOC), National Cancer Center, Tokyo, Japan
| | - Hiroyoshi Nishikawa
- Division of Cancer Immunology, Research Institute/Exploratory Oncology Research and Clinical Trial Center (EPOC), National Cancer Center, Tokyo, Japan
| | | | - Tuulikki Sokka-Isler
- Rheumatology, Jyväskylä Central Hospital, Jyväskylä, Finland.,University of Eastern Finland, Faculty of Health Sciences, Kuopio, Finland
| | - Satu Mustjoki
- Hematology Research Unit Helsinki, University of Helsinki, Helsinki, Finland.,Department of Hematology, Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland.,Department of Clinical Chemistry and Hematology, University of Helsinki, Helsinki, Finland.,Translational Immunology Research Program, University of Helsinki, Helsinki, Finland
| |
Collapse
|
41
|
Kubota Y, Corsi A, Authelet G, Baba H, Caesar C, Calvet D, Delbart A, Dozono M, Feng J, Flavigny F, Gheller JM, Gibelin J, Giganon A, Gillibert A, Hasegawa K, Isobe T, Kanaya Y, Kawakami S, Kim D, Kikuchi Y, Kiyokawa Y, Kobayashi M, Kobayashi N, Kobayashi T, Kondo Y, Korkulu Z, Koyama S, Lapoux V, Maeda Y, Marqués FM, Motobayashi T, Miyazaki T, Nakamura T, Nakatsuka N, Nishio Y, Obertelli A, Ogata K, Ohkura A, Orr NA, Ota S, Otsu H, Ozaki T, Panin V, Paschalis S, Pollacco EC, Reichert S, Roussé JY, Saito AT, Sakaguchi S, Sako M, Santamaria C, Sasano M, Sato H, Shikata M, Shimizu Y, Shindo Y, Stuhl L, Sumikama T, Sun YL, Tabata M, Togano Y, Tsubota J, Yang ZH, Yasuda J, Yoneda K, Zenihiro J, Uesaka T. Surface Localization of the Dineutron in ^{11}Li. Phys Rev Lett 2020; 125:252501. [PMID: 33416401 DOI: 10.1103/physrevlett.125.252501] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/30/2020] [Revised: 06/28/2020] [Accepted: 10/08/2020] [Indexed: 06/12/2023]
Abstract
The formation of a dineutron in the ^{11}Li nucleus is found to be localized to the surface region. The experiment measured the intrinsic momentum of the struck neutron in ^{11}Li via the (p,pn) knockout reaction at 246 MeV/nucleon. The correlation angle between the two neutrons is, for the first time, measured as a function of the intrinsic neutron momentum. A comparison with reaction calculations reveals the localization of the dineutron at r∼3.6 fm. The results also support the density dependence of dineutron formation as deduced from Hartree-Fock-Bogoliubov calculations for nuclear matter.
Collapse
Affiliation(s)
- Y Kubota
- RIKEN Nishina Center, Hirosawa 2-1, Wako, Saitama 351-0198, Japan
- Center for Nuclear Study, University of Tokyo, Hongo 7-3-1, Bunkyo, Tokyo 113-0033, Japan
| | - A Corsi
- Département de Physique Nucléaire, IRFU, CEA, Université Paris-Saclay, F-91191 Gif-sur-Yvette, France
| | - G Authelet
- Département de Physique Nucléaire, IRFU, CEA, Université Paris-Saclay, F-91191 Gif-sur-Yvette, France
| | - H Baba
- RIKEN Nishina Center, Hirosawa 2-1, Wako, Saitama 351-0198, Japan
| | - C Caesar
- Institut für Kernphysik, Technische Universität Darmstadt, D-64289 Darmstadt, Germany
| | - D Calvet
- Département de Physique Nucléaire, IRFU, CEA, Université Paris-Saclay, F-91191 Gif-sur-Yvette, France
| | - A Delbart
- Département de Physique Nucléaire, IRFU, CEA, Université Paris-Saclay, F-91191 Gif-sur-Yvette, France
| | - M Dozono
- Center for Nuclear Study, University of Tokyo, Hongo 7-3-1, Bunkyo, Tokyo 113-0033, Japan
| | - J Feng
- School of Physics and State Key Laboratory of Nuclear Physics and Technology, Peking University, Beijing 100871, China
| | - F Flavigny
- IPN Orsay, Université Paris Sud, IN2P3-CNRS, F-91406 Orsay Cedex, France
| | - J-M Gheller
- Département de Physique Nucléaire, IRFU, CEA, Université Paris-Saclay, F-91191 Gif-sur-Yvette, France
| | - J Gibelin
- LPC Caen, ENSICAEN, Université de Caen Normandie, CNRS/IN2P3, F-14050 Caen Cedex, France
| | - A Giganon
- Département de Physique Nucléaire, IRFU, CEA, Université Paris-Saclay, F-91191 Gif-sur-Yvette, France
| | - A Gillibert
- Département de Physique Nucléaire, IRFU, CEA, Université Paris-Saclay, F-91191 Gif-sur-Yvette, France
| | - K Hasegawa
- Department of Physics, Tohoku University, Aramaki Aza-Aoba 6-3, Aoba, Sendai, Miyagi 980-8578, Japan
| | - T Isobe
- RIKEN Nishina Center, Hirosawa 2-1, Wako, Saitama 351-0198, Japan
| | - Y Kanaya
- Department of Applied Physics, University of Miyazaki, Gakuen-Kibanadai-Nishi 1-1, Miyazaki 889-2192, Japan
| | - S Kawakami
- Department of Applied Physics, University of Miyazaki, Gakuen-Kibanadai-Nishi 1-1, Miyazaki 889-2192, Japan
| | - D Kim
- Center for Exotic Nuclear Studies, Institute for Basic Science (IBS), Daejeon 34126, Korea
| | - Y Kikuchi
- RIKEN Nishina Center, Hirosawa 2-1, Wako, Saitama 351-0198, Japan
- Tokuyama College, National Institute of Technology, Yamaguchi 745-8585, Japan
- Department of Physics, Osaka City University, Osaka 558-8585, Japan
| | - Y Kiyokawa
- Center for Nuclear Study, University of Tokyo, Hongo 7-3-1, Bunkyo, Tokyo 113-0033, Japan
| | - M Kobayashi
- Center for Nuclear Study, University of Tokyo, Hongo 7-3-1, Bunkyo, Tokyo 113-0033, Japan
| | - N Kobayashi
- Department of Physics, University of Tokyo, Hongo 7-3-1, Bunkyo, Tokyo 113-0033, Japan
| | - T Kobayashi
- Department of Physics, Tohoku University, Aramaki Aza-Aoba 6-3, Aoba, Sendai, Miyagi 980-8578, Japan
| | - Y Kondo
- Department of Physics, Tokyo Institute of Technology, 2-12-1 O-Okayama, Meguro, Tokyo 152-8551, Japan
| | - Z Korkulu
- Center for Exotic Nuclear Studies, Institute for Basic Science (IBS), Daejeon 34126, Korea
- Institute for Nuclear Research, Hungarian Academy of Sciences (MTA Atomki), P.O. Box 51, H-4001 Debrecen, Hungary
| | - S Koyama
- Department of Physics, University of Tokyo, Hongo 7-3-1, Bunkyo, Tokyo 113-0033, Japan
| | - V Lapoux
- Département de Physique Nucléaire, IRFU, CEA, Université Paris-Saclay, F-91191 Gif-sur-Yvette, France
| | - Y Maeda
- Department of Applied Physics, University of Miyazaki, Gakuen-Kibanadai-Nishi 1-1, Miyazaki 889-2192, Japan
| | - F M Marqués
- LPC Caen, ENSICAEN, Université de Caen Normandie, CNRS/IN2P3, F-14050 Caen Cedex, France
| | - T Motobayashi
- RIKEN Nishina Center, Hirosawa 2-1, Wako, Saitama 351-0198, Japan
| | - T Miyazaki
- Department of Physics, University of Tokyo, Hongo 7-3-1, Bunkyo, Tokyo 113-0033, Japan
| | - T Nakamura
- Department of Physics, Tokyo Institute of Technology, 2-12-1 O-Okayama, Meguro, Tokyo 152-8551, Japan
| | - N Nakatsuka
- Department of Physics, Kyoto University, Kitashirakawa, Sakyo, Kyoto 606-8502, Japan
| | - Y Nishio
- Department of Physics, Kyushu University, Nishi, Fukuoka 819-0395, Japan
| | - A Obertelli
- Département de Physique Nucléaire, IRFU, CEA, Université Paris-Saclay, F-91191 Gif-sur-Yvette, France
| | - K Ogata
- Department of Physics, Osaka City University, Osaka 558-8585, Japan
- Research Center for Nuclear Physics, Osaka University, 10-1 Mihogaoka, Ibaraki, Osaka 567-0047, Japan
| | - A Ohkura
- Department of Physics, Kyushu University, Nishi, Fukuoka 819-0395, Japan
| | - N A Orr
- LPC Caen, ENSICAEN, Université de Caen Normandie, CNRS/IN2P3, F-14050 Caen Cedex, France
| | - S Ota
- Center for Nuclear Study, University of Tokyo, Hongo 7-3-1, Bunkyo, Tokyo 113-0033, Japan
| | - H Otsu
- RIKEN Nishina Center, Hirosawa 2-1, Wako, Saitama 351-0198, Japan
| | - T Ozaki
- Department of Physics, Tokyo Institute of Technology, 2-12-1 O-Okayama, Meguro, Tokyo 152-8551, Japan
| | - V Panin
- RIKEN Nishina Center, Hirosawa 2-1, Wako, Saitama 351-0198, Japan
| | - S Paschalis
- Institut für Kernphysik, Technische Universität Darmstadt, D-64289 Darmstadt, Germany
| | - E C Pollacco
- Département de Physique Nucléaire, IRFU, CEA, Université Paris-Saclay, F-91191 Gif-sur-Yvette, France
| | - S Reichert
- Physik Department, Technische Universität München, D-85748 Garching, Germany
| | - J-Y Roussé
- Département de Physique Nucléaire, IRFU, CEA, Université Paris-Saclay, F-91191 Gif-sur-Yvette, France
| | - A T Saito
- Department of Physics, Tokyo Institute of Technology, 2-12-1 O-Okayama, Meguro, Tokyo 152-8551, Japan
| | - S Sakaguchi
- Department of Physics, Kyushu University, Nishi, Fukuoka 819-0395, Japan
| | - M Sako
- RIKEN Nishina Center, Hirosawa 2-1, Wako, Saitama 351-0198, Japan
| | - C Santamaria
- Département de Physique Nucléaire, IRFU, CEA, Université Paris-Saclay, F-91191 Gif-sur-Yvette, France
| | - M Sasano
- RIKEN Nishina Center, Hirosawa 2-1, Wako, Saitama 351-0198, Japan
| | - H Sato
- RIKEN Nishina Center, Hirosawa 2-1, Wako, Saitama 351-0198, Japan
| | - M Shikata
- Department of Physics, Tokyo Institute of Technology, 2-12-1 O-Okayama, Meguro, Tokyo 152-8551, Japan
| | - Y Shimizu
- RIKEN Nishina Center, Hirosawa 2-1, Wako, Saitama 351-0198, Japan
| | - Y Shindo
- Department of Physics, Kyushu University, Nishi, Fukuoka 819-0395, Japan
| | - L Stuhl
- RIKEN Nishina Center, Hirosawa 2-1, Wako, Saitama 351-0198, Japan
- Center for Exotic Nuclear Studies, Institute for Basic Science (IBS), Daejeon 34126, Korea
| | - T Sumikama
- Department of Physics, Tohoku University, Aramaki Aza-Aoba 6-3, Aoba, Sendai, Miyagi 980-8578, Japan
| | - Y L Sun
- Département de Physique Nucléaire, IRFU, CEA, Université Paris-Saclay, F-91191 Gif-sur-Yvette, France
| | - M Tabata
- Department of Physics, Kyushu University, Nishi, Fukuoka 819-0395, Japan
| | - Y Togano
- Department of Physics, Tokyo Institute of Technology, 2-12-1 O-Okayama, Meguro, Tokyo 152-8551, Japan
| | - J Tsubota
- Department of Physics, Tokyo Institute of Technology, 2-12-1 O-Okayama, Meguro, Tokyo 152-8551, Japan
| | - Z H Yang
- RIKEN Nishina Center, Hirosawa 2-1, Wako, Saitama 351-0198, Japan
| | - J Yasuda
- Department of Physics, Kyushu University, Nishi, Fukuoka 819-0395, Japan
| | - K Yoneda
- RIKEN Nishina Center, Hirosawa 2-1, Wako, Saitama 351-0198, Japan
| | - J Zenihiro
- RIKEN Nishina Center, Hirosawa 2-1, Wako, Saitama 351-0198, Japan
| | - T Uesaka
- RIKEN Nishina Center, Hirosawa 2-1, Wako, Saitama 351-0198, Japan
- Cluster for Pioneering Research, RIKEN, Hirosawa 2-1, Wako, Saitama 351-0198, Japan
| |
Collapse
|
42
|
Shinmachi K, Takahashi Y, Kaneuji Y, Kawamura R, Kohama K, Hieda Y, Goromaru T, Eto S, Murakami T, Maeda Y. Effect of aluminium ion on bioavailability of levofloxacin following oral administration of cilexetil ester of levofloxacin as prodrug in rats. Pharmazie 2020; 75:554-558. [PMID: 33239128 DOI: 10.1691/ph.2020.0601] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/11/2023]
Abstract
A prodrug of levofloxacin (LVFX), cilexetil ester of LVFX (LVFX-CLX), was synthesized to examine whether the prodrug can avoid chelate formation with metal cations in the gastrointestinal tract. LVFX-CLX exhibited a 10-times higher partition coefficient than LVFX. In vitro, LVFX was precipitated by 76.1% in the presence of a 10-times higher concentration of aluminium chloride (Al3+), but LVFX-CLX was not. LVFX-CLX was rapidly hydrolyzed enzymatically by rat plasma, intestinal mucosal and liver homogenates at 37 °C, but not by pancreatic enzymes and luminal fluid. The minimum inhibitory concentration values of LVFX-CLX against S. aureus, E. coli and P. aeruginosa were far higher than that of LVFX. In rats, area under the plasma concentration-time curve from zero to 4 h (AUC0-4h) of LVFX after oral administration of LVFX-CLX was 1.34-fold higher than that after LVFX, though it did not reach significance level. Co-administration of Al3+ with LVFX and LVFX-CLX in rats decreased AUC0-4h of plasma LVFX by 75% and 60%, respectively, however, the AUC0-4h of plasma LVFX after co-administration of LVFX-CLX and Al3+ was 2.2-times higher than that after co-administration of LVFX and Al3+. These results suggested that the use of LVFX-CLX may reduce the modulation of intestinal microflora caused by LVFX and the suppressive effect of Al3+ on intestinal absorption of LVFX.
Collapse
Affiliation(s)
- K Shinmachi
- Laboratory of Drug Information Analytics, Faculty of Pharmacy & Pharmaceutical Sciences, Fukuyama University, Hiroshima International University, Hiroshima, Japan
| | - Y Takahashi
- Laboratory of Drug Information Analytics, Faculty of Pharmacy & Pharmaceutical Sciences, Fukuyama University, Hiroshima International University, Hiroshima, Japan
| | - Y Kaneuji
- Laboratory of Drug Information Analytics, Faculty of Pharmacy & Pharmaceutical Sciences, Fukuyama University, Hiroshima International University, Hiroshima, Japan
| | - R Kawamura
- Laboratory of Drug Information Analytics, Faculty of Pharmacy & Pharmaceutical Sciences, Fukuyama University, Hiroshima International University, Hiroshima, Japan
| | - K Kohama
- Department of Pharmacy, Chugoku-Rosai Hospital, Hiroshima International University, Hiroshima, Japan
| | - Y Hieda
- Laboratory of Drug Information Analytics, Faculty of Pharmacy & Pharmaceutical Sciences, Fukuyama University, Hiroshima International University, Hiroshima, Japan
| | - T Goromaru
- Laboratory of Drug Information Analytics, Faculty of Pharmacy & Pharmaceutical Sciences, Fukuyama University, Hiroshima International University, Hiroshima, Japan
| | - S Eto
- Laboratory of Drug Information Analytics, Faculty of Pharmacy & Pharmaceutical Sciences, Fukuyama University, Hiroshima International University, Hiroshima, Japan
| | - T Murakami
- Faculty of Pharmaceutical Sciences, Hiroshima International University, Hiroshima, Japan
| | - Y Maeda
- Laboratory of Drug Information Analytics, Faculty of Pharmacy & Pharmaceutical Sciences, Fukuyama University, Hiroshima International University, Hiroshima, Japan;,
| |
Collapse
|
43
|
Abudinén F, Adachi I, Aihara H, Akopov N, Aloisio A, Ameli F, Anh Ky N, Asner DM, Aushev T, Aushev V, Babu V, Baehr S, Bahinipati S, Bambade P, Banerjee S, Bansal S, Baudot J, Becker J, Behera PK, Bennett JV, Bernieri E, Bernlochner FU, Bertemes M, Bessner M, Bettarini S, Bhardwaj V, Bianchi F, Bilka T, Bilokin S, Biswas D, Bračko M, Branchini P, Braun N, Browder TE, Budano A, Bussino S, Campajola M, Casarosa G, Cecchi C, Červenkov D, Chang MC, Chang P, Cheaib R, Chekelian V, Cheon BG, Chilikin K, Chirapatpimol K, Cho HE, Cho K, Cho SJ, Choi SK, Cinabro D, Corona L, Cremaldi LM, Cunliffe S, Dash N, Dattola F, De La Cruz-Burelo E, De Nardo G, De Nuccio M, De Pietro G, de Sangro R, Destefanis M, De Yta-Hernandez A, Di Capua F, Doležal Z, Dong TV, Dort K, Dossett D, Dujany G, Eidelman S, Ferber T, Ferlewicz D, Fiore S, Fodor A, Forti F, Fulsom BG, Ganiev E, Garg R, Garmash A, Gaur V, Gaz A, Gebauer U, Gellrich A, Geßler T, Giordano R, Giri A, Gobbo B, Godang R, Goldenzweig P, Golob B, Gomis P, Gradl W, Graziani E, Greenwald D, Hadjivasiliou C, Halder S, Hartbrich O, Hayasaka K, Hayashii H, Hearty C, Hedges MT, Heredia de la Cruz I, Hernández Villanueva M, Hershenhorn A, Higuchi T, Hill EC, Hirata H, Hoek M, Hohmann M, Hsu CL, Hu Y, Inami K, Inguglia G, Irakkathil Jabbar J, Ishikawa A, Itoh R, Jackson P, Jacobs WW, Jaffe DE, Jang EJ, Jia S, Jin Y, Joo C, Kaliyar AB, Kandra J, Karyan G, Kato Y, Kichimi H, Kiesling C, Kim CH, Kim DY, Kim HJ, Kim SH, Kim YK, Kimmel TD, Kinoshita K, Kleinwort C, Kodyš P, Koga T, Kohani S, Komarov I, Korpar S, Kraetzschmar TMG, Križan P, Krokovny P, Kuhr T, Kumar M, Kumar R, Kumara K, Kurz S, Kwon YJ, Lacaprara S, La Licata C, Lanceri L, Lange JS, Lee IS, Lee SC, Leitl P, Levit D, Lewis PM, Li C, Li LK, Li YB, Libby J, Lieret K, Li Gioi L, Liptak Z, Liu QY, Liventsev D, Longo S, Luo T, MacQueen C, Maeda Y, Manfredi R, Manoni E, Marcello S, Marinas C, Martini A, Masuda M, Matsuoka K, Matvienko D, Meggendorfer F, Meier F, Merola M, Metzner F, Milesi M, Miller C, Miyabayashi K, Mizuk R, Azmi K, Mohanty GB, Moser HG, Mrvar M, Müller FJ, Mussa R, Nakamura I, Nakao M, Nakazawa H, Natochii A, Niebuhr C, Nisar NK, Nishida S, Nouxman MHA, Ogawa K, Ogawa S, Ono H, Oskin P, Ozaki H, Pakhlov P, Paladino A, Panta A, Paoloni E, Pardi S, Park H, Park SH, Paschen B, Passeri A, Pathak A, Patra S, Paul S, Pedlar TK, Peruzzi I, Peschke R, Piccolo M, Piilonen LE, Polat G, Popov V, Praz C, Prencipe E, Prim MT, Purohit MV, Rad N, Rados P, Rasheed R, Reif M, Reiter S, Remnev M, Ripp-Baudot I, Ritter M, Ritzert M, Rizzo G, Robertson SH, Rodríguez Pérez D, Roney JM, Rosenfeld C, Rostomyan A, Rout N, Sahoo D, Sakai Y, Sanders DA, Sandilya S, Sangal A, Santelj L, Sato Y, Savinov V, Scavino B, Schwanda C, Schwartz AJ, Seddon RM, Seino Y, Selce A, Senyo K, Serrano J, Sevior ME, Sfienti C, Shiu JG, Sibidanov A, Simon F, Sobie RJ, Soffer A, Solovieva E, Spataro S, Spruck B, Starič M, Stefkova S, Stottler ZS, Stroili R, Strube J, Sumihama M, Sumiyoshi T, Summers DJ, Sutcliffe W, Svidras H, Tabata M, Takizawa M, Tamponi U, Tanaka S, Tanida K, Tanigawa H, Taras P, Tenchini F, Tonelli D, Torassa E, Trabelsi K, Uchida M, Uglov T, Unger K, Unno Y, Uno S, Urquijo P, Ushiroda Y, Vahsen SE, van Tonder R, Varner GS, Varvell KE, Vinokurova A, Vitale L, Waheed E, Wakai M, Wakeling HM, Wang CH, Wang MZ, Wang XL, Warburton A, Watanabe M, Watanuki S, Webb J, Wehle S, Welsch M, Wessel C, Wiechczynski J, Windel H, Won E, Wu LJ, Xu XP, Yabsley B, Yan W, Yang SB, Ye H, Yonenaga M, Yuan CZ, Yusa Y, Zani L, Zhou QD, Zhukova VI. Search for Axionlike Particles Produced in e^{+}e^{-} Collisions at Belle II. Phys Rev Lett 2020; 125:161806. [PMID: 33124872 DOI: 10.1103/physrevlett.125.161806] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/26/2020] [Accepted: 09/08/2020] [Indexed: 06/11/2023]
Abstract
We present a search for the direct production of a light pseudoscalar a decaying into two photons with the Belle II detector at the SuperKEKB collider. We search for the process e^{+}e^{-}→γa, a→γγ in the mass range 0.2<m_{a}<9.7 GeV/c^{2} using data corresponding to an integrated luminosity of (445±3) pb^{-1}. Light pseudoscalars interacting predominantly with standard model gauge bosons (so-called axionlike particles or ALPs) are frequently postulated in extensions of the standard model. We find no evidence for ALPs and set 95% confidence level upper limits on the coupling strength g_{aγγ} of ALPs to photons at the level of 10^{-3} GeV^{-1}. The limits are the most restrictive to date for 0.2<m_{a}<1 GeV/c^{2}.
Collapse
Affiliation(s)
- F Abudinén
- INFN Sezione di Trieste, I-34127 Trieste
| | - I Adachi
- The Graduate University for Advanced Studies (SOKENDAI), Hayama 240-0193
- High Energy Accelerator Research Organization (KEK), Tsukuba 305-0801
| | - H Aihara
- Department of Physics, University of Tokyo, Tokyo 113-0033
| | - N Akopov
- Alikhanyan National Science Laboratory, Yerevan 0036
| | - A Aloisio
- INFN Sezione di Napoli, I-80126 Napoli
- Dipartimento di Scienze Fisiche, Università di Napoli Federico II, I-80126 Napoli
| | - F Ameli
- INFN Sezione di Roma, I-00185 Roma
| | - N Anh Ky
- Institute of Theoretical and Applied Research (ITAR), Duy Tan University, Hanoi 100000
- Institute of Physics, Vietnam Academy of Science and Technology (VAST), Hanoi
| | - D M Asner
- Brookhaven National Laboratory, Upton, New York 11973
| | - T Aushev
- Higher School of Economics (HSE), Moscow 101000
| | - V Aushev
- Taras Shevchenko National University of Kiev, Kiev
| | - V Babu
- Deutsches Elektronen-Synchrotron, 22607 Hamburg
| | - S Baehr
- Institut für Experimentelle Teilchenphysik, Karlsruher Institut für Technologie, 76131 Karlsruhe
| | - S Bahinipati
- Indian Institute of Technology Bhubaneswar, Satya Nagar 751007
| | - P Bambade
- Université Paris-Saclay, CNRS/IN2P3, IJCLab, 91405 Orsay
| | - Sw Banerjee
- University of Louisville, Louisville, Kentucky 40292
| | - S Bansal
- Panjab University, Chandigarh 160014
| | - J Baudot
- Université de Strasbourg, CNRS, IPHC, UMR 7178, 67037 Strasbourg
| | - J Becker
- Institut für Experimentelle Teilchenphysik, Karlsruher Institut für Technologie, 76131 Karlsruhe
| | - P K Behera
- Indian Institute of Technology Madras, Chennai 600036
| | - J V Bennett
- University of Mississippi, University, Mississippi 38677
| | | | | | - M Bertemes
- Institute of High Energy Physics, Vienna 1050
| | - M Bessner
- University of Hawaii, Honolulu, Hawaii 96822
| | - S Bettarini
- INFN Sezione di Pisa, I-56127 Pisa
- Dipartimento di Fisica, Università di Pisa, I-56127 Pisa
| | - V Bhardwaj
- Indian Institute of Science Education and Research Mohali, SAS Nagar, 140306
| | - F Bianchi
- INFN Sezione di Torino, I-10125 Torino
- Dipartimento di Fisica, Università di Torino, I-10125 Torino
| | - T Bilka
- Faculty of Mathematics and Physics, Charles University, 121 16 Prague
| | - S Bilokin
- Ludwig Maximilians University, 80539 Munich
| | - D Biswas
- University of Louisville, Louisville, Kentucky 40292
| | - M Bračko
- J. Stefan Institute, 1000 Ljubljana
- University of Maribor, 2000 Maribor
| | | | - N Braun
- Institut für Experimentelle Teilchenphysik, Karlsruher Institut für Technologie, 76131 Karlsruhe
| | - T E Browder
- University of Hawaii, Honolulu, Hawaii 96822
| | - A Budano
- INFN Sezione di Roma Tre, I-00146 Roma
| | - S Bussino
- INFN Sezione di Roma Tre, I-00146 Roma
- Dipartimento di Matematica e Fisica, Università di Roma Tre, I-00146 Roma
| | - M Campajola
- INFN Sezione di Napoli, I-80126 Napoli
- Dipartimento di Scienze Fisiche, Università di Napoli Federico II, I-80126 Napoli
| | - G Casarosa
- INFN Sezione di Pisa, I-56127 Pisa
- Dipartimento di Fisica, Università di Pisa, I-56127 Pisa
| | - C Cecchi
- INFN Sezione di Perugia, I-06123 Perugia
- Dipartimento di Fisica, Università di Perugia, I-06123 Perugia
| | - D Červenkov
- Faculty of Mathematics and Physics, Charles University, 121 16 Prague
| | - M-C Chang
- Department of Physics, Fu Jen Catholic University, Taipei 24205
| | - P Chang
- Department of Physics, National Taiwan University, Taipei 10617
| | - R Cheaib
- University of British Columbia, Vancouver, British Columbia V6T 1Z1
| | - V Chekelian
- Max-Planck-Institut für Physik, 80805 München
| | - B G Cheon
- Department of Physics and Institute of Natural Sciences, Hanyang University, Seoul 04763
| | - K Chilikin
- P.N. Lebedev Physical Institute of the Russian Academy of Sciences, Moscow 119991
| | | | - H-E Cho
- Department of Physics and Institute of Natural Sciences, Hanyang University, Seoul 04763
| | - K Cho
- Korea Institute of Science and Technology Information, Daejeon 34141
| | - S-J Cho
- Yonsei University, Seoul 03722
| | - S-K Choi
- Gyeongsang National University, Jinju 52828
| | - D Cinabro
- Wayne State University, Detroit, Michigan 48202
| | - L Corona
- INFN Sezione di Pisa, I-56127 Pisa
- Dipartimento di Fisica, Università di Pisa, I-56127 Pisa
| | - L M Cremaldi
- University of Mississippi, University, Mississippi 38677
| | - S Cunliffe
- Deutsches Elektronen-Synchrotron, 22607 Hamburg
| | - N Dash
- Indian Institute of Technology Madras, Chennai 600036
| | - F Dattola
- Deutsches Elektronen-Synchrotron, 22607 Hamburg
| | - E De La Cruz-Burelo
- Centro de Investigacion y de Estudios Avanzados del Instituto Politecnico Nacional, Mexico City 07360
| | - G De Nardo
- INFN Sezione di Napoli, I-80126 Napoli
- Dipartimento di Scienze Fisiche, Università di Napoli Federico II, I-80126 Napoli
| | - M De Nuccio
- Deutsches Elektronen-Synchrotron, 22607 Hamburg
| | | | - R de Sangro
- INFN Laboratori Nazionali di Frascati, I-00044 Frascati
| | - M Destefanis
- INFN Sezione di Torino, I-10125 Torino
- Dipartimento di Fisica, Università di Torino, I-10125 Torino
| | - A De Yta-Hernandez
- Centro de Investigacion y de Estudios Avanzados del Instituto Politecnico Nacional, Mexico City 07360
| | - F Di Capua
- INFN Sezione di Napoli, I-80126 Napoli
- Dipartimento di Scienze Fisiche, Università di Napoli Federico II, I-80126 Napoli
| | - Z Doležal
- Faculty of Mathematics and Physics, Charles University, 121 16 Prague
| | - T V Dong
- Key Laboratory of Nuclear Physics and Ion-beam Application (MOE) and Institute of Modern Physics, Fudan University, Shanghai 200443
| | - K Dort
- Justus-Liebig-Universität Gießen, 35392 Gießen
| | - D Dossett
- School of Physics, University of Melbourne, Victoria 3010
| | - G Dujany
- Université de Strasbourg, CNRS, IPHC, UMR 7178, 67037 Strasbourg
| | - S Eidelman
- Budker Institute of Nuclear Physics SB RAS, Novosibirsk 630090
- P.N. Lebedev Physical Institute of the Russian Academy of Sciences, Moscow 119991
- Novosibirsk State University, Novosibirsk 630090
| | - T Ferber
- Deutsches Elektronen-Synchrotron, 22607 Hamburg
| | - D Ferlewicz
- School of Physics, University of Melbourne, Victoria 3010
| | - S Fiore
- INFN Sezione di Roma, I-00185 Roma
| | - A Fodor
- McGill University, Montréal, Québec, H3A 2T8
| | - F Forti
- INFN Sezione di Pisa, I-56127 Pisa
- Dipartimento di Fisica, Università di Pisa, I-56127 Pisa
| | - B G Fulsom
- Pacific Northwest National Laboratory, Richland, Washington 99352
| | - E Ganiev
- INFN Sezione di Trieste, I-34127 Trieste
- Dipartimento di Fisica, Università di Trieste, I-34127 Trieste
| | - R Garg
- Panjab University, Chandigarh 160014
| | - A Garmash
- Budker Institute of Nuclear Physics SB RAS, Novosibirsk 630090
- Novosibirsk State University, Novosibirsk 630090
| | - V Gaur
- Virginia Polytechnic Institute and State University, Blacksburg, Virginia 24061
| | - A Gaz
- Graduate School of Science, Nagoya University, Nagoya 464-8602
- Kobayashi-Maskawa Institute, Nagoya University, Nagoya 464-8602
| | - U Gebauer
- II. Physikalisches Institut, Georg-August-Universität Göttingen, 37073 Göttingen
| | - A Gellrich
- Deutsches Elektronen-Synchrotron, 22607 Hamburg
| | - T Geßler
- Justus-Liebig-Universität Gießen, 35392 Gießen
| | - R Giordano
- INFN Sezione di Napoli, I-80126 Napoli
- Dipartimento di Scienze Fisiche, Università di Napoli Federico II, I-80126 Napoli
| | - A Giri
- Indian Institute of Technology Hyderabad, Telangana 502285
| | - B Gobbo
- INFN Sezione di Trieste, I-34127 Trieste
| | - R Godang
- University of South Alabama, Mobile, Alabama 36688
| | - P Goldenzweig
- Institut für Experimentelle Teilchenphysik, Karlsruher Institut für Technologie, 76131 Karlsruhe
| | - B Golob
- J. Stefan Institute, 1000 Ljubljana
- Faculty of Mathematics and Physics, University of Ljubljana, 1000 Ljubljana
| | - P Gomis
- Instituto de Fisica Corpuscular, Paterna 46980
| | - W Gradl
- Johannes Gutenberg-Universität Mainz, Institut für Kernphysik, D-55099 Mainz
| | | | - D Greenwald
- Department of Physics, Technische Universität München, 85748 Garching
| | - C Hadjivasiliou
- Pacific Northwest National Laboratory, Richland, Washington 99352
| | - S Halder
- Tata Institute of Fundamental Research, Mumbai 400005
| | - O Hartbrich
- University of Hawaii, Honolulu, Hawaii 96822
| | | | | | - C Hearty
- Institute of Particle Physics (Canada), Victoria, British Columbia V8W 2Y2
- University of British Columbia, Vancouver, British Columbia V6T 1Z1
| | - M T Hedges
- University of Hawaii, Honolulu, Hawaii 96822
| | - I Heredia de la Cruz
- Centro de Investigacion y de Estudios Avanzados del Instituto Politecnico Nacional, Mexico City 07360
- Consejo Nacional de Ciencia y Tecnología, Mexico City 03940
| | | | - A Hershenhorn
- University of British Columbia, Vancouver, British Columbia V6T 1Z1
| | - T Higuchi
- Kavli Institute for the Physics and Mathematics of the Universe (WPI), University of Tokyo, Kashiwa 277-8583
| | - E C Hill
- University of British Columbia, Vancouver, British Columbia V6T 1Z1
| | - H Hirata
- Graduate School of Science, Nagoya University, Nagoya 464-8602
| | - M Hoek
- Johannes Gutenberg-Universität Mainz, Institut für Kernphysik, D-55099 Mainz
| | - M Hohmann
- School of Physics, University of Melbourne, Victoria 3010
| | - C-L Hsu
- School of Physics, University of Sydney, New South Wales 2006
| | - Y Hu
- Institute of High Energy Physics, Chinese Academy of Sciences, Beijing 100049
| | - K Inami
- Graduate School of Science, Nagoya University, Nagoya 464-8602
| | - G Inguglia
- Institute of High Energy Physics, Vienna 1050
| | - J Irakkathil Jabbar
- Institut für Experimentelle Teilchenphysik, Karlsruher Institut für Technologie, 76131 Karlsruhe
| | - A Ishikawa
- The Graduate University for Advanced Studies (SOKENDAI), Hayama 240-0193
- High Energy Accelerator Research Organization (KEK), Tsukuba 305-0801
| | - R Itoh
- The Graduate University for Advanced Studies (SOKENDAI), Hayama 240-0193
- High Energy Accelerator Research Organization (KEK), Tsukuba 305-0801
| | - P Jackson
- Department of Physics, University of Adelaide, Adelaide, South Australia 5005
| | - W W Jacobs
- Indiana University, Bloomington, Indiana 47408
| | - D E Jaffe
- Brookhaven National Laboratory, Upton, New York 11973
| | - E-J Jang
- Gyeongsang National University, Jinju 52828
| | - S Jia
- Key Laboratory of Nuclear Physics and Ion-beam Application (MOE) and Institute of Modern Physics, Fudan University, Shanghai 200443
| | - Y Jin
- INFN Sezione di Trieste, I-34127 Trieste
| | - C Joo
- Kavli Institute for the Physics and Mathematics of the Universe (WPI), University of Tokyo, Kashiwa 277-8583
| | - A B Kaliyar
- Tata Institute of Fundamental Research, Mumbai 400005
| | - J Kandra
- Faculty of Mathematics and Physics, Charles University, 121 16 Prague
| | - G Karyan
- Alikhanyan National Science Laboratory, Yerevan 0036
| | - Y Kato
- Graduate School of Science, Nagoya University, Nagoya 464-8602
- Kobayashi-Maskawa Institute, Nagoya University, Nagoya 464-8602
| | - H Kichimi
- High Energy Accelerator Research Organization (KEK), Tsukuba 305-0801
| | - C Kiesling
- Max-Planck-Institut für Physik, 80805 München
| | - C-H Kim
- Department of Physics and Institute of Natural Sciences, Hanyang University, Seoul 04763
| | - D Y Kim
- Soongsil University, Seoul 06978
| | - H J Kim
- Kyungpook National University, Daegu 41566
| | - S-H Kim
- Seoul National University, Seoul 08826
| | - Y-K Kim
- Yonsei University, Seoul 03722
| | - T D Kimmel
- Virginia Polytechnic Institute and State University, Blacksburg, Virginia 24061
| | - K Kinoshita
- University of Cincinnati, Cincinnati, Ohio 45221
| | - C Kleinwort
- Deutsches Elektronen-Synchrotron, 22607 Hamburg
| | - P Kodyš
- Faculty of Mathematics and Physics, Charles University, 121 16 Prague
| | - T Koga
- High Energy Accelerator Research Organization (KEK), Tsukuba 305-0801
| | - S Kohani
- University of Hawaii, Honolulu, Hawaii 96822
| | - I Komarov
- Deutsches Elektronen-Synchrotron, 22607 Hamburg
| | - S Korpar
- J. Stefan Institute, 1000 Ljubljana
- University of Maribor, 2000 Maribor
| | | | - P Križan
- J. Stefan Institute, 1000 Ljubljana
- Faculty of Mathematics and Physics, University of Ljubljana, 1000 Ljubljana
| | - P Krokovny
- Budker Institute of Nuclear Physics SB RAS, Novosibirsk 630090
- Novosibirsk State University, Novosibirsk 630090
| | - T Kuhr
- Ludwig Maximilians University, 80539 Munich
| | - M Kumar
- Malaviya National Institute of Technology Jaipur, Jaipur 302017
| | - R Kumar
- Punjab Agricultural University, Ludhiana 141004
| | - K Kumara
- Wayne State University, Detroit, Michigan 48202
| | - S Kurz
- Deutsches Elektronen-Synchrotron, 22607 Hamburg
| | | | | | - C La Licata
- Kavli Institute for the Physics and Mathematics of the Universe (WPI), University of Tokyo, Kashiwa 277-8583
| | - L Lanceri
- INFN Sezione di Trieste, I-34127 Trieste
| | - J S Lange
- Justus-Liebig-Universität Gießen, 35392 Gießen
| | - I-S Lee
- Department of Physics and Institute of Natural Sciences, Hanyang University, Seoul 04763
| | - S C Lee
- Kyungpook National University, Daegu 41566
| | - P Leitl
- Max-Planck-Institut für Physik, 80805 München
| | - D Levit
- Department of Physics, Technische Universität München, 85748 Garching
| | | | - C Li
- Liaoning Normal University, Dalian 116029
| | - L K Li
- University of Cincinnati, Cincinnati, Ohio 45221
| | - Y B Li
- Peking University, Beijing 100871
| | - J Libby
- Indian Institute of Technology Madras, Chennai 600036
| | - K Lieret
- Ludwig Maximilians University, 80539 Munich
| | - L Li Gioi
- Max-Planck-Institut für Physik, 80805 München
| | - Z Liptak
- University of Hawaii, Honolulu, Hawaii 96822
| | - Q Y Liu
- Key Laboratory of Nuclear Physics and Ion-beam Application (MOE) and Institute of Modern Physics, Fudan University, Shanghai 200443
| | - D Liventsev
- High Energy Accelerator Research Organization (KEK), Tsukuba 305-0801
- Wayne State University, Detroit, Michigan 48202
| | - S Longo
- Deutsches Elektronen-Synchrotron, 22607 Hamburg
| | - T Luo
- Key Laboratory of Nuclear Physics and Ion-beam Application (MOE) and Institute of Modern Physics, Fudan University, Shanghai 200443
| | - C MacQueen
- School of Physics, University of Melbourne, Victoria 3010
| | - Y Maeda
- Graduate School of Science, Nagoya University, Nagoya 464-8602
- Kobayashi-Maskawa Institute, Nagoya University, Nagoya 464-8602
| | - R Manfredi
- INFN Sezione di Trieste, I-34127 Trieste
- Dipartimento di Fisica, Università di Trieste, I-34127 Trieste
| | - E Manoni
- INFN Sezione di Perugia, I-06123 Perugia
| | - S Marcello
- INFN Sezione di Torino, I-10125 Torino
- Dipartimento di Fisica, Università di Torino, I-10125 Torino
| | - C Marinas
- Instituto de Fisica Corpuscular, Paterna 46980
| | - A Martini
- INFN Sezione di Roma Tre, I-00146 Roma
- Dipartimento di Matematica e Fisica, Università di Roma Tre, I-00146 Roma
| | - M Masuda
- Earthquake Research Institute, University of Tokyo, Tokyo 113-0032
- Research Center for Nuclear Physics, Osaka University, Osaka 567-0047
| | - K Matsuoka
- Graduate School of Science, Nagoya University, Nagoya 464-8602
- Kobayashi-Maskawa Institute, Nagoya University, Nagoya 464-8602
| | - D Matvienko
- Budker Institute of Nuclear Physics SB RAS, Novosibirsk 630090
- P.N. Lebedev Physical Institute of the Russian Academy of Sciences, Moscow 119991
- Novosibirsk State University, Novosibirsk 630090
| | | | - F Meier
- Duke University, Durham, North Carolina 27708
| | - M Merola
- INFN Sezione di Napoli, I-80126 Napoli
- Dipartimento di Agraria, Università di Napoli Federico II, I-80055 Portici (NA)
| | - F Metzner
- Institut für Experimentelle Teilchenphysik, Karlsruher Institut für Technologie, 76131 Karlsruhe
| | - M Milesi
- School of Physics, University of Melbourne, Victoria 3010
| | - C Miller
- University of Victoria, Victoria, British Columbia V8W 3P6
| | | | - R Mizuk
- Higher School of Economics (HSE), Moscow 101000
- P.N. Lebedev Physical Institute of the Russian Academy of Sciences, Moscow 119991
| | - K Azmi
- National Centre for Particle Physics, University Malaya, 50603 Kuala Lumpur
| | - G B Mohanty
- Tata Institute of Fundamental Research, Mumbai 400005
| | - H-G Moser
- Max-Planck-Institut für Physik, 80805 München
| | - M Mrvar
- Institute of High Energy Physics, Vienna 1050
| | - F J Müller
- Deutsches Elektronen-Synchrotron, 22607 Hamburg
| | - R Mussa
- INFN Sezione di Torino, I-10125 Torino
| | - I Nakamura
- The Graduate University for Advanced Studies (SOKENDAI), Hayama 240-0193
- High Energy Accelerator Research Organization (KEK), Tsukuba 305-0801
| | - M Nakao
- The Graduate University for Advanced Studies (SOKENDAI), Hayama 240-0193
- High Energy Accelerator Research Organization (KEK), Tsukuba 305-0801
| | - H Nakazawa
- Department of Physics, National Taiwan University, Taipei 10617
| | - A Natochii
- University of Hawaii, Honolulu, Hawaii 96822
| | - C Niebuhr
- Deutsches Elektronen-Synchrotron, 22607 Hamburg
| | - N K Nisar
- Brookhaven National Laboratory, Upton, New York 11973
| | - S Nishida
- The Graduate University for Advanced Studies (SOKENDAI), Hayama 240-0193
- High Energy Accelerator Research Organization (KEK), Tsukuba 305-0801
| | - M H A Nouxman
- National Centre for Particle Physics, University Malaya, 50603 Kuala Lumpur
| | - K Ogawa
- Niigata University, Niigata 950-2181
| | - S Ogawa
- Toho University, Funabashi 274-8510
| | - H Ono
- Niigata University, Niigata 950-2181
| | - P Oskin
- P.N. Lebedev Physical Institute of the Russian Academy of Sciences, Moscow 119991
| | - H Ozaki
- The Graduate University for Advanced Studies (SOKENDAI), Hayama 240-0193
- High Energy Accelerator Research Organization (KEK), Tsukuba 305-0801
| | - P Pakhlov
- P.N. Lebedev Physical Institute of the Russian Academy of Sciences, Moscow 119991
- Moscow Physical Engineering Institute, Moscow 115409
| | - A Paladino
- INFN Sezione di Pisa, I-56127 Pisa
- Dipartimento di Fisica, Università di Pisa, I-56127 Pisa
| | - A Panta
- University of Mississippi, University, Mississippi 38677
| | - E Paoloni
- INFN Sezione di Pisa, I-56127 Pisa
- Dipartimento di Fisica, Università di Pisa, I-56127 Pisa
| | - S Pardi
- INFN Sezione di Napoli, I-80126 Napoli
| | - H Park
- Kyungpook National University, Daegu 41566
| | | | | | - A Passeri
- INFN Sezione di Roma Tre, I-00146 Roma
| | - A Pathak
- University of Louisville, Louisville, Kentucky 40292
| | - S Patra
- Indian Institute of Science Education and Research Mohali, SAS Nagar, 140306
| | - S Paul
- Department of Physics, Technische Universität München, 85748 Garching
| | | | - I Peruzzi
- INFN Laboratori Nazionali di Frascati, I-00044 Frascati
| | - R Peschke
- University of Hawaii, Honolulu, Hawaii 96822
| | - M Piccolo
- INFN Laboratori Nazionali di Frascati, I-00044 Frascati
| | - L E Piilonen
- Virginia Polytechnic Institute and State University, Blacksburg, Virginia 24061
| | - G Polat
- Aix Marseille Université, CNRS/IN2P3, CPPM, 13288 Marseille
| | - V Popov
- Higher School of Economics (HSE), Moscow 101000
| | - C Praz
- Deutsches Elektronen-Synchrotron, 22607 Hamburg
| | | | - M T Prim
- Institut für Experimentelle Teilchenphysik, Karlsruher Institut für Technologie, 76131 Karlsruhe
| | - M V Purohit
- Okinawa Institute of Science and Technology, Okinawa 904-0495
| | - N Rad
- Deutsches Elektronen-Synchrotron, 22607 Hamburg
| | - P Rados
- Deutsches Elektronen-Synchrotron, 22607 Hamburg
| | - R Rasheed
- Université de Strasbourg, CNRS, IPHC, UMR 7178, 67037 Strasbourg
| | - M Reif
- Max-Planck-Institut für Physik, 80805 München
| | - S Reiter
- Justus-Liebig-Universität Gießen, 35392 Gießen
| | - M Remnev
- Budker Institute of Nuclear Physics SB RAS, Novosibirsk 630090
- Novosibirsk State University, Novosibirsk 630090
| | - I Ripp-Baudot
- Université de Strasbourg, CNRS, IPHC, UMR 7178, 67037 Strasbourg
| | - M Ritter
- Ludwig Maximilians University, 80539 Munich
| | - M Ritzert
- University of Heidelberg, 68131 Mannheim
| | - G Rizzo
- INFN Sezione di Pisa, I-56127 Pisa
- Dipartimento di Fisica, Università di Pisa, I-56127 Pisa
| | - S H Robertson
- Institute of Particle Physics (Canada), Victoria, British Columbia V8W 2Y2
- McGill University, Montréal, Québec, H3A 2T8
| | | | - J M Roney
- Institute of Particle Physics (Canada), Victoria, British Columbia V8W 2Y2
- University of Victoria, Victoria, British Columbia V8W 3P6
| | - C Rosenfeld
- University of South Carolina, Columbia, South Carolina 29208
| | - A Rostomyan
- Deutsches Elektronen-Synchrotron, 22607 Hamburg
| | - N Rout
- Indian Institute of Technology Madras, Chennai 600036
| | - D Sahoo
- Tata Institute of Fundamental Research, Mumbai 400005
| | - Y Sakai
- The Graduate University for Advanced Studies (SOKENDAI), Hayama 240-0193
- High Energy Accelerator Research Organization (KEK), Tsukuba 305-0801
| | - D A Sanders
- University of Mississippi, University, Mississippi 38677
| | - S Sandilya
- University of Cincinnati, Cincinnati, Ohio 45221
| | - A Sangal
- University of Cincinnati, Cincinnati, Ohio 45221
| | - L Santelj
- J. Stefan Institute, 1000 Ljubljana
- Faculty of Mathematics and Physics, University of Ljubljana, 1000 Ljubljana
| | - Y Sato
- Department of Physics, Tohoku University, Sendai 980-8578
| | - V Savinov
- University of Pittsburgh, Pittsburgh, Pennsylvania 15260
| | - B Scavino
- Johannes Gutenberg-Universität Mainz, Institut für Kernphysik, D-55099 Mainz
| | - C Schwanda
- Institute of High Energy Physics, Vienna 1050
| | - A J Schwartz
- University of Cincinnati, Cincinnati, Ohio 45221
| | - R M Seddon
- McGill University, Montréal, Québec, H3A 2T8
| | - Y Seino
- Niigata University, Niigata 950-2181
| | - A Selce
- INFN Sezione di Roma, I-00185 Roma
- Università di Roma "La Sapienza," I-00185 Roma
| | - K Senyo
- Yamagata University, Yamagata 990-8560
| | - J Serrano
- Aix Marseille Université, CNRS/IN2P3, CPPM, 13288 Marseille
| | - M E Sevior
- School of Physics, University of Melbourne, Victoria 3010
| | - C Sfienti
- Johannes Gutenberg-Universität Mainz, Institut für Kernphysik, D-55099 Mainz
| | - J-G Shiu
- Department of Physics, National Taiwan University, Taipei 10617
| | - A Sibidanov
- University of Victoria, Victoria, British Columbia V8W 3P6
| | - F Simon
- Max-Planck-Institut für Physik, 80805 München
| | - R J Sobie
- Institute of Particle Physics (Canada), Victoria, British Columbia V8W 2Y2
- University of Victoria, Victoria, British Columbia V8W 3P6
| | - A Soffer
- Tel Aviv University, School of Physics and Astronomy, Tel Aviv 69978
| | - E Solovieva
- P.N. Lebedev Physical Institute of the Russian Academy of Sciences, Moscow 119991
| | - S Spataro
- INFN Sezione di Torino, I-10125 Torino
- Dipartimento di Fisica, Università di Torino, I-10125 Torino
| | - B Spruck
- Johannes Gutenberg-Universität Mainz, Institut für Kernphysik, D-55099 Mainz
| | - M Starič
- J. Stefan Institute, 1000 Ljubljana
| | - S Stefkova
- Deutsches Elektronen-Synchrotron, 22607 Hamburg
| | - Z S Stottler
- Virginia Polytechnic Institute and State University, Blacksburg, Virginia 24061
| | - R Stroili
- INFN Sezione di Padova, I-35131 Padova
- Dipartimento di Fisica e Astronomia, Università di Padova, I-35131 Padova
| | - J Strube
- Pacific Northwest National Laboratory, Richland, Washington 99352
| | - M Sumihama
- Gifu University, Gifu 501-1193
- Research Center for Nuclear Physics, Osaka University, Osaka 567-0047
| | - T Sumiyoshi
- Tokyo Metropolitan University, Tokyo 192-0397
| | - D J Summers
- University of Mississippi, University, Mississippi 38677
| | | | - H Svidras
- Deutsches Elektronen-Synchrotron, 22607 Hamburg
| | - M Tabata
- Chiba University, Chiba 263-8522
| | - M Takizawa
- J-PARC Branch, KEK Theory Center, High Energy Accelerator Research Organization (KEK), Tsukuba 305-0801
- Theoretical Research Division, Nishina Center, RIKEN, Saitama 351-0198
- Showa Pharmaceutical University, Tokyo 194-8543
| | - U Tamponi
- INFN Sezione di Torino, I-10125 Torino
| | - S Tanaka
- The Graduate University for Advanced Studies (SOKENDAI), Hayama 240-0193
- High Energy Accelerator Research Organization (KEK), Tsukuba 305-0801
| | - K Tanida
- Advanced Science Research Center, Japan Atomic Energy Agency, Naka 319-1195
| | - H Tanigawa
- Department of Physics, University of Tokyo, Tokyo 113-0033
| | - P Taras
- Université de Montréal, Physique des Particules, Montréal, Québec H3C 3J7
| | - F Tenchini
- Deutsches Elektronen-Synchrotron, 22607 Hamburg
| | - D Tonelli
- INFN Sezione di Trieste, I-34127 Trieste
| | - E Torassa
- INFN Sezione di Padova, I-35131 Padova
| | - K Trabelsi
- Université Paris-Saclay, CNRS/IN2P3, IJCLab, 91405 Orsay
| | - M Uchida
- Tokyo Institute of Technology, Tokyo 152-8550
| | - T Uglov
- Higher School of Economics (HSE), Moscow 101000
- P.N. Lebedev Physical Institute of the Russian Academy of Sciences, Moscow 119991
| | - K Unger
- Institut für Experimentelle Teilchenphysik, Karlsruher Institut für Technologie, 76131 Karlsruhe
| | - Y Unno
- Department of Physics and Institute of Natural Sciences, Hanyang University, Seoul 04763
| | - S Uno
- The Graduate University for Advanced Studies (SOKENDAI), Hayama 240-0193
- High Energy Accelerator Research Organization (KEK), Tsukuba 305-0801
| | - P Urquijo
- School of Physics, University of Melbourne, Victoria 3010
| | - Y Ushiroda
- The Graduate University for Advanced Studies (SOKENDAI), Hayama 240-0193
- High Energy Accelerator Research Organization (KEK), Tsukuba 305-0801
- Department of Physics, University of Tokyo, Tokyo 113-0033
| | - S E Vahsen
- University of Hawaii, Honolulu, Hawaii 96822
| | | | - G S Varner
- University of Hawaii, Honolulu, Hawaii 96822
| | - K E Varvell
- School of Physics, University of Sydney, New South Wales 2006
| | - A Vinokurova
- Budker Institute of Nuclear Physics SB RAS, Novosibirsk 630090
- Novosibirsk State University, Novosibirsk 630090
| | - L Vitale
- INFN Sezione di Trieste, I-34127 Trieste
- Dipartimento di Fisica, Università di Trieste, I-34127 Trieste
| | - E Waheed
- High Energy Accelerator Research Organization (KEK), Tsukuba 305-0801
| | - M Wakai
- University of British Columbia, Vancouver, British Columbia V6T 1Z1
| | | | - C H Wang
- National United University, Miao Li 36003
| | - M-Z Wang
- Department of Physics, National Taiwan University, Taipei 10617
| | - X L Wang
- Key Laboratory of Nuclear Physics and Ion-beam Application (MOE) and Institute of Modern Physics, Fudan University, Shanghai 200443
| | - A Warburton
- McGill University, Montréal, Québec, H3A 2T8
| | | | - S Watanuki
- Université Paris-Saclay, CNRS/IN2P3, IJCLab, 91405 Orsay
| | - J Webb
- School of Physics, University of Melbourne, Victoria 3010
| | - S Wehle
- Deutsches Elektronen-Synchrotron, 22607 Hamburg
| | | | | | | | - H Windel
- Max-Planck-Institut für Physik, 80805 München
| | - E Won
- Korea University, Seoul 02841
| | - L J Wu
- Institute of High Energy Physics, Chinese Academy of Sciences, Beijing 100049
| | - X P Xu
- Soochow University, Suzhou 215006
| | - B Yabsley
- School of Physics, University of Sydney, New South Wales 2006
| | - W Yan
- University of Science and Technology of China, Hefei 230026
| | | | - H Ye
- Deutsches Elektronen-Synchrotron, 22607 Hamburg
| | - M Yonenaga
- Tokyo Metropolitan University, Tokyo 192-0397
| | - C Z Yuan
- Institute of High Energy Physics, Chinese Academy of Sciences, Beijing 100049
| | - Y Yusa
- Niigata University, Niigata 950-2181
| | - L Zani
- Aix Marseille Université, CNRS/IN2P3, CPPM, 13288 Marseille
| | - Q D Zhou
- Graduate School of Science, Nagoya University, Nagoya 464-8602
| | - V I Zhukova
- P.N. Lebedev Physical Institute of the Russian Academy of Sciences, Moscow 119991
| |
Collapse
|
44
|
Tanaka A, Nishikawa H, Noguchi S, Sugiyama D, Morikawa H, Takeuchi Y, Ha D, Shigeta N, Kitawaki T, Maeda Y, Saito T, Shinohara Y, Kameoka Y, Iwaisako K, Monma F, Ohishi K, Karbach J, Jäger E, Sawada K, Katayama N, Takahashi N, Sakaguchi S. Tyrosine kinase inhibitor imatinib augments tumor immunity by depleting effector regulatory T cells. J Exp Med 2020; 217:jem.20191009. [PMID: 31704808 PMCID: PMC7041710 DOI: 10.1084/jem.20191009] [Citation(s) in RCA: 51] [Impact Index Per Article: 12.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/06/2019] [Revised: 09/23/2019] [Accepted: 10/10/2019] [Indexed: 12/27/2022] Open
Abstract
As a novel type of anticancer reagent, imatinib inhibits not only BCR-ABL oncogenic protein but also LCK in T cells as an off-target, being able to selectively deplete mature T reg cells and thereby evoke effective immune responses to various cancers. This report addresses whether small molecules can deplete FoxP3-expressing regulatory T (T reg) cells, thereby augmenting antitumor immunity. Imatinib, a tyrosine kinase inhibitor of oncogenic BCR-ABL protein expressed by chronic myelogenous leukemia (CML) cells, possesses off-targets including LCK expressed in T cells. We showed that imatinib-treated CML patients in complete molecular remission (CMR) exhibited selective depletion of effector T reg (eT reg) cells and significant increase in effector/memory CD8+ T cells while non-CMR patients did not. Imatinib at CML-therapeutic concentrations indeed induced apoptosis specifically in eT reg cells and expanded tumor antigen–specific CD8+ T cells in vitro in healthy individuals and melanoma patients, and suppressed colon tumor growth in vivo in mice. Mechanistically, because of FoxP3-dependent much lower expression of LCK and ZAP-70 in T reg cells compared with other T cells, imatinib inhibition of LCK further reduced their TCR signal intensity, rendering them selectively susceptible to signal-deprived apoptotis. Taken together, eT reg cell depletion by imatinib is instrumental in evoking effective immune responses to various cancers.
Collapse
Affiliation(s)
- Atsushi Tanaka
- Experimental Immunology, Immunology Frontier Research Center, Osaka University, Osaka, Japan
| | - Hiroyoshi Nishikawa
- Experimental Immunology, Immunology Frontier Research Center, Osaka University, Osaka, Japan
| | - Shinsuke Noguchi
- Experimental Immunology, Immunology Frontier Research Center, Osaka University, Osaka, Japan.,Department of Hematology, Nephrology, and Rheumatology, Akita University Graduate School of Medicine, Akita, Japan
| | - Daisuke Sugiyama
- Experimental Immunology, Immunology Frontier Research Center, Osaka University, Osaka, Japan
| | - Hiromasa Morikawa
- Experimental Immunology, Immunology Frontier Research Center, Osaka University, Osaka, Japan
| | - Yoshiko Takeuchi
- Experimental Immunology, Immunology Frontier Research Center, Osaka University, Osaka, Japan
| | - Danbee Ha
- Experimental Immunology, Immunology Frontier Research Center, Osaka University, Osaka, Japan
| | - Naoya Shigeta
- Experimental Immunology, Immunology Frontier Research Center, Osaka University, Osaka, Japan
| | - Toshio Kitawaki
- Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan
| | - Yuka Maeda
- Experimental Immunology, Immunology Frontier Research Center, Osaka University, Osaka, Japan
| | - Takuro Saito
- Experimental Immunology, Immunology Frontier Research Center, Osaka University, Osaka, Japan
| | - Yoshinori Shinohara
- Department of Hematology, Nephrology, and Rheumatology, Akita University Graduate School of Medicine, Akita, Japan
| | - Yoshihiro Kameoka
- Department of Hematology, Nephrology, and Rheumatology, Akita University Graduate School of Medicine, Akita, Japan
| | - Keiko Iwaisako
- Department of Target Therapy Oncology, Kyoto University Graduate School of Medicine, Kyoto, Japan
| | - Fumihiko Monma
- Department of Hematology and Oncology, Mie University Graduate School of Medicine, Mie, Japan
| | - Kohshi Ohishi
- Department of Hematology and Oncology, Mie University Graduate School of Medicine, Mie, Japan
| | - Julia Karbach
- Hämatologie-Onkologie Krankenhaus Nordwest, Frankfurt, Germany
| | - Elke Jäger
- Hämatologie-Onkologie Krankenhaus Nordwest, Frankfurt, Germany
| | - Kenichi Sawada
- Department of Hematology, Nephrology, and Rheumatology, Akita University Graduate School of Medicine, Akita, Japan
| | - Naoyuki Katayama
- Department of Hematology and Oncology, Mie University Graduate School of Medicine, Mie, Japan
| | - Naoto Takahashi
- Department of Hematology, Nephrology, and Rheumatology, Akita University Graduate School of Medicine, Akita, Japan
| | - Shimon Sakaguchi
- Experimental Immunology, Immunology Frontier Research Center, Osaka University, Osaka, Japan
| |
Collapse
|
45
|
Kumagai S, Togashi Y, Kamada T, Sugiyama E, Nishinakamura H, Takeuchi Y, Vitaly K, Itahashi K, Maeda Y, Matsui S, Shibahara T, Yamashita Y, Irie T, Tsuge A, Fukuoka S, Kawazoe A, Udagawa H, Kirita K, Aokage K, Ishii G, Kuwata T, Nakama K, Kawazu M, Ueno T, Yamazaki N, Goto K, Tsuboi M, Mano H, Doi T, Shitara K, Nishikawa H. The PD-1 expression balance between effector and regulatory T cells predicts the clinical efficacy of PD-1 blockade therapies. Nat Immunol 2020. [PMID: 32868929 DOI: 10.1038/s41590-020-0769-3.] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
Immune checkpoint blockade has provided a paradigm shift in cancer therapy, but the success of this approach is very variable; therefore, biomarkers predictive of clinical efficacy are urgently required. Here, we show that the frequency of PD-1+CD8+ T cells relative to that of PD-1+ regulatory T (Treg) cells in the tumor microenvironment can predict the clinical efficacy of programmed cell death protein 1 (PD-1) blockade therapies and is superior to other predictors, including PD ligand 1 (PD-L1) expression or tumor mutational burden. PD-1 expression by CD8+ T cells and Treg cells negatively impacts effector and immunosuppressive functions, respectively. PD-1 blockade induces both recovery of dysfunctional PD-1+CD8+ T cells and enhanced PD-1+ Treg cell-mediated immunosuppression. A profound reactivation of effector PD-1+CD8+ T cells rather than PD-1+ Treg cells by PD-1 blockade is necessary for tumor regression. These findings provide a promising predictive biomarker for PD-1 blockade therapies.
Collapse
Affiliation(s)
- Shogo Kumagai
- Division of Cancer Immunology, Research Institute/Exploratory Oncology Research & Clinical Trial Center (EPOC), National Cancer Center, Tokyo, Chiba, Japan.,Department of Immunology, Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - Yosuke Togashi
- Division of Cancer Immunology, Research Institute/Exploratory Oncology Research & Clinical Trial Center (EPOC), National Cancer Center, Tokyo, Chiba, Japan
| | - Takahiro Kamada
- Division of Cancer Immunology, Research Institute/Exploratory Oncology Research & Clinical Trial Center (EPOC), National Cancer Center, Tokyo, Chiba, Japan.,Department of Immunology, Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - Eri Sugiyama
- Division of Cancer Immunology, Research Institute/Exploratory Oncology Research & Clinical Trial Center (EPOC), National Cancer Center, Tokyo, Chiba, Japan.,Department of Immunology, Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - Hitomi Nishinakamura
- Division of Cancer Immunology, Research Institute/Exploratory Oncology Research & Clinical Trial Center (EPOC), National Cancer Center, Tokyo, Chiba, Japan
| | - Yoshiko Takeuchi
- Division of Cancer Immunology, Research Institute/Exploratory Oncology Research & Clinical Trial Center (EPOC), National Cancer Center, Tokyo, Chiba, Japan
| | - Kochin Vitaly
- Department of Immunology, Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - Kota Itahashi
- Division of Cancer Immunology, Research Institute/Exploratory Oncology Research & Clinical Trial Center (EPOC), National Cancer Center, Tokyo, Chiba, Japan
| | - Yuka Maeda
- Division of Cancer Immunology, Research Institute/Exploratory Oncology Research & Clinical Trial Center (EPOC), National Cancer Center, Tokyo, Chiba, Japan
| | - Shigeyuki Matsui
- Department of Biostatics, Nagoya University Graduate School of Medicine, Nagoya, Japan
| | | | | | - Takuma Irie
- Division of Cancer Immunology, Research Institute/Exploratory Oncology Research & Clinical Trial Center (EPOC), National Cancer Center, Tokyo, Chiba, Japan
| | - Ayaka Tsuge
- Division of Cancer Immunology, Research Institute/Exploratory Oncology Research & Clinical Trial Center (EPOC), National Cancer Center, Tokyo, Chiba, Japan.,Department of Immunology, Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - Shota Fukuoka
- Division of Cancer Immunology, Research Institute/Exploratory Oncology Research & Clinical Trial Center (EPOC), National Cancer Center, Tokyo, Chiba, Japan
| | - Akihito Kawazoe
- Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Chiba, Japan
| | - Hibiki Udagawa
- Department of Thoracic Oncology, National Cancer Center Hospital East, Chiba, Japan
| | - Keisuke Kirita
- Department of Thoracic Oncology, National Cancer Center Hospital East, Chiba, Japan
| | - Keiju Aokage
- Department of Thoracic Surgery, National Cancer Center Hospital East, Chiba, Japan
| | - Genichiro Ishii
- Pathology and Clinical Laboratories, National Cancer Center Hospital East, Chiba, Japan
| | - Takeshi Kuwata
- Pathology and Clinical Laboratories, National Cancer Center Hospital East, Chiba, Japan
| | - Kenta Nakama
- Department of Dermatologic Oncology, National Cancer Center Hospital, Tokyo, Japan
| | - Masahito Kawazu
- Division of Cellular Signaling, National Cancer Center Research Institute, Tokyo, Japan
| | - Toshihide Ueno
- Division of Cellular Signaling, National Cancer Center Research Institute, Tokyo, Japan
| | - Naoya Yamazaki
- Department of Dermatologic Oncology, National Cancer Center Hospital, Tokyo, Japan
| | - Koichi Goto
- Department of Thoracic Oncology, National Cancer Center Hospital East, Chiba, Japan
| | - Masahiro Tsuboi
- Department of Thoracic Surgery, National Cancer Center Hospital East, Chiba, Japan
| | - Hiroyuki Mano
- Division of Cellular Signaling, National Cancer Center Research Institute, Tokyo, Japan
| | - Toshihiko Doi
- Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Chiba, Japan
| | - Kohei Shitara
- Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Chiba, Japan
| | - Hiroyoshi Nishikawa
- Division of Cancer Immunology, Research Institute/Exploratory Oncology Research & Clinical Trial Center (EPOC), National Cancer Center, Tokyo, Chiba, Japan. .,Department of Immunology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
| |
Collapse
|
46
|
Akita K, Hayama M, Tsuda T, Maeda Y, Akazawa H, Nakatani A, Obata S, Takeda K, Inohara H. Factors impacting postoperative haemorrhage after transnasal endoscopic surgery. RHINOL 2020. [DOI: 10.4193/rhinol/20.059] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022] Open
|
47
|
Abstract
This European Society of Coloproctology guidance focuses on a proposed conceptual framework to resume standard service in colorectal surgery. The proposed conceptual framework is a schematic and stepwise approach including: in-depth assessment of damage to non-COVID-19-related colorectal service; the return of service (integration with the COVID-19-specific service and the existing operational continuity planning); safety arrangements in parallel with minimizing downtime; the required support for staff and patients; the aftermath of the pandemic and continued strategic planning. This will be dynamic guidance with ongoing updates using critical appraisal of emerging evidence. We will welcome input from all stakeholders (statutory organizations, healthcare professionals, public and patients). Any new questions, new data and discussion are welcome via https://www.escp.eu.com/guidelines.
Collapse
Affiliation(s)
- G. Pellino
- Department of Advanced Medical and Surgical SciencesUniversità degli Studi della Campania ‘Luigi Vanvitelli’NaplesItaly,Colorectal SurgeryVall d’Hebron University HospitalBarcelonaSpain
| | - C. J. Vaizey
- Department of Colorectal SurgerySt Mark’s HospitalLondonUK
| | - Y. Maeda
- Department of Colorectal SurgeryWestern General HospitalEdinburghUK,University of EdinburghEdinburghUK
| | | |
Collapse
|
48
|
Maeda Y, Dunlop MG, Din FVN. Risk mitigation for suspected colorectal cancer diagnostic pathway during COVID-19 pandemic. Br J Surg 2020; 107:e361-e362. [PMID: 32700778 PMCID: PMC7404413 DOI: 10.1002/bjs.11798] [Citation(s) in RCA: 12] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/18/2020] [Accepted: 05/20/2020] [Indexed: 02/06/2023]
Affiliation(s)
- Y Maeda
- Department of Colorectal Surgery, Western General Hospital and University of Edinburgh
| | - M G Dunlop
- Department of Colorectal Surgery, Western General Hospital and University of Edinburgh
| | - F V N Din
- Department of Colorectal Surgery, Western General Hospital and University of Edinburgh
| |
Collapse
|
49
|
Kamachi H, Homma S, Kawamura H, Yoshida T, Ohno Y, Ichikawa N, Yokota R, Funakoshi T, Maeda Y, Takahashi N, Amano T, Taketomi A. Intermittent pneumatic compression versus additional prophylaxis with enoxaparin for prevention of venous thromboembolism after laparoscopic surgery for gastric and colorectal malignancies: multicentre randomized clinical trial. BJS Open 2020; 4:804-810. [PMID: 32700415 PMCID: PMC7528532 DOI: 10.1002/bjs5.50323] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/29/2019] [Accepted: 06/09/2020] [Indexed: 11/06/2022] Open
Abstract
Background The role of antithrombotic chemoprophylaxis in prevention of venous thromboembolism (VTE) in laparoscopic surgery for gastric and colorectal malignancies is unknown. This study compared the addition of enoxaparin following intermittent pneumatic compression (IPC) with IPC alone in patients undergoing laparoscopic surgery for gastrointestinal malignancy. Methods In this multicentre RCT, eligible patients were older than 40 years and had a WHO performance status of 0 or 1. Exclusion criteria were prescription of antiplatelet or anticoagulant drugs and history of VTE. Patients were allocated to IPC or to ICP with enoxaparin in a 1 : 1 ratio. Stratification factors included sex, location of cancer, age 61 years and over, and institution. Enoxaparin was administered on days 1–7 after surgery. Primary outcome was VTE, evaluated by multidetector CT on day 7. Results Of 448 patients randomized, 208 in the IPC group and 182 in the IPC with enoxaparin group were evaluated. VTE occurred in ten patients (4·8 per cent) in the IPC group and six (3·3 per cent) in the IPC with enoxaparin group (P = 0·453). Proximal deep vein thrombosis and/or pulmonary embolism occurred in seven patients (3·4 per cent) in the IPC group and one patient (0·5 per cent) in the IPC with enoxaparin group (P = 0·050). All VTE events were asymptomatic and non‐fatal. Bleeding occurred in 11 of 202 patients in the IPC with enoxaparin group, and one patient needed a transfusion. All bleeding events were managed by discontinuation of the drug. Conclusion IPC with enoxaparin after laparoscopic surgery for gastric and colorectal malignancies did not reduce the rate of VTE. Registration number: UMIN000011667 (
https://www.umin.ac.jp/).
Collapse
Affiliation(s)
- H Kamachi
- Department of Gastroenterological Surgery I, Graduate School of Medicine, Hokkaido University, Hokkaido, Japan
| | - S Homma
- Department of Gastroenterological Surgery I, Graduate School of Medicine, Hokkaido University, Hokkaido, Japan
| | - H Kawamura
- Department of Gastroenterological Surgery I, Graduate School of Medicine, Hokkaido University, Hokkaido, Japan
| | - T Yoshida
- Department of Gastroenterological Surgery I, Graduate School of Medicine, Hokkaido University, Hokkaido, Japan
| | - Y Ohno
- Department of Gastroenterological Surgery I, Graduate School of Medicine, Hokkaido University, Hokkaido, Japan
| | - N Ichikawa
- Department of Gastroenterological Surgery I, Graduate School of Medicine, Hokkaido University, Hokkaido, Japan
| | - R Yokota
- Department of Surgery, Sunagawa City Medical Centre, Sunagawa, Japan
| | - T Funakoshi
- Department of Surgery, Asahikawa-Kosei General Hospital, Asahikawa, Japan
| | - Y Maeda
- Department of Gastrointestinal Surgery, National Hospital Organization Hokkaido Cancer Centre, Hokkaido
| | | | - T Amano
- Clinical Research and Medical Innovation Centre, Hokkaido University Hospital, Hokkaido, Japan
| | - A Taketomi
- Department of Gastroenterological Surgery I, Graduate School of Medicine, Hokkaido University, Hokkaido, Japan
| |
Collapse
|
50
|
Ebina K, Hirano T, Maeda Y, Yamamoto W, Hashimoto M, Murata K, Takeuchi T, Shiba H, Son Y, Amuro H, Onishi A, Akashi K, Hara R, Katayama M, Yamamoto K, Kumanogoh A, Hirao M. OP0025 DRUG RETENTION OF 7 BIOLOGICS AND TOFACITINIB IN BIOLOGICS-NAÏVE AND BIOLOGICS-SWITCHED PATIENTS WITH RHEUMATOID ARTHRITIS -THE ANSWER COHORT STUDY. Ann Rheum Dis 2020. [DOI: 10.1136/annrheumdis-2020-eular.814] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
Background:EULAR recommendation announced that biological disease-modifying antirheumatic drugs (bDMARDs) and janus kinase inhibitors (JAKi) are considered as equivalent in the treatment of rheumatoid arthritis (RA). However, we still lack reliable evidence of direct comparison between these agents’ retention, which may reflect both effectiveness and safety.Objectives:The aim of this multi-center (7 university-related hospitals), retrospective study is to clarify retention rates and reasons for discontinuation of 7 bDMARDs and tofacitinib (TOF), one of the JAKi, in both bDMARDs-naïve and bDMARDs-switched cases.Methods:This study assessed 3,897 patients and 4,415 treatment courses of with bDMARDs and TOF from 2001 to 2019 (2,737 bDMARDs-naïve patients and 1,678 bDMARDs-switched patients [59.5% switched to their second agent], female 82.3%, baseline age 57.4 years, disease duration 8.5 years; rheumatoid factor positivity 78.4%; DAS28-ESR 4.3; concomitant prednisolone [PSL] 6.1 mg/day [42.4%] and methotrexate [MTX] 8.5 mg/week [60.9%]). Treatment courses included abatacept (ABT; n=663), adalimumab (ADA; n=536), certolizumab pegol (CZP; n=226), etanercept (ETN; n=856), golimumab (GLM; n=458), infliximab (IFX; n=724), tocilizumab (TCZ; n=851), and TOF (n=101/only bDMARDs-switched cases). Reasons for discontinuation were classified into four categories by each attending physician: 1) lack of effectiveness, 2) toxic adverse events, 3) non-toxic reasons, and 4) remission. Retention rates of each discontinuation reason were estimated at 36 months using the Kaplan-Meier method and adjusted for potential clinical confounders (age, sex, disease duration, concomitant PSL and MTX, starting date and number of switched bDMARDs) using Cox proportional hazards modeling.Results:Adjusted drug retention rates for each discontinuation reason were as follows: lack of effectiveness in the bDMARDs-naïve group (from 70.8% [CZP] to 85.1% [ABT]; P=0.001 between agents) and the bDMARDs-switched group (from 52.8% [CZP] to 78.7% [TCZ]; P<0.001 between agents). Toxic adverse events in the bDMARDs-naïve group (from 86.9% [IFX] to 96.3% [ABT]; P<0.001 between agents) and the bDMARDs-switched group (from 81.1% [ADA] to 95.4% [ETN]; P=0.01 between agents). Finally, overall retention rates excluding discontinuation for non-toxic reasons or remission ranged from 64.2% (IFX) to 82.0% (ABT) (P<0.001 between agents) in the bDMARDs-naïve group (figure a) and from 44.2% (ADA) to 66.8% (TCZ) (P<0.001 between agents) in the bDMARDs-switched group (figure b).Conclusion:Remarkable differences were observed in drug retention of 7 bDMARDs and TOF between bDMARDs-naïve and bDMARDs-switched cases.Disclosure of Interests:Kosuke Ebina Grant/research support from: KE has received research grants from Abbie, Asahi-Kasei, Astellas, Chugai, Eisai, Ono Pharmaceutical, and UCB Japan., Employee of: KE is affiliated with the Department of Musculoskeletal Regenerative Medicine, Osaka University, Graduate School of Medicine, which is supported by Taisho., Speakers bureau: KE has received payments for lectures from Abbie, Asahi-Kasei, Astellas, Ayumi, Bristol-Myers Squibb, Chugai, Eisai, Eli Lilly, Janssen, Mitsubishi-Tanabe, Ono Pharmaceutical, Sanofi, and UCB Japan., Toru Hirano Grant/research support from: TH received a research grant and/or speaker fee from Astellas, Chugai, Nippon Shinyaku, Abbvie, Eisai, and Ono Pharmaceutical, Speakers bureau: TH received a research grant and/or speaker fee from Astellas, Chugai, Nippon Shinyaku, Abbvie, Eisai, and Ono Pharmaceutical, Yuichi Maeda Grant/research support from: YM received a research grant and/or speaker fee from Eli Lilly, Chugai, Pfizer, Bristol-Myers Squibb, and Mitsubishi-Tanabe, Speakers bureau: YM received a research grant and/or speaker fee from Eli Lilly, Chugai, Pfizer, Bristol-Myers Squibb, and Mitsubishi-Tanabe, Wataru Yamamoto: None declared, Motomu Hashimoto Grant/research support from: Bristol-Myers Squibb, Eisai, and Eli Lilly and Company., Speakers bureau: Bristol-Myers Squibb and Mitsubishi Tanabe Pharma., Koichi Murata Grant/research support from: KMurata belong to a department that has been financially supported by four pharmaceutical companies (Mitsubishi-Tanabe, Chugai, AYUMI and UCB Japan)., Employee of: KMurata belong to a department that has been financially supported by four pharmaceutical companies (Mitsubishi-Tanabe, Chugai, AYUMI and UCB Japan)., Speakers bureau: KMurak has received speaking fees, and/or consulting fees from Eisai Co. Ltd, Chugai Pharmaceutical Co. Ltd., Pfizer Japan Inc, Bristol-Myers Squibb, Mitsubishi-Tanabe Pharma Corporation, UCB, Daiichi Sankyo Co. Ltd. and Astellas Pharma Inc., Tohru Takeuchi Grant/research support from: TT received a research grant from Chugai, CoverLetter and a speaker fee from Astellas, Chugai, Eisai, Mitsubishi-Tanabe, Abbvie, Bristol-Myers Squibb, Ayumi, Daiichi Sankyo, Eisai, Takeda, and Asahi-Kasei, Employee of: TT is affiliated with a department that is financially supported by six pharmaceutical companies (Mitsubishi-Tanabe, Chugai, Ayumi, Astellas, Eisai, and Takeda), Hideyuki Shiba: None declared, Yonsu Son: None declared, Hideki Amuro: None declared, Akira Onishi Speakers bureau: AO received a speaker fee from Chugai, Ono Pharmaceutical, Eli Lilly, Mitsubishi-Tanabe, Asahi-Kasei, and Takeda, Kengo Akashi: None declared, Ryota Hara Speakers bureau: RH received a speaker fee from AbbVie, Masaki Katayama: None declared, Keiichi Yamamoto: None declared, Atsushi Kumanogoh Grant/research support from: AK received a research grant and/or speaker fee from Mitsubishi-Tanabe, Chugai, Eisai, Asahi-Kasei, Astellas, Abbvie, Bristol-Myers Squibb, Ono Pharmaceutical, and Pfizer, Speakers bureau: AK received a research grant and/or speaker fee from Mitsubishi-Tanabe, Chugai, Eisai, Asahi-Kasei, Astellas, Abbvie, Bristol-Myers Squibb, Ono Pharmaceutical, and Pfizer, Makoto Hirao Speakers bureau: MHirao received a speaker fee from Astellas, Ono Pharmaceutical, Eli Lilly, Mitsubishi-Tanabe, Pfizer, Ayumi, and Takeda
Collapse
|